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Summary 
Neurodegenerative disease patients suffer from cognitive decline and/or motor 
dysfunctions, depending on the different regions affected by the neuron loss. With aging 
being the major risk factor and a society with increased life expectancy, there is an urgent 
need to develop new effective treatments to alleviate the situation faced by patients, their 
families and society. Although neurodegenerative diseases including Alzheimer’s disease 
(AD), amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD) lead to 
different clinical symptoms, they share common pathomechanisms, such as protein 
aggregation and altered RNA metabolism. A subset of ALS and FTD cases, for instance, 
is pathologically characterized by neuronal cytoplasmic inclusions containing aggregated 
Fused in Sarcoma (FUS) protein. There is also a genetic link, since FUS mutations cause 
ALS with FUS pathology. FUS is a DNA/RNA-binding protein known to regulate 
different steps of RNA metabolism, however, its exact function and target genes in 
neurons were unknown.  
In this study, I evaluated the neuronal role of FUS in alternative splicing using a 
candidate approach focusing on the microtubule-associated protein TAU. TAU is one of 
the most widely studied proteins in neurodegeneration research due to its aggregation in 
different tauopathies, most notably AD. Mutations in the TAU gene MAPT, that affect 
alternative splicing of exon 10, are known to cause another subtype of FTD. Here, I 
demonstrate that FUS depleted rat neurons, although having normal viability, show 
aberrant alternative splicing of TAU, with increased inclusion of exon 3 and exon 10, 
resulting in higher expression of the 2N and 4R TAU isoforms. Importantly, 
reintroduction of human FUS rescues aberrant splicing of TAU in FUS depleted neurons. 
Accordingly, overexpression of FUS decreases expression of 2N and 4R TAU isoforms. 
In mouse brain lysates, I detected direct FUS binding to TAU pre-mRNA, with strong 
binding around the regulated exon 10, often at AUU-rich RNA stretches. Since TAU 
splicing is regulated differently in humans and rodents, I also confirmed the role of 
human FUS in TAU exon 10 splicing using a TAU minigene and a human neuronal cell 
line. In addition, I analyzed the morphology and development of axons to evaluate the 
functional consequences of FUS depletion in neurons. Although FUS depleted neurons 
develop neurites normally, their axons are significantly shorter than in the control cells. 
Similar to observations in TAU/MAP1B knockout neurons, axons of FUS depleted 
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neurons develop significantly larger growth cones with abnormal cytoskeletal 
organization. The development of growth cones in vivo is an essential step in axonal 
maintenance and repair.  
Altogether, this study identified TAU as the first physiological splice target of FUS in 
neurons. The newly discovered role of FUS in regulating the axonal cytoskeleton 
indicates that aberrant axonal function could contribute to the neuron loss seen in 
ALS/FTD cases with FUS aggregates.  
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Zusammenfassung 
 
Patienten mit neurodegenerativen Erkrankungen können an kognitivem Abbau und/oder 
motorische Störungen leiden, je nachdem welche Gehirnregion von dem Verlust von 
Neuronen betroffen ist. Da sich das Risiko einer neurodegenerativen Erkrankung mit 
zunehmendem Alter drastisch erhöht und wir eine Gesellschaft mit steigender 
Lebenserwartung haben, ist es dringend notwending, neue wirksame 
Behandlungsmethoden zu entwickeln, um die Situation, mit der sich Patienten, ihre 
Familien und die Gesellschaft konfrontiert sehen, zu erleichtern. Obwohl sich 
verschiedene neurodegenerative Erkrankungen wie die Alzheimer-Erkrankung (AD), 
Amyotrophe Lateralsklerose (ALS) oder Frontotemporale Demenz (FTD) klinisch 
unterscheiden, gibt es gemeinsame Pathomechanismen, wie Proteinaggregation und 
Störungen im RNA-Metabolismus. Bei einem Teil der ALS und FTD Patienten 
beobachtet man Ablagerungen aus aggregiertem Fused in Sarcoma (FUS) Protein. Des 
Weiteren verursachen FUS Mutationen ALS mit FUS neuronalen Aggregaten. FUS ist ein 
DNA/RNA-bindendes Protein, das verschiedene Schritte des RNA-Metabolismus 
reguliert. Die genaue Funktion von FUS und seine Zielgene in Neuronen waren jedoch 
bisher unbekannt.  
In dieser Studie habe ich die Funktion von FUS auf neuronales alternatives Spleißen mit 
einem Kandidaten-Ansatz untersucht, und mich insbesondere auf das Mikrotubuli-
bindende Protein TAU fokussiert. Tau ist eines der bekanntesten Proteine in der 
Demenzforschung, da TAU Aggregate in verschiedenen sogenannten Tauopathien, 
insbesondere AD, gefunden wurden. Mutationen im TAU Gen MAPT, die das alternative 
Spleißen von TAU Exon 10 beeinflussen, können einen anderen Subtyp der FTD 
verursachen. Diese Studie zeigt, dass die Herunterregulierung (Gen-Knockdown) von 
FUS in murinen Neuronen das Überleben der Neuronen nicht beeinträchtigt, aber zu 
verändertem alternativen Spleißen von TAU mit einem erhöhten Einschluss von Exon 3 
und Exon 10 führt und somit eine höhere Expression von den 2N und 4R TAU Isoformen 
verursacht. Eine wichtige Beobachtung dieser Studie war auch, dass die Expression von 
humanem FUS in FUS knockdown Neuronen aberrantes TAU Spleißen korrigieren kann. 
Dementsprechend führte auch die alleinige Überexpression von FUS zu einer 
verminderten Expression von 2N und 4R TAU. In Lysaten von Mausgehirnen konnte ich 
eine direkte Interaktion zwischen FUS und TAU RNA nachweisen, und zwar mit 
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bevorzugter FUS Bindung nahe am regulierten TAU Exon 10 und oft an AUU-reichen 
RNA-Abschnitten. Da das Spleißen von TAU in Menschen und Nagetieren 
unterschiedlich reguliert wird, bestätigte ich mit sowohl einer menschlichen neuronalen 
Zelllinie als auch einem TAU-Minigen Konstrukt die Rolle von humanem FUS in TAU 
Exon 10 Spleißen. Um die funktionalen Konsequenzen von FUS knockdown in Neuronen 
zu bewerten, analysierte ich die Morphologie und Entwicklung der Axone. Obwohl 
Neuronen mit FUS knockdown normalen Neuriten bilden, sind ihre Axone deutlich kürzer 
als die der Kontroll-Neuronen. Wie auch schon in TAU/MAP1B knockout Neuronen 
beobachtet wurde, entwickeln FUS knockdown Neuronen Axone mit einem deutlich 
größeren Wachstumskegel und abnormer Zytoskelett-Organisation. Die dynamische 
Bildung axonaler Wachstumskegel ist ein wesentlicher Schritt in der axonalen 
Aufrechterhaltung und Reparatur in vivo. 
Insgesamt konnte diese Studie TAU als erstes physiologisches splice Zielgen von FUS in 
Neuronen identifizieren. Die neu entdeckte Funktion von FUS bei der Regulation des 
axonalen Zytoskelettes spricht für eine mögliche Rolle der veränderten axonalen Funktion 
beim Verlust von Neuronen in ALS/FTD Fällen mit FUS Aggregaten.  
.
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1. Introduction 
1.1. Neurodegenerative diseases 
Neurodegenerative diseases are caused by the chronic and progressive loss of neurons 
(neurodegeneration) in the central and peripheral nervous system, which leads to impaired 
cognitive function (dementia), movement dysfunction or both. Currently 35.6 million 
people are estimated to suffer from dementia worldwide (WHO, 2012), with aging being 
the most important risk factor (Bertram & Tanzi, 2005). Without a preventive or curative 
treatment, predictions estimate this number could double every 20 years, reaching 81 
million by 2040 (Ferri et al, 2005). The worldwide increase in life expectancy and the 
progressive nature of neurodegenerative diseases underscore the alarming situation (CDC, 
2003; Trojanowski, 2008).  
Scientific research has responded to the pressing public health problem with huge 
progress achieved by applying the tools of modern molecular biology and genetics. The 
identification of disease-associated gene mutations has revealed the cellular processes 
affected and has directed the efforts towards causal therapies for Alzheimer's disease 
(AD), amyotrophic lateral sclerosis (ALS) and other dementias. Some of the common 
cellular processes affected are proteosomal degradation, RNA metabolism, and 
aggregation of misfolded proteins (Bai et al, 2013; Ross & Poirier, 2004; Thomas et al, 
2013). It is still unclear if the protein aggregation, observed in virtually all 
neurodegenerative diseases, acts as a disease causing agent, a protective agent, or an 
innocent bystander (Ross & Poirier, 2004; Taylor et al, 2002). 
The existence of underlying common mechanisms in neurodegenerative diseases opens 
up the possibility of expanding our understanding from one disease to the others (Ross & 
Poirier, 2004). In order to establish such links, an adequate classification based on 
symptoms, pathology, and genetics is required. The focus of my thesis is the molecular 
parallels between two related neurodegenerative diseases: ALS and frontotemporal lobar 
degeneration (FTLD). I will provide an overview of ALS and FTLD, including their 
classification and a current understanding of the pathomechanisms. This overview also 
introduces the questions that are experimentally addressed in this study.  
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1.2. Amyotrophic lateral sclerosis - ALS 
Amyotrophic lateral sclerosis (ALS), also known as Charcot disease or Lou Gehrig’s 
disease, is a fatal neurodegenerative disease that affects both upper and lower motor 
neurons (Cleveland & Rothstein, 2001; Kiernan et al, 2011). Upper motor neurons are 
located in the motor cortex (Brodmann area 4) and extend their long axons along the 
spinal cord. They communicate with the lower motor neurons in the spinal cord via the 
neurotrasmitter glutamate. In turn, they transmit information to muscles primarily with 
the neurotransmitter acetylcholine (ACh) at the neuromuscular junction (NMJ) 
(Nishimaru et al, 2005).  
ALS is one of the most common neuromuscular diseases worldwide with an incidence 
rate of 2.08 in 100,000 and a prevalence of 5.40 in 100,000 (Chiò et al, 2013). It affects 
all races and ethnic backgrounds equally, except for the Guam Island in the South Pacific, 
which shows a higher incidence of disease (ALS-Guam variant). Although the cause for 
this is still unknown, genetic and environmental factors unique to the indigenous 
Chamorro population have been proposed (Steele & McGeer, 2008).  
Early symptoms may vary among patients and can include muscle weakness, spasticity 
(stiffness) or fasciculations (muscle twitches). Other patients present initial symptoms of 
dysarthria or dysphagia (difficulties in forming words or swallowing, respectively). A 
characteristic feature of ALS patients is hyperreflexia without sensory disturbance 
(Kinsley et al, 2001; NINDS, 2013). Regardless of the type of initial symptom, muscle 
atrophy and weakness spread progressively in the body, eventually preventing voluntary 
control of arms and legs (Figure 1A). At late stages of ALS respiratory muscles also 
succumb to this disease, increasing the risk of pneumonia. Respiratory failure is the 
primary cause of death in ALS and typically occurs within 2 to 10 years after disease 
onset.  
ALS is diagnosed based on a combination of physical examination and neurologic tests 
including electromyography (EMG) and nerve conduction velocity (NCV) test. 
Differential diagnosis excludes other conditions with ALS-resembling symptoms such as 
spinal muscular atrophy (SMA), multiple sclerosis (MS), and spinal cord tumors. 
The vast majority (about 90%) of ALS patients shows no clear history of 
neurodegenerative disease in the family and is thus classified as sporadic cases. In 
contrast, about 10% of patients are affected by familial ALS (Ling et al, 2013). The 
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occurrence of recessive inherited mutations, missing familial medical history, and 
paternity issues hinder, however, correct classification between sporadic and familial 
cases. Although familial cases tend to have earlier disease onset (46 years) than sporadic 
cases (56 years), they are virtually indistinguishable in terms of symptoms and disease 
course. The juvenile form of familial ALS has a remarkably early age of onset before 25 
years (Aggarwal & Shashiraj, 2006). 
 
Figure 1 Clinical presentation of amyotrophic lateral sclerosis and frontotemporal dementia  
(A) Amyotrophic lateral sclerosis (ALS) patients present symmetrical upper limb wasting. Note 
also the ALS typical feature of a “split-hand”, which is caused by disproportionate wasting of the 
hand muscles. Adapted from: (Kiernan et al, 2011). (B) Frontotemporal dementia (FTD) patients 
show reduced perfusion in frontal brain regions (arrow, middle panel) compared to a cognitive 
normal (CN) individual and an Alzheimer disease patient (AD). In contrast, AD patients show 
diminished perfusion in the posterior region of the brain (arrow, right panel) in comparison to CN 
individual and FTD patient. This is visualized here by structural and arterial spin labeling 
magnetic resonance perfusion images after partial volume corrections. Adapted from:(Du et al, 
2006).  
Treatment opportunities for ALS patients are very limited and the lack of specific reliable 
biomarkers hinders the development of treatments. The only FDA approved drug 
available for ALS is Riluzole (Rilutek, Sanofi-Aventis), which appears to protect neurons 
from glutamate excitotoxicity either by blocking receptors or by stimulating glutamate 
uptake. Riluzole prolongs survival of patients by several months and delays the need for 
mechanical ventilation. Symptomatic treatment aims to reduce pain, cramps, fatigue, and 
excess saliva. As normal cognitive functions are often sustained in ALS patients, the 
progressive deterioration of health can cause depression. Overall, a multidisciplinary team 
of physicians, physiotherapists, and nutritionists is recommended to support the patients 
and caregivers.  
Introduction 
22 
1.3. Frontotemporal lobar degeneration - FTLD 
Frontotemporal lobar degeneration (FTLD) is the pathological entity underlying a group 
of diseases classified by the umbrella term of frontotemporal dementia (FTD). In the 
following sections the term FTLD is used to designate both disease and pathology. FTLD, 
as indicated in the name, is characterized by specific degeneration of the frontal and 
temporal cortex, brain areas that usually control emotional and social behavior. As a 
consequence, FTLD patients typically suffer from difficulties in controlling emotions, 
speech/language dysfunction and changes in social behavior, while memory, perception 
and spatial skills are generally preserved.  
FTLD is the second most common dementia after AD in the presenile group (<65 years) 
with an incidence of 3.5 - 4.1 per 100,000/year and a prevalence of 10-20 per 100,000 
(van Langenhove et al, 2012). The typical age of onset is around 60 years and the life 
expectancy after diagnosis ranges from 2-10 years (Bird et al, 2003; Hsiung & Feldman, 
2013). FTLD is a rapidly progressing disease and patients eventually require full-time 
care. The combination of disease onset at presenile age and a rapid progression of disease 
results in a devastating emotional and financial situation for the patients and families. 
Interestingly, in comparison to other neurodegenerative diseases, FTLD has a strong 
genetic component with about 50% familial and 50% sporadic cases (Rademakers et al, 
2012; Rohrer et al, 2009).  
Depending on the main symptom FTLD is subdivided in three different variants: 
behavioral variant (bvFTD), primary progressive aphasia (PPA), and variant with 
combined dementia and movement disorders. The most common variant is bvFTD, which 
results in patients suffering from progressive deterioration of behavior and diminished 
executive functions. Some examples include impulsive actions, apathy, repetitive 
movements, and dietary changes (overeating) (Rascovsky et al, 2011). Primary 
progressive aphasia (PPA) is the second most common clinical variant. PPA patients have 
difficulties in word naming or word comprehension, and are eventually unable to 
communicate and become mute. PPA cases are further subclassified as progressive non-
fluent aphasia (PNFA) or semantic dementia (SD) based on clinical features and 
neuroimaging techniques (Gorno-Tempini et al, 2011). PNFA is characterized by patients 
showing apraxia of speech and impaired comprehension of complex sentences. Object 
knowledge or single-word comprehension is, however, unaffected. In contrast, SD is 
characterized by impaired single-word comprehension and recognition of objects or 
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familiar faces, while speech production is spared. In FTLD with movement disorders, 
patients present dementia and bradykinesia (slow movement), akinesia (no movement), or 
limb dystonia often causing postural disequilibrium (Hsiung & Feldman, 2013). 
Eventually patients lose the ability to walk. The accompanying movement disorder can 
manifest early on or it may develop with the disease. Importantly, the current 
classification is not definite as there is also significant overlap between variants (Seeley et 
al, 2005). It has been reported, for example, that the vast majority of bvFTD patients with 
GRN mutations eventually develop language problems (Josephs, 2007).  
The clinical variants are diagnosed based on clinical features and neuroimaging findings 
from magnetic resonance imaging (MRI), computed tomography (CT), or positron 
emission tomography (PET). CT and MRI typically show asymmetric atrophy in frontal 
and/or temporal regions of FTLD patients (Figure 1B). Differential diagnosis excludes 
AD or psychiatric conditions such as depression or psychosis, which result in similar 
unusual behavior. A definite diagnosis is only possible with postmortem 
neuropathological evidence or if a disease causing mutation is detected. 
There is currently no cure for FTLD, but symptomatic treatment is available for 
behavioral symptoms. Selective serotonin reuptake inhibitors (SSRIs), for example, are 
used to control compulsive behaviors. Although there is no FTLD specific biomarker 
available, TAU and Progranulin protein levels in the cerebral spinal fluid (CSF) are useful 
monitoring tools. Caregivers also need training and psychological support due to the 
difficulties in managing the behavioral changes of some patients.  
 
1.4. ALS-FTLD disease spectrum 
1.4.1. Clinical overlap  
In ALS cases cognition and memory are usually not affected, however, about 5-20% of 
cases present symptoms related to FTD (Kinsley et al, 2001; Ringholz et al, 2005). 
Similarly, 14% of FTD patients also meet the criteria for ALS (Lomen-Hoerth et al, 2002) 
(Figure 2). Cases with overlapping clinical presentation of ALS symptoms and FTLD 
symptoms are classified as ALS-FTD.  
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Figure 2 Overview on clinical, pathological and genetic overlap between ALS and FTLD  
Clinical overlap: The scheme presents the clinical overlap between ALS and FTD, and denotes 
the percentage of ALS cases with significant FTD symptoms and vice versa. Pathologic overlap: 
The frequencies of the different pathological subtypes are depicted according to protein deposited. 
Note that the pathology is usually mutually exclusive so that the main aggregating protein defines 
the classification. Note also that TDP-43 and FUS pathology is observed in ALS and FTD 
subtypes. Genetic overlap: The spectrum is presented as a gradient between pure ALS and pure 
FTD. The major genes are plotted along the gradient according to the disease caused by 
mutations. Mutations in SOD1 or GRN cause pure ALS or FTD respectively, while mutation in 
C9orf72 can cause ALS or FTD. Adapted partially from: (Al-Chalabi et al, 2012; Ling et al, 
2013). 
1.4.2. Molecular pathology of ALS and FTLD 
In the last decade, tremendous progress has been made in ALS and FTLD research, with 
new disease causing mutations, new histological markers for classification, and new risk 
factor genes being discovered every year. This poses a challenge in updating the 
classification scheme of the diseases. The table presented here corresponds to a summary 
of the latest classifications available (Figure 3) (Bahia et al, 2013; Dormann & Haass, 
2013; Ling et al, 2013; Rademakers et al, 2012; Sieben et al, 2012; Thomas et al, 2013). 
In stark contrast to AD, where amyloid-beta pathology co-occurs with TAU pathology, 
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the aggregating marker proteins of ALS or FTLD subtypes are usually mutually exclusive 
and are used to classify the different subtypes. In ALS, the main aggregating proteins are 
either transactive response DNA binding protein 43 kDa (TDP-43) (97%), SOD1 (2%) or 
FUS (1%) (Ling et al, 2013) (Figure 2). The major ALS subtypes are termed accordingly: 
ALS-TDP, ALS-SOD1 and ALS-FUS (Figure 3). In FTLD, the most common 
neuropathologic findings are either aggregated TAU (45%) or aggregated TDP-43 (45%) 
(Ling et al, 2013). Additionally, about 9% of the cases show aggregated FUS as the 
pathologic hallmark (Ling et al, 2013) (Figure 2). FUS pathology is observed in the vast 
majority of TDP-43 and TAU negative cases, thus constituting an important subtype of 
FTLD (Urwin et al, 2010b). The remaining 1% of cases (TDP-43, TAU and FUS 
negative) are positive for markers of the ubiquitin-proteasome system (UPS). Analogous 
to ALS, the major FTLD subtypes are classified accordingly as: FTLD-TAU, FTLD-
TDP, FTLD-FUS or FTLD-UPS (Figure 3). Importantly, there is no perfect correlation 
between the histopathological and the clinical variants. Thus each pathology subtype can 
be associated with any clinical variant, however, with somewhat different frequencies 
(Sieben et al, 2012; Van Langenhove et al, 2013). There is, therefore, a growing notion 
that the anatomical distribution of degeneration rather than the type of pathology define 
the symptoms (Morrison & Hof, 1997; Skovronsky et al, 2006). Similar to the selective 
vulnerability found in ALS for motor neurons, in FTD (bvFTD), a selective vulnerability 
has been proposed for spindle neurons or von Economo neurons (VENs) located in the 
anterior cingulate cortex (ACC) (Santillo et al, 2013; Seeley, 2008). Early bvFTD seems 
to affect focally the ACC, in contrast to AD, where it is spared (Seeley, 2008). The exact 
mechanism behind this selective vulnerability remains, however, unknown.  
1.4.3. Pathomechanism behind major ALS and FTLD subtypes 
This thesis focuses on the molecular link between FUS and TAU and the consequences 
for ALS and FTLD. In order to provide an appropriate context to this link, the major ALS 
and FTLD subtypes are discussed first, including their genetic components and potential 
molecular pathomechanisms.  
1.4.3.1. ALS-TDP and FTLD-TDP 
TDP-43 pathology is observed in all major neurodegenerative diseases including AD 
(Amador-Ortiz et al, 2007), Huntington’s disease (HD) (Schwab et al, 2008) and 
Parkinson’s disease (PD) (Lattante et al, 2013; Nakashima-Yasuda et al, 2007). In ALS-
TDP, TDP-43 pathology is mainly found in spinal cord and cortex (Arai et al, 2006; 
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Lattante et al, 2013; Neumann et al, 2006). In FTLD-TDP, TDP-43 pathology is observed 
in various cortical layers and TDP-43 positive inclusions can be detected in the nucleus or 
cytoplasm of affected neurons (Mackenzie et al, 2011b). Biochemical characteristics of 
TDP-43 aggregates in both ALS and FTLD include hyperphosphorylation, truncation, and 
cytoplasmic localization accompanied with a nuclear clearance of TDP-43 (Lee et al, 
2012; Ling et al, 2013). 
TDP-43 is a multifunctional DNA/RNA-binding protein involved in different steps of 
RNA metabolism (Buratti & Baralle, 2008; Buratti & Baralle, 2010; Lagier-Tourenne et 
al, 2010); including transcription, alternative splicing and transport of RNA 
(Polymenidou et al, 2011; Tollervey et al, 2011). Additionally, TPD-43 may be involved 
in microRNA biogenesis (Kawahara & Mieda-Sato, 2012).  
Heterozygous mutations in GRN cause autosomal dominant FTLD-TDP, while mutations 
in C9orf72, VCP, UBQLN2 or the TDP-43 coding gene TARDBP can cause familial ALS-
TDP or FTLD-TDP (Figure 3). GRN mutations were first described in 2006, solving the 
mystery of TAU negative familial cases with a strong genetic linkage to chromosome 
17q21. Currently 69 GRN mutations have been identified in 231 families and all 
mutations are considered loss of function because they result in haploinsufficency ((Cruts 
et al, 2012), http://www.molgen.vib-ua.be/FTDMutations). GRN codes for the 
Progranulin protein, which is ubiquitously expressed and proteolytically processed to 7.5 
Granulin peptides. In the CNS, Progranulin functions as a neurotrophic factor with an 
important role in neurite survival and outgrowth. Progranulin also functions in 
inflammation and wound repair, where it antagonizes the Granulins function (Eriksen & 
Mackenzie, 2008).  
The recently discovered mutations in the uncharacterized C9orf72 gene are now 
considered the major genetic cause for both FTLD-TDP and ALS-TDP (DeJesus-
Hernandez et al, 2011; Gijselinck et al, 2012; Renton et al, 2011). The C9orf72 gene of 
healthy individuals contains only 3 to 25 GGGGCC repeats in the first intron. In ALS-
FTLD patients with C9orf72 mutations, the gene contains a massive expansion of 700-
1,600 GGGGCC repeats (DeJesus-Hernandez et al, 2011). The C9orf72 protein is 
ubiquitously expressed but its function is still unknown.  
The massive repeat expansion leads to a reduction of expression, which indicates a 
possible loss of function component in the disease (Belzil et al, 2013; Ciura et al, 2013; 
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DeJesus-Hernandez et al, 2011; Mori et al, 2013b). However, alternative mechanisms are 
also being investigated, such as non-ATG translation of the repeat and RNA toxic gain-
of-function (Ling et al, 2013; Mori et al, 2013a; Mori et al, 2013b). 
 
Figure 3 Clinical, pathological and genetic classification of ALS and FTD  
Clinics: Based on the symptoms, FTD can be diagnosed as: FTD with motor neuron disease 
(MND, ALS/FTD); behavioral variant FTD (bvFTD); semantic dementia (SD) or progressive 
nonfluent aphasia (PFNA). The proximal muscle weakness disease inclusion body myopathy with 
Paget's disease of bone (IBMPPD) is caused by mutations in the VCP gene. The classification 
presented here is not absolute, since significant overlap is seen between clinical variants. 
Pathology: According to the aggregated protein, ALS is classified as ALS-SOD1, ALS-TDP or 
ALS-FUS with SOD1, TDP-43 or FUS protein deposits, respectively. In FTLD, cases are divided 
as FTLD-TAU with TAU protein deposits or as FTLD-U with ubiquitin (Ub) positive aggregates. 
The subdivision of FTLD-TAU cases (also called tauopathies) as progressive supranuclear palsy 
(PSP), argyrophilic grain disease (AGD), Pick’s disease or neurofibrillary tangle dementia is 
based on the nature and location of TAU aggregates. In the case of PSP, CBD and AGD, the 
aggregates consist mainly of the 4R TAU isoform. In contrast, Pick’s disease is characterized by 
aggregates consisting of 3R TAU. In neurofibrillary tangle dementia, both isoforms 3R and 4R 
are present in aggregates. FTLD-U cases are subdivided as FTLD-FUS, FTLD-TDP or FTLD-
UPS when the aggregates are positive for FUS, TDP-43 or markers of the ubiquitin-proteasome 
system (UPS), respectively. *Note that in FTLD-FUS the related proteins TAF-15 and EWS also 
co-aggregate, which contrasts the sole aggregation of FUS in ALS-FUS. Genetics: ALS causing 
mutations have been found in the SOD1, TARDBP (coding for TDP-43) and FUS genes. 
Mutations associated with TDP-43 pathology have also been found in C9orf72, UBQLN2, VCP, 
and other genes. Rare mutations in UBQLN2 are associated to ALS with TDP-43 and FUS 
pathology. FTLD-TAU cases are usually linked to mutations in the MAPT gene, coding for TAU. 
FTLD-TDP pathology is associated with mutations in GRN, C9orf72, VCP, UBQLN2, or in rare 
cases TARDBP. FTLD-U cases are associated with mutations in C9orf72 or CHMP2B. Only rare 
cases of mutations in FUS have been reported to cause FTLD-FUS, thus most cases are currently 
classified as sporadic cases. Despite the significant genetic component, in FTD and less in ALS, 
many sporadic cases remain to be resolved. Note that the size of the boxes is not proportional to 
the relative incidence. Adapted from: (Bahia et al, 2013; Dormann & Haass, 2013; Ling et al, 
2013; Rademakers et al, 2012; Sieben et al, 2012; Thomas et al, 2013; Van Langenhove et al, 
2010) 
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Mutations in the TARDBP gene are usually associated with pure ALS (Figure 2). 
However, mutation carrier families can have members affected by FTD, ALS or a 
combination of both (Al-Chalabi et al, 2012). Up to now, more than 40 mutations have 
been identified and the majority cluster around the C-terminal glycine-rich region, which 
functions in alternative splicing and mediates protein-protein interactions (Al-Chalabi et 
al, 2012; Lagier-Tourenne et al, 2010; Renton et al, 2014).  
Additionally, rare mutations in VCP have also been implicated in ALS-TDP and FTLD-
TDP (Johnson et al, 2010; Neumann et al, 2007). Previously, VCP mutations were known 
to cause inclusion body myositis and Paget's disease of bone (IBMPFD) (Watts et al, 
2004). VCP codes for the valosin containing protein (VCP), which is an ATPase that 
interacts with ubiquitinated proteins and functions in protein clearance pathway, 
autophagy, and protein sorting (Ling et al, 2013). Therefore, mutations are thought to 
disturb the ubiquitin dependent proteasomal degradation. Also Ubqln-2 mutations that 
impair protein degradation and autophagy regulated by the Ubiquilin-2 protein are 
associated with ALS and FTLD. Curiously, Ubiquilin 2 pathology may be accompanied 
by TDP-43 and FUS pathology (Deng et al, 2011; Ling et al, 2013; Williams et al, 2012). 
In summary, mutations in genes involved in diverse pathways as RNA metabolism and 
protein degradation can cause ALS or FTLD with TDP pathology. 
1.4.3.2. ALS-FUS and FTLD-FUS 
In ALS-FUS cases, severe motor neuron loss is observed in the spinal cord and to a lesser 
extend in the brain stem (Al-Chalabi et al, 2012). Histopathologically, FUS is found 
mislocalized to the cytoplasmic compartment and aggregates are found in both neurons 
and glia cells (Kwiatkowski et al, 2009; Tateishi et al, 2010; Vance et al, 2009) (Figure 
4A). Two different types of pathology are observed depending on the severity of the 
disease. Neuronal basophilic inclusions and round aggregates in the cytoplasm are typical 
for early-onset ALS. In late-onset ALS, tangle-like FUS inclusions are found in both 
neurons and glia (Ling et al, 2013). Also in FTLD-FUS, FUS pathology is observed in 
both neurons and glia cells (Mackenzie et al, 2011a; Neumann et al, 2009a) (Figure 4A). 
The location and morphology of the inclusions define the three pathology subtypes: 
atypical FTLD-U (aFTLD-U), basophilic inclusions body disease (BIBD), and neuronal 
intermediate filament inclusion disease (NIFID) (Lashley et al, 2011; Mackenzie et al, 
2011a; Munoz et al, 2009; Neumann et al, 2009b; Sieben et al, 2012). aFTLD-U is the 
most common FTLD-FUS subtype and is associated with early onset disease (40-50 years 
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of age) with a mean duration of disease of about 7 years (Lashley et al, 2011). aFLTD-U 
cases show neuropathologically severe atrophy in the caudate nucleus and the 
frontotemporal cortex. FUS inclusions can be either compact oval shaped neuronal 
cytoplasmic inclusions (NCI) or vermiform neuronal intranuclear inclusions (NII) located 
in the neocortex, granule layer of the dentate gyrus and striatum, while the cerebral cortex 
is spared (Mackenzie et al, 2011a; Munoz et al, 2009). In BIBD, in contrast, basophilic 
NCI are found in the pontine nuclei, brain stem, cerebral and frontal cortex. BIBD is also 
typically found in early-onset disease (Sieben et al, 2012). The third subtype, NIFID, is 
characterized by FUS inclusions that are also positive for interfilaments, alpha-internexin, 
and neurofilaments (Neumann et al, 2009b). Asymmetric atrophy is additionally seen in 
the frontotemporal cortex and neostriatum (Sieben et al, 2012). In contrast to aFTLD-U, 
NIFID FUS inclusions are abundant in the CA1 layer, leaving the granular layer of the 
dentate gyrus largely spared. NIFID is often associated with bvFTD and has an age of 
onset between 40-60 years of age, with a rapid progression (3 years disease duration) 
(Sieben et al, 2012).  
Interestingly, one key distinction between ALS-FUS and FTLD-FUS is the co-
aggregation of the FET family members, Ewing sarcoma protein (EWS) and TATA-
binding protein (TBP)-associated factor (TAF15 or TAFII68), present only in FTLD-FUS 
and not in ALS-FUS. Nuclear FUS aggregates have also been observed in HD (Doi et al, 
2008) and spinocerebellar ataxias (Doi et al, 2010) cases without FUS mutations.  
Mutations in the FUS gene are the main genetic cause for ALS-FUS, but in rare cases 
also UBQLN2 mutations can cause ALS with Ubiquilin-2, TDP-43 and FUS pathology 
(Deng et al, 2011; Williams et al, 2012). ALS FUS mutations, considered loss of function 
mutations, usually cluster around the C-terminus or around the G-rich domain (Figure 
4B). So far FUS mutations have been reported only in a few FTLD-FUS cases and their 
pathogenicity is still unclear. Thus, almost all FTLD-FUS cases are considered sporadic 
cases (Snowden et al, 2011; Van Langenhove et al, 2010). Although it is still under 
debate how exactly FUS mutations or aggregation cause neurodegeneration, multiple 
functions might be impaired, including regulation of transcription, genomic stability, 
microRNA biogenesis, mRNA transport, and alternative splicing.  
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1.4.3.3. ALS-SOD1 
As discussed in a recent review, ALS and FTLD are related but different disorders 
(Dormann & Haass, 2013). Contrary to the neuropathological and genetic overlap seen 
with TDP-43 and FUS, SOD1 or TAU mutations cause pure ALS or FTD, respectively 
(Figure 2). In ALS-SOD1, the main aggregating protein is the copper/zinc superoxide 
dismutase 1 (SOD1). Mutations in SOD1 were first discovered in 1993 (Rosen et al, 
1993) and, in contrast to TDP-43 or FUS mutations, SOD1 mutations do not cluster in 
any specific gene region. The current understanding is that SOD1 mutations cause a toxic 
gain of function, possibly by increasing the propensity to aggregate (Al-Chalabi et al, 
2012). 
1.4.3.4. FTLD-TAU 
FTLD cases with TAU pathology are the major form of FTLD, apart from FTLD-U cases, 
and are further subclassified, among others, as Pick's disease (PiD), corticobasal 
degeneration (CBD), progressive supranuclear palsy (PSP) or argyrophilic grain disease 
(AGD) (Bahia et al, 2013; Lee et al, 2001), depending on the characteristics of the 
pathology and the aggregated TAU isoforms (Figure 3). These diseases belong to a wider 
class termed tauopathies, which are neurodegenerative diseases that show characteristic 
aggregation of hyperphosphorylated TAU in the somatodentritic compartment. TAU 
forms paired helical filaments (PHF) that can aggregate into insoluble neurofibrillary 
tangles (NFT) (Ballatore et al, 2007). NFTs are, together with amyloid-beta plaques, the 
pathological hallmark of AD, thus AD is the most common tauopathy (Ballatore et al, 
2007). 
Pick's disease is a tauopathy with characteristic TAU aggregates called Pick bodies and 
Pick cells, named after the Czech neurologist Arnold Pick, who made the initial 
observations of this characteristic pathology in 1892 (Pick, 1892). Pick bodies consist of 
predominantly 3R TAU isoform. This is in contrast to CBD, PSP and AGD, where the 
predominantly aggregated TAU isoform is the 4R isoform (Bahia et al, 2013). In AD, all 
TAU isoforms aggregate in apparently similar proportions. CBD is characterized by 
typical glial TAU pathology termed astrocytic plaques (Feany & Dickson, 1995; Lee et 
al, 2001). 4R TAU aggregates in CBD are found, among other regions, in the neocortex 
and subcortical white matter. In PSP, neuronal loss is found predominantly in the 
substantia nigra and the anterior thalamus. Lesions can also be found in the primary 
motor and premotor cortices. PSP is neuropathologically characterized by tufted 
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astrocytes and globose neurofibrillary tangles. Finally, AGD typically presents as the 
neuropathological hallmark hyperphosphorylated 4R TAU and often truncated TAU in so 
called pre-tangle neurons and in oligodendroglial cells (Ferrer et al, 2008). 
Mutations in the TAU coding gene MAPT in chromosome 17q21 were the first mutations 
identified to cause a form of familial FTLD (Frontotemporal dementia and parkinsonism 
linked to chromosome 17 (FTDP-17)). Currently, 44 different mutations have been 
identified in 134 families. The most common mutations are P301L and the intronic 
mutation IVS10+16C>T (Rademakers et al, 2004). MAPT mutations typically cluster 
around exons 9-13, which code the microtubule binding domains (Figure 5). Mutations 
can cause altered binding to microtubules either by disturbing the balance between 
isoforms or by changing the binding properties of the protein. This has functional 
consequences in terms of neuronal plasticity, axonal transport and cytoskeleton dynamic 
stability (Ballatore et al, 2007).  
1.4.3.5. FTLD-UPS 
Finally, some FTLD cases remain unclassifiable because protein aggregates are negative 
for TAU, TDP-43 or FUS but positive for ubiquitin and p62, which label most 
aggregating proteins. These cases are termed ubiquitin-proteasome system positive cases 
or FTLD-UPS (Figure 3). Note that for the purpose of clarity the distinction is made here 
between FTLD-U and FTLD-UPS, with FTLD-U cases being all Ubiquitin positive and 
TAU negative cases that can be further divided into FTLD-TDP, FTLD-FUS and FTLD-
UPS. Mutations in the charged multivesicular body protein 2B gene CHMP2B are linked 
to some cases of FTLD-UPS (Momeni et al, 2006; van der Zee et al, 2008) and ALS (Cox 
et al, 2010; Parkinson et al, 2006). CHMP2B is a core component of the endosomal 
sorting complexes required for transport-III (ESCRT-III), which regulates protein 
trafficking in the lysosomal degradation pathway. CHMP2B mutations are known to 
disrupt the endosome-lysosomal pathway, but the detailed pathomechanism is still 
unknown (Han et al, 2012; Urwin et al, 2010a).  
1.4.4. Other genes, epigenetic and environmental risk factors related to ALS/FTLD 
Curiously, other genes associated with rare cases of ALS and FTLD also have functions 
in either transport, cytoskeleton stability or in RNA metabolism. They include: DCTN1, a 
gene encoding a subunit of the dynactin transporter protein (Puls et al, 2003); NEFH, a 
gene encoding the heavy neurofilament unit (Al-Chalabi et al, 1999); PRPH, a gene 
encoding the type III intermediate filament peripherin (Leung et al, 2004); and SMN1, 
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encoding the survival motor neuron protein 1, which functions in RNA metabolism 
(Blauw et al, 2012). 
Although some risk factors and susceptibility genes have recently been discovered, little 
is still known about their function in pathological and physiological context. In the case 
of FTLD, the APOE E2 allele is reported to be a risk factor (Verpillat et al, 2002), but not 
the E4 allele, which is usually associated with AD (Geschwind et al, 1998). ApoE 
transports lipoproteins and regulates the lipid metabolism in the brain. Also, a 
polymorphism in TMEM106B was identified in a genome wide association study 
(GWAS) as the strongest risk factor for FTLD-TDP (Van Deerlin et al, 2010; van der Zee 
et al, 2011). TMEM106B is a transmembrane protein that is primarily found in late 
endosomes and lysosomes (Brady et al, 2013; Chen-Plotkin et al, 2012; Lang et al, 2012). 
TMEM106B has been shown to control dendritic trafficking of lysosomes via its 
interaction with the microtubule associated protein MAP6 (Schwenk et al, 2013). The 
MAPT H1 haplotype is also considered a genetic risk for FTLD, because it is 
overrepresented in the group of 4R TAU disorders (Baker et al, 1999; Houlden et al, 
2001; Sobrido et al, 2003). 
The abundance of sporadic cases and the different age of onset among ALS and FTLD 
subtypes already point towards the influence of non-genetic factors on the disease 
progression. There are variations regarding type and severity of disease even between 
individuals carrying the same mutation. As in the case of TARDBP mutations, families 
carrying C9orf72 mutations can have members suffering from ALS, FTLD, or a 
combination of ALS-FTLD (Gijselinck et al, 2012; Renton et al, 2011). Epigenetic and 
environmental factors could account for such differences and are being extensively 
studied (Jakovcevski & Akbarian, 2012; Morahan et al, 2009). Additionally, for ALS, 
elevated levels of glutamate in the nervous system have been proposed to be a risk factor 
(Rothstein et al, 1992; Shaw & Ince, 1997). One possible mechanism behind this is the 
selective vulnerability of motor neurons to glutamate mediated excitotoxicity due to their 
high expression of glutamate receptors (Kawahara & Kwak, 2005).  
1.5. The role of FUS and TAU in disease 
The pathological and genetic link between FUS or TAU and different subtypes of ALS or 
FTLD is now well-established. TAU is one of the most widely studied proteins in the 
field of neurodegeneration because of its pathological link to AD, FTLD and the 
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ALS/Parkinsonism-dementia (ALS-Guam variant). However, the exact role of FUS and 
TAU in disease onset or progression remains still unclear. In order to gain further insight 
into possible pathomechanisms, a more in depth study of protein structure, location, and 
physiological function is required. 
1.5.1. FUS 
1.5.1.1. FUS protein domain structure 
The N-terminal part of FUS contains a region rich in glutamine, glycine, serine, and 
tyrosine (QGSY), and a glycine-rich region (G-rich). The N-terminal part of FUS acts as 
a transcriptional activation domain, which is responsible for the oncogenic potential of 
the FUS fusion proteins found in some sarcoma patients (Crozat et al, 1993; Prasad et al, 
1994; Rabbitts et al, 1993; Zinszner et al, 1994). The QGSY domain confers aggregation 
propensity in vitro (Kato et al, 2012) and has been predicted to have prion-like properties 
(King et al, 2012). The C-terminal part of the protein mediates DNA/RNA-binding 
through a RNA recognition motif (RRM), two arginine-/glycine-rich regions (RGG), and 
a zinc finger domain (ZnF) (Iko et al, 2004; Lagier-Tourenne et al, 2010) (Figure 4B). 
Finally, FUS contains a proline-tyrosine nuclear localization signal (PY-NLS) at the C-
terminus. This protein structure is common to the FET family of proteins including EWS 
and TAF15 (Tan & Manley, 2009).  
1.5.1.2. FUS protein function 
FUS binds single and double stranded DNA, regulates transcription and different stages 
of RNA metabolism (Lagier-Tourenne et al, 2010; Tan & Manley, 2009). FUS regulation 
of transcription involves, on the one hand, the direct binding to RNA polymerase II and 
regulation of its phosphorylation, which can affect general transcription and elongation 
(Schwartz et al, 2012; Yang et al, 2000). On the other hand, FUS can also regulate 
transcription of specific targets by binding to specific DNA sequences in the promoter 
region of target genes (Tan et al, 2012) or by binding to nuclear hormone receptors 
(Powers et al, 1998). The DNA binding function of FUS is generally associated with the 
role in transcription; however, it could also be important for the role of FUS in genomic 
stability (Hicks et al, 2000). FUS interaction with the histone deacetylase 1 protein 
(HDAC1) has been reported as crucial for FUS function in DNA damage response (Wang 
et al, 2013). 
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FUS regulation of transcription and RNA splicing could function simultaneously, since 
both processes are tightly interdependent (Das et al, 2007; Lagier-Tourenne et al, 2010; 
Reed, 2003).  
FUS is also part of the spliceosome (Hartmuth et al, 2002; Rappsilber et al, 2002; Zhou et 
al, 2002), and upon loss of FUS almost 1,000 transcripts are affected in their abundance 
or splicing in the adult mouse brain (Lagier-Tourenne et al, 2012). FUS shuttles between 
nucleus and cytosol (Zinszner et al, 1997) and has been proposed to localize to dendrites 
in response to neuronal activation (Fujii et al, 2005). The Transportin 1 dependent FUS 
nuclear import is mediated through the PY-NLS and by its arginine-methylation 
(Dormann et al, 2012; Dormann et al, 2010; Tradewell et al, 2012). Additionally, FUS is 
phosphorylated, but the function of this post-translational modification remains largely 
unknown (Klint et al, 2004; Rappsilber et al, 2003). FUS can also regulate synaptic 
function probably through its role in RNA transport and local translation at the synapse 
where it is also part of the N-methyl-D-aspartate receptor NMDAR multiprotein complex 
(NRC) (Husi et al, 2000). One FUS target RNA transported along dendrites is the Nd1-L 
mRNA, which codes an actin-stabilizing protein (Fujii & Takumi, 2005). 
In addition to the conserved protein domain structure, the FET family members also share 
various protein functions in DNA/RNA processing (Tan & Manley, 2009). They all have 
important functions both in the nucleus and in the cytoplasm, for example pre-mRNA 
splicing and mRNA transport, respectively (Law et al, 2006; Tan & Manley, 2009). Also 
their nuclear import is regulated by PY-NLS (Lee et al, 2006; Marko et al, 2012; 
Zakaryan & Gehring, 2006). 
1.5.1.3. FUS animal models 
Animal models have been generated to better understand FUS physiological function and 
to evaluate potential pathomechanisms behind ALS/FTD-FUS. Two FUS knockout 
mouse (KO) lines show quite different phenotypes (Hicks et al, 2000; Kuroda et al, 
2000). Inbred KO mice die within a few hours postnatal, due to inability to suckle (Hicks 
et al, 2000) and outbred KO mice, although they do reach adulthood, show sterility in 
male mice (Kuroda et al, 2000). Both KO mouse lines show one common phenotype: 
genomic instability. Cells from inbred FUS KO mouse line showed an increased number 
of karyotypic aberrations (e.g. chromosome breakage) (Hicks et al, 2000) and the outbred 
FUS KO mice showed increased sensitivity to ionizing irradiation (Kuroda et al, 2000). 
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When cultured, FUS KO neurons show less mature spines and more filopodia-like 
dendritic protrusions than the control neurons (Fujii et al, 2005). 
 
Figure 4 FUS pathology in ALS/FTD-FUS, FUS protein structure and mutations 
FUS pathology in ALS-FUS and FTD-FUS cases. (A, left panel) FUS immunohistochemical 
staining of frontal cortex sections from a control individual or a FUS mutation carrier (ALS-
FUS). FUS staining in the control section shows normal nuclear localization (left). In contrast, the 
ALS-FUS section shows FUS cytoplasmic inclusions (right). Scale bar: 20μm. Adapted from 
(Kwiatkowski et al, 2009). (A, right panel) FUS immunohistochemical staining of neocortex 
sections from controls or aFTLD-U/FTD-FUS cases. The control staining shows normal FUS 
nuclear staining and weak cytoplasmic staining. FTD-FUS sections show FUS positive neuronal 
cytoplasmic inclusions (NCI) with oval shape and some of the affected cells show partial FUS 
nuclear clearence. Scale bar: control 20 µm, FTD-FUS 15 µm. Adapted from (Neumann et al, 
2009a). (B) FUS protein structure including domains responsible for its transcriptional activity 
(QGSY-rich domain, and G-rich domain) and DNA/RNA binding domains (RRM, RGG, ZnF and 
the C-terminal NLS). Below, is a schematic representation of the mutations known to cause ALS-
FUS. Note the prominent accumulation of mutations at the G-rich domain and the C-terminal 
NLS. Adapted from (Dormann & Haass, 2011). 
Also rat and mouse FUS overexpression models have been generated. Rats with inducible 
expression of mutant FUS (R521C) show strong motor deficits and neurodegeneration 
already at an early age (Huang et al, 2011). Interestingly, rat expressing wildtype human 
FUS, although asymptomatic at an early age, develop spatial learning and memory 
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deficiency at an advanced age (Huang et al, 2011). Overexpression of wildtype human 
FUS in mice is highly deleterious and the mice show severe paralysis and die after 12 
weeks. The pathology observed is reminiscent of the human FUS pathology (Mitchell et 
al, 2012). Recently, a mouse model expressing mutated FUS (R521C) was reported 
showing severe motor behavioral deficits and higher postnatal lethality (Qiu et al, 2014). 
Despite the deleterious effects of increased FUS expression, there is generally no FUS 
aggregation observed in the different models (Shelkovnikova, 2013). This raises the 
question of a missing additional stress factor needed to induce the aggregation and 
propagation cascade in the different animal models. Also FUS overexpression in non-
mammalian models as D. melanogaster (fruitfly) and C. elegans (worm) have 
demonstrated, although with some variation, that increased levels of wildtype or mutant 
FUS can cause decreased lifespan, cell loss and locomotor deficiencies, even in the 
absence of FUS aggregates (Chen et al, 2011; Lanson et al, 2011; Miguel et al, 2012; 
Shelkovnikova, 2013; Vaccaro et al, 2012; Xia et al, 2012). FUS knockout and 
overexpression models consequently demonstrate that a balanced FUS expression is 
required to maintain normal cellular function.  
1.5.1.4. The role of FUS in neurodegeneration 
RNA and protein homeostasis are the recurring themes constantly identified when 
evaluating the function of genes and proteins involved in neurodegeneration (Dormann & 
Haass, 2013; Renton et al, 2014; Thomas et al, 2013). In the case of FUS, the prominent 
clustering of mutations around the C-terminal part of the protein, which mislocalizes the 
protein to the cytoplasm, also offers clues on the pathomechanism behind ALS-FUS 
(Dormann et al, 2010; Kwiatkowski et al, 2009; Vance et al, 2009). However, FUS 
pathology is also observed in the absence of FUS mutations, for example in FTLD-FUS 
and HD cases, which indicates that other mechanisms can also cause disease. Disease 
could therefore result from a loss of FUS nuclear function or from a gain-of-toxic 
function of mislocalized FUS. Furthermore, based on the animal models presented above, 
the enigma about the origin and function of FUS aggregates in disease also gains 
relevance. Two mechanisms have been proposed for the origin of FUS aggregates. The 
first one includes a sequential development of inclusions starting from stress granules that 
at some point cannot longer be dissolved (Bentmann et al, 2013). The second mechanism 
proposes a sudden generation of aggregates due to an increase in local protein 
concentration. FUS protein that loses normal interaction with other proteins or RNA 
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could start a cascade of aberrant interactions resulting in aggregates (Ross & Poirier, 
2004; Shelkovnikova, 2013). The characteristic prion-like domain of FUS has been 
proposed to mediate its aggregation propensity in yeast models (Sun et al, 2011) and the 
in vitro formation of hydrogels (Kato et al, 2012). Importantly, the prion-like properties 
of FUS could also have a major role in cell-to-cell propagation of the disease (Gitler & 
Shorter, 2011; King et al, 2012; Ling et al, 2013). 
1.5.2. TAU 
1.5.2.1. TAU protein domain structure 
The TAU protein can be divided into a N-terminal projection domain and a microtubule 
binding domain close to the C-terminus (Mandelkow et al, 1996) (Figure 5A, Annex I). 
TAU binds to the outside of microtubules primarily with the microtubule binding 
domains and adjacent regions, which leaves the N- and C-terminal regions pointing 
outwards (Gustke et al, 1994; Kar et al, 2003; Santarella et al, 2004). The interaction with 
the microtubules is mediated by the positive net charge of the microtubule binding 
domains and the negative charge from the tubulin units.  
1.5.2.2. TAU protein function 
TAU can directly regulate transport along the highly polarized neurons (Dixit et al, 2008) 
by binding and stabilizing microtubules (Gustke et al, 1994; Weingarten et al, 1975). 
TAU is highly phosphorylated at sites that affect the microtubule binding affinity. The 
degree of phosphorylation together with the isoform abundance offers a delicate 
regulation of affinity to the microtubules. The projection domain of TAU has been shown 
to be responsible for the microtubule spacing (Al-Bassam et al, 2002; Chen et al, 1992; 
Frappier et al, 1994) and may affect cellular signaling by mediating interaction with the 
kinase Fyn (Morris et al, 2011). Additional functions attributed to TAU include the role 
as scaffolding protein in cell signaling mediated by multiple lipids and protein binding 
partners (Morris et al, 2011). TAU has also been proposed to mediate toxicity in cellular 
and mouse models of AD (Ballatore et al, 2007; Haass & Mandelkow, 2010; Ittner et al, 
2010), which provides an interesting pathomechanism that combines the roles of amyloid-
beta and TAU in AD. Research focusing on TAU’s multifaceted functions may contribute 
to a better understanding of its role in major neurodegenerative diseases, and as a result 
treatment opportunities could expand. 
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1.5.2.3. TAU/MAPT alternative splicing 
The TAU coding gene MAPT consists of 16 exons and is expressed in the central and 
peripheral nervous system, mainly in neurons. However, some TAU isoforms are also 
expressed in the skeletal muscle (Wei & Andreadis, 1998). In the brain, TAU protein is 
translated from six main transcripts generated by alternative splicing of exons 2 and 3, 
and exon 10 (Figure 5A). In the projection domain, inclusion of exon 2 only or exon 2 
and exon 3 introduces one or two short acidic regions (1N, 2N) (Figure 5A). Exon 10 
inclusion inserts a fourth microtubule binding domain (4R) at the C-terminal part of the 
protein. The combination of these splicing events leads to the six isoforms termed: 0N3R, 
1N3R, 2N3R, 0N4R, 1N4R, 2N4R (Figure 5A).  
MAPT alternative splicing is regulated tightly during development and expression shifts 
toward longer isoforms at mature age. The regulation of alternative splicing involves the 
interplay of cis- and trans-elements (Andreadis, 2012). The RNA-binding protein SRp75, 
for example, inhibits the splicing of exon 10 via its interaction with an intronic splicing 
silencer sequence downstream of exon 10 (Wang et al, 2011). Other factors do not bind 
RNA directly, but rather regulate splicing by binding other splicing factors. HnRNPG acts 
synergistically with SRp75 to regulate TAU exon 10 and, in contrast, this effect is 
antagonized by hnRNPE2 (Wang et al, 2011). Additionally, TAU splicing can also be 
regulated at the level of kinases that phosphorylate splicing factors and regulate their 
activity. One such example is the group of CDC2-like kinases CLK1, 2, 3, and 4 and 
CDK5 that regulate TAU exon 10 splicing (Hartmann et al, 2001). Although the exact 
target remains to be identified, a general change in phosphorylation status across different 
splice factors could mediate the effect (Hartmann et al, 2001). 
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Figure 5 MAPT/TAU genetic structure and disease causing mutations 
(A) Genetic structure of the human MAPT gene coding for the TAU protein. Exons 6 and 8 
(brown) are not expressed in the human brain, and exon 4a (violet) is only expressed in the 
peripheral nervous system. Exons 0 and 14 (white) are noncoding. Exons 2, 3 and 10 (red) are 
alternatively spliced and give rise to six different isoforms (0N3R, 0N4R, 1N3R, 1N4R, 2N3R, 
2N4R). Inclusion of E2 or E2/E3 adds one or two acidic regions (1N, 2N) in the projection 
domain (N-terminal part). Alternative splicing of E10 is regulated independently. Exons 9–12 
code for microtubule binding domains. Inclusion of E10 adds a fourth microtubule binding 
domain (4R). Taken from (Orozco & Edbauer, 2013). (B) Mutations in MAPT known to cause 
frontotemporal dementia and parkisonism linked to chromosome 17 (FTDP-17) are shown for the 
coding region in exons 1, 9-13 (lower part) and in the intronic regions flanking exon 10 (upper 
part). Note that the intronic region next to exon 10 is predicted to form a stem loop structure. 
Adapted from (Goedert & Spillantini, 2006). 
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1.6. The role of alternative splicing in neurodegeneration 
1.6.1. Mechanism and regulation alternative splicing  
Alternative splicing is the mechanism that, on the one hand, extends the diversity of the 
transcriptome and proteome and, on the other hand, offers a third level of regulation of 
protein homeostasis next to transcription and translation. Different protein isoforms, often 
with distinct functions, are transcribed from one single gene (Dredge et al, 2001; Li et al, 
2007; Licatalosi & Darnell, 2010). With this, it is possible to have tailored protein 
functions specific to each tissue and developmental stage. The high degree of diversity is 
best exemplified by the D. melanogaster Down syndrome cell adhesion molecule 
(DSCAM) gene, which is expressed in up to 38.016 different isoforms through alternative 
splicing of variable exon clusters. Different isoforms of DSCAM regulate the binding 
affinity in the crucial process of dendritic self-avoidance (homophilic repulsion) during 
neuronal development (Hattori et al, 2008). In the case of TAU, alternative splicing of 
exon 2, exon 3, and exon 10 result in 6 different isoforms. The expression of these 
isoforms is tightly regulated during development. 
Alternative splicing is regulated through a complex interplay of cis- and trans-acting 
elements. Cis-acting elements are, for example, splicing enhancer and inhibitory 
sequences within the pre-mRNA that recruit trans-acting RNA-binding proteins. 
Posttranscriptional modification of these trans-acting factors allows the integration of 
cellular signaling and the regulation of alternative splicing. Furthermore, the relative 
abundance of targeted transcript and regulatory factors also determines alternative 
splicing (Licatalosi & Darnell, 2010). A combination of biochemical methods, next-
generation sequencing and bioinformatics is currently being applied to unravel the 
regulatory code of alternative splicing (Licatalosi & Darnell, 2010).  
The human brain relies, more than other tissues, on alternative splicing to regulate 
expression, with more than 40% of the genes presenting one or more alternative splicing 
events, followed by the testis and the liver with <40% of genes spliced (Yeo et al, 2004).  
1.6.2. Alternative splicing in neurodegeneration 
The role of alternative spicing in neurodegeneration has repeatedly been demonstrated. In 
AD brains, for example, a recent study identified 3,014 mRNAs with altered splicing 
through an unbiased RNA sequencing approach (Bai et al, 2013). Additionally, 
pathogenic mutations affecting alternative splicing have been identified at the level of cis-
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acting elements or trans-acting factors (Keene, 2007). For example, mutations in the 
TAU gene MAPT located around the alternatively spliced exon 10 affect correct splicing 
and cause TAU aggregation (Hong et al, 1998). Mutations in the RNA-binding protein 
(trans-acting factor) survival motor neuron protein 1 (SMN1) cause spinal muscular 
atrophy (Cooper et al, 2009; Lorson & Androphy, 1998). SMN1 has an important role in 
the assembly of ribonucleoprotein complexes. Defects in alternative splicing or RNA 
transport are still discussed as pathomechanism behind SMA (Burghes & Beattie, 2009). 
Similar to SMN1, FUS could also affect different stages of alternative splicing in the 
disease. Understanding which targets are affected by FUS under normal and disease 
conditions would contribute to our understanding of the pathogenesis of ALS/FTD-FUS. 
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2. Aims of the Study 
 
The DNA/RNA-binding protein FUS is pathologically and genetically linked to ALS and 
FTD, however, the pathomechanism is still unclear (Kwiatkowski et al, 2009; Mackenzie 
et al, 2011a; Neumann et al, 2009a; Vance et al, 2009). The redistribution of nuclear FUS 
into the cytoplasm in ALS/FTD-FUS immediately suggests two potential 
pathomechanisms that are not mutually exclusive. On the one hand, loss of nuclear FUS 
function may have detrimental consequences for normal cell physiology. On the other 
hand, mislocalized cytoplasmic FUS may cause a toxic gain-of-function (Ling et al, 
2013).  
The aim of my thesis project was to evaluate the FUS loss-of-function component in 
ALS/FTD-FUS by focusing on mRNA splicing, because ample evidence supports a key 
role of FUS in alternative splicing, although no physiological splice target was known. 
First, FUS binds pre-mRNA directly (Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; 
Nakaya, 2013; Rogelj et al, 2012). Second, FUS is a known component of the 
spliceosome (Hartmuth et al, 2002; Rappsilber et al, 2002; Zhou et al, 2002) and third, it 
interacts with multiple splice factors (Gerbino et al, 2013; Meissner et al, 2003; Yang et 
al, 1998). Therefore, I aimed to identify physiological FUS splice targets. I focused on 
genes that are crucial to maintain normal neuronal function, such as the axonal protein 
TAU. Already slight alterations in the splicing of TAU affect the binding affinity for 
microtubules and mutations near the exon 10 splice site can cause FTD with TAU 
inclusions (Dredge et al, 2001; Liu & Gong, 2008). Finally, I asked how FUS loss-of- 
function in neurons affects axonal morphology and development.  
In summary, my aims for this thesis were: 
 to identify a physiological FUS splicing target in neurons and elucidate its regulation  
 to assess the impact of FUS pathogenic mutations on its function in alternative splicing 
 to validate the identified splice target in a human neuronal cell line 
 to evaluate functional consequences of FUS depletion in neurons and link them to 
ALS/FTD pathophysiology 
Together, these findings could help to understand the pathomechanisms of FUS related 
neurodegenerative disorders and elucidate therapeutic opportunities. 
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3. Materials and Methods  
3.1. Materials 
3.1.1. Equipment and tools 
3.1.1.1. General equipment 
Name Company 
Amaxa 4D-Nucleofector Lonza 
analytical balance (0.0001 – 200 g) Mettler-Toledo 
autoclave Systec 
automated Potter Multifix Record Johann Gg Bachhofer 
balance (0.01 – 2000 g) Mettler-Toledo 
Bunsen burner Heraeus 
CFX384 Real-Time System quantitative PCR Biorad 
CO2-incubator Thermo Scientific 
cooling centrifuge 5417R  Eppendorf 
digital sonifier 250 Branson 
DNA electrophoresis gel system Thermo Scientific 
Dynabeads magnet Life technologies 
film cassette G. Kisker 
film developer CaWo 
freezer (-20°C) Liebherr 
freezer (-80°C) Heraeus 
fridge  Santo electronic 
glassware  VWR 
heating block MR Hei-Tec Heidolph instrument 
hemocytometer Optik Labor 
hood for cell culture Heraeus 
incubator B. Braun Biotech International 
microsurgical instruments (Dumont forceps 
and scissors) 
FST 
microwave Sharp 
Milli Q plus filtration system Merck Millipore 
N2-tank Messer Griesheim 
Nano Drop Implen 
oven Memmert 
PCR thermal cycler  Eppendorf 
pH meter Thermo Scientific 
pipette boy Integra 
power suppliers Biorad, Major Science 
Powerwave XS plate reader BioTek 
protein electrophoresis gel system Bio-Rad 
rotors (TLA-55, SW28) Beckmann Coulter 
scanner Epson 
shaker Edmund Bühler GMBH 
thermomixer Eppendorf 
ultracentrifuge Beckmann Coulter 
UV crosslinker StrataLinker 1800 Stratagene 
UV lamp Intas 
vortex Scientific Industries 
water bath GFL 
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3.1.1.2. Microscope equipment 
Name Company 
confocal laser scanning microscope  
(LSM510, LSM 710) 
Zeiss 
epifluorescence microscope (Axiovert.A2) Zeiss 
Immersol 518 F Zeiss 
light microscope (Wilovert S) Hund Wetzlar 
microscope cover glasses (18 mm, 20 mm) VWR 
microscope slides Superfrost plus  Thermo Scientific 
objective (Plan Apochromat, 40x/1.4 oil DIC) Zeiss 
objective (Plan Apochromat, 63x/1.4 oil DIC) Zeiss 
phase contrast microscope (CKX41) Olympus 
Vectashield H-1000 mounting medium Vectorlabs 
 
3.1.1.3. Consumables  
Name Company 
cell culture dish (3.5 cm, 6 cm, 10 cm) Nunc 
cell culture plate (12 well, 96 well) Nunc 
centrifuge tubes (1.5 ml for TLA-55) Beckmann Coulter 
centrifuge tubes for rotor SW28 Beckmann Coulter 
filter paper Schleicher & Schüll 
gloves (Latex) Semperit 
gloves (Nitrile) Meditrade 
hard shell PCR plates 384-well  BioRad 
Immobilon-P membrane, PVDF, 0.45 µM Merck Millipore 
nitrocellulose membran GE Healthcare 
parafilm “M“ Pechiney Plastic Packaging 
PCR tubes, strips, 96 well plates Sarstedt  
PES membrane filter (0.45 µm) VWR International 
pH indicator strips Merck Millipore 
pipette tips (10 µl, 200 µl, 1000 µl) Sarstedt, VWR 
pipettes Gilson, Raynon 
serological pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt 
tubes (1.5 ml, 2 ml) Sarstedt 
tubes (15 ml, 50 ml) Sarstedt 
X-ray films Fuji 
 
3.1.1.4. List of software and online tools  
Name Company/Link 
Adobe Illustrator Adobe Systems 
APE Wayne Davis 
AxioVision Zeiss 
BioRad CFX manager  BioRad 
BLAST NCBI, 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web
&PAGE_TYPE=BlastHome 
CLC bio CLC bio 
Ensembl EMBL-EBI, Sanger Centre 
http://www.ensembl.org/index.html 
GraphPad Prism GraphPad Software, Inc 
ImageJ NIH 
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iScore designer KAKENHI, http://www.med.nagoya-
u.ac.jp/neurogenetics/i_Score/i_score.html 
LSM Zeiss 
NCBI http://www.ncbi.nlm.nih.gov/ 
Primer3 Whitehead Institute for Biomedical Research, 
http://bioinfo.ut.ee/primer3/ 
Spidey NCBI, http://www.ncbi.nlm.nih.gov/spidey/ 
 
3.1.1.5. List of services 
Name Company 
antibody production Eurogentec 
DNA sequencing GATC Biotech 
oligonucleotide synthesis Sigma-Aldrich 
 
3.1.2. Chemicals 
3.1.2.1. General chemicals 
Name Company 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) 
Biomol 
acrylamide (19:1 / 40 % (w/v)) Bio-Rad 
agarose ultrapure Life Technologies 
ammonium persulfate (APS) Roche 
ampicillin Boehringer Mannheum 
boric acid Merck Millipore 
bovine serum albumin Sigma-Aldrich 
bromophenol blue Merck Millipore 
CaCl2 AppliChem 
DMSO Roth 
DTT Biomol 
ECL Thermo Scientific 
ECL plus Thermo Scientific 
EDTA USB 
EGTA Sigma-Aldrich 
ethanol Sigma-Aldrich 
ethidiumbromide ROTH 
fish gelatin Sigma-Aldrich 
gelatin Sigma-Aldrich 
glutaraldehyde Sigma-Aldrich 
glycerol USB 
glycine Biomol 
I-Block Tropix 
IPTG ROTH 
isopropanol Merck Millipore 
kanamycine ROTH 
KCl USB 
KH2PO4 Merck Millipore 
methanol Merck Millipore 
MgSO4 Sigma-Aldrich 
Na2[B4O5(OH)4] Sigma-Aldrich 
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Na2HPO4 Merck Millipore 
NaCl Merck Millipore 
NaH2PO4 Sigma-Aldrich 
NaHCO3 Merck Millipore 
NaN3 Merck Millipore 
NaOH Merck Millipore 
NH4HCO3 Merck Millipore 
N-N’-Methylene-bisacrylamide 
(bisacrylamide) 
SERVA 
paraformaldehyde Sigma-Aldrich 
PIPES Sigma-Aldrich 
sodium borate decahydrate (Borax) Sigma-Aldrich 
sodium deoxycholate  Sigma-Aldrich 
sodium dodecyl sulfate (SDS) Roth 
staurosporine Sigma-Aldrich 
suberic acid bis(3-sulfo-N-hydroxysuccinimide 
ester) sodium salt (BS3) 
Sigma-Aldrich 
sucrose Sigma-Aldrich 
tetramethylethylenediamine (TEMED) USB 
TO-PRO-3 Life Technologies 
tris base AppliChem 
Triton X100 Merck Millipore 
tryptone BD Biosciences 
yeast extract BD Biosciences 
β-mercaptoethanol ROTH 
 
3.1.2.2. List of kits  
Name Company 
DNase digest kit Qiagen 
Electrophoretic Mobility-Shift Assay (EMSA) 
Kit with SYBR® Green & SYPRO® Ruby  
Molecular Probes 
 
endofree plasmid Maxi kit Qiagen 
Gel and PCR clean-up kit Macherey-Nagel 
MAXIscript T7 in vitro transcription kit  Ambion 
neurons nucleoporation kit 
primary culture kit P3 amaxa 
Lonza 
NucleoBond Xtra Midi EF Macherey-Nagel 
Nucleospin Plasmid kit Macherey-Nagel 
Red/ET system Gene Bridges 
RNeasy Mini Kit  Qiagen 
RT-PCR kit 
TaqMan MicroRNA Reverse Transcription Kit 
Applied Biosystems 
SsoFast™ EvaGreen® Supermix BioRad 
XTT assay Roche 
 
3.1.3. Molecular Biology and Biochemistry 
3.1.3.1. General reagents 
Name Company 
biotin-16-UTP Roche 
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calf-intestinal alkaline phosphatase (CIP) NEB 
DNA ladder Life Technologies 
DNA polymerase (Pfu Ultra II Fusion) Agilent 
DNA polymerase (Pfu) Agilent 
DNA polymerase (Pwo) PEQLAB Biotechnologie 
DNA polymerase (Taq) Roche Applied Science 
deoxyribonucleotides (dNTPs) Roche Applied Sciences 
glutathion sepharose 4B GE Healthcare 
lysozyme Merck Millipore 
phosphatase inhibitor Sigma-Aldrich 
Protein A sepharose beads GE Healthcare 
Protein G Dynabeads  Life Technologies 
proteinase inhibitor Sigma-Aldrich 
restriction enzymes NEB 
RNA Later Ambion 
RNAse A Sigma-Aldrich 
SeaBlue Prestained Protein Ladder Plus2 Life Technologies 
Streptavidin-Peroxidase Sigma-Aldrich 
SUPERase RNase inhibitor Ambion 
T4-Ligase NEB 
 
3.1.3.2. List of antibodies 
Name Company 
3R TAU, clone 8E6/C11 Millipore 
4R TAU, clone 1E1/A6 Millipore 
acetylated tubulin, clone 6-11B-1 Sigma-Aldrich 
actin, clone AC-15 Sigma-Aldrich 
Alexa secondary antibodies Life Technologies 
anti-mouse HRP Promega 
anti-rabbit HRP Promega 
anti-rat HRP Santa Cruz Biotechnology 
EWS Santa Cruz Biotechnology 
FUS, clone A300-292A Bethyl 
GFP Neuromab, Fitzgerald Industries International 
GluR2, clone L21/32 Neuromab 
HA, clone 3F10 Roche 
MAP2, AP-20  Sigma-Aldrich 
NR1, clone 54.1 BD 
NR2A, clone PRB-513P Covance 
Phalloidin Life Technologies 
PSD-95, clone K28/43 Neuromab 
streptavidin HRP Sigma-Aldrich 
synaptophysin, clone SY38 Millipore 
TAU, clone A 0024 Dako 
Tau1, clone PC1C6 Millipore 
TDP-43 Sigma-Aldrich 
tubulin beta 3, SDL.3D10 Sigma-Aldrich 
tubulin beta 3, Tuj1 Covance 
tyrosinated tubulin, clone YL1/2 Abcam 
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3.1.3.3. Cloning vectors and oligonucleotides 
Cloning vectors 
Name Company 
FUW lentivirus vector Lois et al (Lois et al, 2002) 
mouse MAPT genomic BAC Imagenes 
pBUD-CE4 Invitrogen 
pCR-blunt2 TOPO Invitrogen 
pGEM3 Promega 
pSUPER Oligoengine 
 
List of oligonucleotide sequences for shRNA cloning 
The target sequence is marked in bold. Oligonucleotides were cloned in pSuper using 
BglII/HindIII. 
Name Species Sequence sense 
shC9orf72 mr gatccccGGATGGAAGATCAGGGTCAttcaagagaTGACCCTGATCTTCCATCCt
ttttggaaa 
shEWS hmr gatccccCAGCAGAGTTCATTCCGACttcaagagaGTCGGAATGAACTCTGCTGt
ttttggaaa 
shFUS #1 mr gatccccGTGCAAGGCCTAGGCGAtAttcaagagaTCTCGCCTAGGCCTTGCACt
ttttggaaa 
shFUS #2 mr gatccccGGCCTAGGCGAGAATGTTAttcaagagaTAACATTCTCGCCTAGGCCt
ttttggaaa 
sh-hFUS h gatccccGGACAGCAGCAAAGCTATGttcaagagaCATAGCTTTGCTGCTGTCCt
ttttggaaa 
shLuc - gatccccCGTACGCGGAATACTTCGAttcaagagaTCGAAGTATTCCGCGTACGt
ttttggaaa 
shTAF15 mr gatccccTATGATGAGCAGTCCAATTATttcaagagaATAATTGGACTGCTCATC
ATAtttttggaaa 
shTDP mr gatccccGTAGATGTCTTCATTCCCAAAttcaagagaTTTGGGAATGAAGACATC
TACtttttggaaa 
h= human, m= mouse, r= rat 
 
List of primers for cloning 
Name Species sense antisense 
GAPDH e3 m atgGAATTCtcagctcccctgttt
cttgtctttca 
gatTCTAGAaccttcagctttccg
gccacttac 
GAPDH e5 m atgGAATTCcctcactcattgccc
ccgtgtttt 
gatGCTAGCactgtcacaccagag
acaagccca 
HA-FUS* 
mutagenesis 3’ 
h GGCCTGGGTGAaAAcGTgAcaatt
gagtctgtggctg 
gaGATATCTTAATACGGCCTCTCC
CTtCGgTCtTGcCTGTGCTCACCC
CTGGAA 
HA-FUS* 
mutagenesis 5’ 
h gaggatccGCGGACATGTACCCAT
ACGACGTC 
caattgTcACgTTtTCACCCAGGC
Cttgcacaaagatgg 
MAPT exon 1-4  m gtgtaatctccagcatggtcttcc
attgtgtcaaactcctggcgaggg
tcagcCAGGTCCTCCTCCGAGATA
AGCTTCTGCTC 
catcggagacaccccgaaccagga
ggaccaagccgctgggcatgtgac
tcaaACGCGTTACCCATACGACGT
CCCAGACTAC 
MAPT exon 9-11 m caatcttcgacctgacattcttta
ggtctggcatgggcacaggggcag
tctgcagCAGGTCCTCCTCCGAGA
TAAGCTTCTGCTC 
gagcaaagtgacctccaagtgtgg
ctcgttagggaacatccatcacaa
gccaACGCGTTACCCATACGACGT
CCCAGACTAC 
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TAU e10 m atgGAATTCgccatcccaggcagc
ttctgagc 
gatTCTAGAggaacagggagggga
gtctgggg 
TAU e11 m atgGAATTCgcagcagctgatggg
agccactg 
gatTCTAGAagacccaggtccaag
gccacaca 
TAU e3 m atgGAATTCcactccttgcactgc
ccctgcat 
gatTCTAGAtgcacccgactatga
gggtgacct 
TAU e9 m atgGAATTCctcagggactttgca
gacgccgc 
gatTCTAGAtactggctaggtggg
agtctggct 
TAU i10-1 m atgGAATTCgctgcagtgcctagg
gtatcaggga 
gatTCTAGAtagatcccacagagc
agcccgagag 
TAU i10-2 m atgGAATTCtccactgGGtgtcAT
Tggcctttca 
gatTCTAGACCACCggcttgtaga
ctatttgcaCCt 
TAU i10-3 m atgGAATTCtgcaggggtgggctc
tctttcct 
gatTCTAGAgtagccaacagcccc
gcctttcc 
TAU i2-1 m atgGAATTCctgaacatggcttgg
gcattctgtt 
gatTCTAGAcctgccccagctttg
gctcc 
TAU i9-1 m atgGAATTCaggaatgacagcctg
tttctacacct 
gatTCTAGAacacctttgaaggag
aaagatgaagtctttga 
TAU i9-2 m atgGAATTCaccgtgtgcgattgc
ttaatgtcct 
gatTCTAGATgctattttgaggcg
gggtctctct 
TAU i9-3 m atgGAATTCaaggtcgatctccac
cacaggcaaa 
gatTCTAGAccatctcaccagacc
caagcccttt 
TAU i9-4 m atgGAATTCTaggttggggcttgt
cactagaggg 
ataGTCGACggcacacactattcc
tggagccaca 
TAU i9-5 m atgGAATTCagtcaggcATTgaaG
GTGGtgcaga 
ataGTCGACgtgcttggtgagagg
acgcaggAAT 
TAU i9-6 m atgGAATTCtcttggcccactcac
agttgttgct 
ataGTCGACtcccggaagccAATg
aggaaaaagga 
TAU isoforms r atggctAGCAGCATGGCTGAACCC
CGCCAGGAG 
catgaattcTCACAAACCCTGCTT
GGCCAAAGAGGCGG 
h= human, m= mouse, r= rat 
 
3.1.3.4. List of qPCR primers  
Name Species sense antisense 
0N TAU r ccatggcttaaaaGCtgaaga cctgtcctgtctttgcttacg 
0N TAU h cgaagtgatggaagatcacg ctgcttcttcagctttcagg 
1N TAU r tgctgaaGCtgaagaagcag cctgtcctgtctttgcttacg 
1N TAU h aagaccaagagggtgacacg cttcttcagcttccgctgtt 
2N TAU r gaagagagagctcccgacaa cagcttggtcctccatgttc 
2N TAU h tgtgacagcacccttagtgg tctccaatgcctgcttcttc 
3R TAU r gcggcaaGGtgcaaatagt acgatttctgctccatggtc 
3R TAU h gtccgtactccacccaagtc ggtttgtagactatttgcaccttc 
4R endpoint PCR mr gcactccccctaagtcacc ctggcttgtgatggatgttc 
4R TAU m/r aagaagctggatcttagcaacg ctggcttgtgatggatgttc 
4R TAU h aagatcggctccactgagaa cacacttggactggacgttg 
C9orf72 mr ccagaaaattgtcttggaagg cagctgtcaccaatgtcatca 
EWS hmr cccagcctaggatatggaca ctgcccatagctgctttgtt 
FUS m/r ctggcaagttgaagggtgaggc gctcgttgctgtcctccacctc 
FUS h acggacacttcaggctatgg tagccagggtaggaggactg 
GAPDH m/r ccgcatcttcttgtgcagtgcc agactccacgacatactcagcacc 
pre-mRNA GAPDH 
exon 4 
m tctgaaatcaacttctttccctta tgtctccccactgcctacat 
pre-mRNA TAU 
exon 10 
m ctccggtgtggttgtctctc agcacacctcatggagactg 
SON m/r tcttctcagcttgctctgga caggcaaaggtccctctatg 
TAF15 hmr acttggggagggtgtgtcta tcaatggctgccttagctg 
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TDP-43 m/r agtgttgggtctcccctggaaa acagtcacaccatcgcccatct 
total TAU m/r tccagtcgaagattggctccttgg aggtgccgtggagatgtgtccc 
total TAU h tccagtcgaagattgggtccctgg agatgccgtggagacgtgtccc 
YWHAZ m/r tgagcagaagacggaaggtgctg tctgatggggtgtgtcggctgc 
YWHAZ h ttcttgatccccaatgcttc aggctttctctggggagttc 
h= human, m= mouse, r= rat 
 
3.1.4. Cell culture 
3.1.4.1. Cell culture reagents  
Name Company 
B27 supplement Life Technologies 
basic fibroblast growth factor (bFGF) R&D 
bovine serum albumin Sigma-Aldrich 
dibutyril cAMP (dcAMP) Sigma-Aldrich 
DMEM glutamax-I Life Technologies 
DMEM/F12 Lonza 
DNAse Sigma-Aldrich 
fetal bovine serum Life Technologies 
fibronectin Sigma-Aldrich 
glial cell-derived neurotrophic factor (GDNF) R&D 
laminin Roche Applied Science 
L-glutamate Sigma-Aldrich 
L-glutamine Sigma-Aldrich 
Lipofectamine 2000 Life Technologies 
N2 supplement Invitrogen 
Neurobasal Life Technologies 
non-essential amino acids (NEAA) Life Technologies 
OptiMEM Life Technologies 
penicillin/streptomycin Life Technologies 
poly-D-lysine (PDL) Sigma-Aldrich 
poly-L-lysine (PLL) Sigma-Aldrich 
tetracycline Sigma-Aldrich 
trypsin (2.5 %) Life Technologies 
trypsin-EDTA Life Technologies 
 
 
3.1.4.2. List of cell lines and bacteria strains  
Name Company 
DH5α – E. coli competent cells Life Technologies 
HEK 293-FT Life Technologies 
LUHMES (Lotharius et al, 2002; Lotharius et al, 2005; 
Scholz et al, 2011) 
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3.1.5. Buffers and Media 
All buffers are prepared with dH2O unless otherwise specified. 
 
3.1.5.1. Protein biochemistry  
Name Composition 
4x Laemmli buffer 4% SDS  
20% glycerol  
5% β-mercaptoethanol  
200 mM Na2HPO4 
bromophenol blue 
adjust to pH 7.4 
4x SDS PAGE running gel 1.5 M Tris base 
0.4 % (w/v) SDS 
adjust to pH 8.8 
4x SDS PAGE stacking gel 0.5 M Tris base 
0.4 % (w/v) SDS 
adjust to pH 6.8 
acrylamide-Schägger buffer 49.5% acrylamide 
3% bisacrylamide 
anode buffer 0.2 M Tris-HCl 
adjust to pH 8.9 
blotting buffer 25 mM Tris  
0.2 M Glycine 
cathode buffer 0.1 M Tris-HCl 
0.1 M Tricine 
0.1% SDS 
I-block buffer 0.2% I-block in TBSTx  
IP lysis buffer (TNE 450) 20 mM Tris–HCl, pH 7.4  
450 mM NaCl 
0.1 mM EDTA 
1.5 mM MgCl2  
1 mM CaCl2 
0.6% Triton X-100 
IP lysis buffer no salt (TNE 0) 20 mM Tris–HCl, pH 7.4 
0.1 mM EDTA 
1.5 mM MgCl2 
1 mM CaCl2 
0.6% Triton X-100 
RIPA buffer 137 mM NaCl 
20 mM Tris, pH 7.5 
0.1% SDS 
10% glycerol 
1% Triton X-100 
0.5% sodium deoxycholate 
2 mM EDTA 
SDS PAGE running buffer 1x with SDS 25 mM Tris 
0.2 M Glycine 
0.1% SDS 
separating gel buffer 1.5 M Tris  
0.4% (w/v) SDS 
adjust to pH 8.8 
 
Materials and Methods 
52 
stacking gel buffer 0.5 M Tris 
0.4 % (w/v) SDS 
adjust to pH 6.8 
TBSTx 20 mM Tris 
0.14 M NaCl 
0.2% Triton X-100 
adjust to pH 7.6 
tricine-Schägger gel buffer 3 M Tris-HCl 
0.3% SDS 
adjust to pH 8.45 
 
3.1.5.2. Antibody purification  
Name Composition 
100x lysozyme stock 20 mg/mL lysozyme stock in STE buffer 
100x NaN3 for antibody dilutions 10% NaN3 
acid elution buffer  
 
0.1 M Glycine-HCl 
150 mM NaCl 
adjust to pH 2.5 
BS3 stock solution (25mM) 
 
25 mg suberic acid bis(3-sulfo-N-
hydroxysuccinimide ester) sodium salt (BS3) 
in 1.75 mL 20mM sodium phosphate buffer 
adjust to pH 7.4 
column wash buffer 
 
0.2 M Tris-HCl 
0.5 M NaCl 
adjust to pH 8 
conjugation buffer  20 mM sodium phosphate Na2HPO4 
0.15 M NaCl 
adjust to pH 8 
neutralization buffer  
 
1 M Tris, 
adjust to pH 9.5 
quenching buffer for antibody purification 
 
1 M Tris 
adjust to pH 7.5 
STE 
 
10 mM Tris-HCl 
150 mM NaCl 
1 mM EDTA 
adjust pH 8 
 
3.1.5.3. Immunofluorescence  
Name Composition 
2x GDB 0.2% gelatin powder 
0.33 M Na2HPO4 
0.9 M NaCl 
0.6% Triton X-100 
adjust to pH 7.4 
immunofluorescence blocking buffer  2% fetal bovine serum 
2% bovine serum albumin 
0.2% fish gelatin  
dissolved in PBS 
permeabilization/quenching buffer for nuclear 
proteins 
0.2% Triton X-100 
50 mM NH4Cl 
dissolved in PBS 
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PFA-fix 4 % PFA 
0.15 mM NaOH 
0.13 mM NaH2PO4 sodium phosphate 
monobasic 
0.12 mM sucrose 
adjust to pH 7.5 
PHEM buffer 60 mM PIPES 
25 mM HEPES 
10 mM EGTA 
2 mM MgCl2 
adjust to pH 6.9 
PHEM fixative 3.7% (w/v) PFA/sucrose 
0.25% (w/v) glutaraldehyde 
0.1% (v/v) Triton X-100 
dissolved in PHEM buffer 
 
 
3.1.5.4. DNA Biochemistry  
Name Composition 
20x SB agarose gel buffer (100mM) 38.17 g sodium borate decahydrate (Borax) 
33 g boric acid  
1L dH2O  
adjust to pH 8.0 
5x DNA loading buffer  
 
50 % glycerol 
50 mM Na2EDTA 
0.05 % bromophenol blue  
adjust to pH 8.0 
 
3.1.5.5. Cell and bacterial culture  
Name Composition 
borate buffer 40 mM boric acid 
10 mM sodium tetra borate Na2B4O7·10H2O 
adjust to pH 8.5 
coating solution for cover glasses  1.5% PDL 
0.5% Laminin 
dissolve in borat buffer 
coating solution for plastic culture plates 1.5 % PDL 
dissolve in borat buffer 
cortical primary neurons medium  0.25% L-Glutamine (200 mM stock) 
2% B27 
1% penicillin/streptomycin 
in Neurobasal medium 
HBSS 0.14 M NaCl 
5.4 mM KCl 
0.25 mM Na2HPO4 
5.6 mM glucose 
0.44 mM KH2PO4 
1.3 mM CaCl2 
1.0 mM MgSO4 
4.2 mM NaHCO3 
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HEK 293-FT cells medium 1% penicillin/streptomycin 
1% NEAA 
10% FCS 
in DMEM Glutamax 
high BSA HEK medium 6.4% high BSA stock in HEK medium 
prepare fresh 
high BSA stock 20% BSA in DMEM medium 
sterile filter 
hippocampal primary neurons medium 2% B27 
0.25% L-Glutamine (200 mM stock) 
0.125% L-Glutamate (10 mM stock) 
1% penicillin/streptomycin 
in Neurobasal medium 
LB agar 1.5% agar  
dissolve in LB medium 
LB medium 1% tryptone 
0.5% yeast extract 
86 mM NaCl 
LUHMES differentiation medium 1 µg/mL tetracycline 
2 ng/mL GDNF 
0.49 mg/mL dcAMP 
1% N2 supplement 
1% penicillin/streptomycin 
in DMEM/F12 medium 
LUHMES growth medium 1% N2 supplement 
0.04 µg/mL bFGF 
1% penicillin/streptomycin 
in DMEM/F12 medium  
phosphate-buffered saline (PBS) 0.14 M NaCl 
10 mM Na2HPO4 
2.8 mM KH2PO4 
2.7 mM KCl 
ajust to pH 7.4 
poly-D-lysine stock 10 mg/mL  
in borate buffer 
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3.2. Methods 
3.2.1. Biochemistry 
3.2.1.1. Protein biochemistry  
Neuron lysates 
Protein lysates from primary neuronal culture were prepared by adding 2x Laemmli 
buffer directly to the culture dish after washing once with PBS. Samples were then boiled 
at 95°C for 10 min and used immediately or frozen for storage.   
HEK 293-FT lysates and LUHMES lysates 
Protein lysates from HEK 293-FT cells or LUHMES cells were prepared with cold RIPA 
buffer supplemented with proteinase and phosphatase inhibitors. After washing the 
culture dish once with PBS, RIPA buffer was added directly to the cells and the plate was 
incubated 15 min on ice. The lysate was centrifuged for 15 min at 17 000 g. The 
supernatant was mixed with 1/3 volume of 4x Laemmli buffer. Samples were boiled at  
95 °C for 10 min and used immediately or frozen for storage. 
SDS PAGE 
10% acrylamide gels with a 4% stacking gel were prepared by mixing the following 
components (for 4 gels): 
4% stacking gel 6.5 mL H2O  
2.5 mL stacking buffer 
1 mL acrylamide 
10% separating gel 10 mL H2O  
5 mL running buffer  
5 mL acrylamide 
 
The gels were polymerized by adding 100μL APS and 10μL TEMED for 10mL mixture. 
After complete polymerization, the samples were loaded and the gel was run first at 90V, 
and afterwards at 120V after the samples formed a single front. The gel was then blotted 
onto a PVDF or nitrocellulose membrane with a wet blotting chamber at 400 mA for 1 
hour. After blotting, the membranes were blocked with blocking buffer (0.2% I-block in 
TBST) while shaking at room temperature (RT) for 1 hour.  
The membranes were incubated overnight with the first antibody in blocking buffer while 
shaking at 4°C. On the next day, the membranes were washed for at least one hour 
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extensively with TBSTx before and after incubation with the secondary antibody. ECL or 
ECL plus was used following the manufacturer’s instructions to develop the membranes. 
Tricine-SDS-Schägger Gels 
The tricine-SDS gels, developed by Schägger et al (Schägger & Von Jagow, 1987), were 
used here to detect proteins below 20 kDa. The following solutions are used: 
4% stacking gel 2.1 mL H2O  
0.775 mL tricine-Schägger gel buffer 
0.25 mL acrylamide Schägger buffer 
16.5% running gel 1.75 mL 32% glycerol 
1.75 mL tricine-Schägger gel buffer 
1.75 mL acrylamide Schägger buffer 
10% running gel 1.75 mL H2O 
1.25 mL tricine-Schägger gel buffer 
0.75 mL acrylamide Schägger buffer 
 
The gradient in the running gel was prepared by adding APS and TEMED and overlaying 
16.5% acrylamide solution with the 10% acrylamide solution. The acrylamide solutions 
were let to polymerize together. A 4% acrylamide solution was used for the stacking gel. 
To run the gels, the cathode buffer (inner chamber) and anode buffer (bottom chamber) 
were filled accordingly in the gel chamber without mixing. In order to increase the 
detection of small proteins, a nitrocellulose membrane was used for the transfer. After 
completion of the transfer, the nitrocellulose membrane was heated to 95°C in PBS for 5 
min. The membrane was then blocked and used as described above. 
3.2.1.2. RNA binding assay  
In vitro transcription (IT) 
To generate RNA probes for the crosslinking experiments, the DNA plasmids were first 
linearized with a single cutter restriction enzyme for several hours. A small amount of 
DNA was visualized with an agarose gel to confirm the completion of the reaction. The 
linearized plasmid was in vitro transcribed using the MAXIscript T7 kit with biotin-16-
UTP to label the RNA according to the manufacturer's instructions. The RNA probes 
were visualized in acrylamide gels with SYBR® Green (Molecular Probes) to assess the 
reaction and semi-quantify the product.  
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FUS immunoprecipitation and RNA extraction (RIP) 
For the immunoprecipiation of endogenous FUS from mouse brain (P15), the brains were 
homogenized with a potter homogenizer in 2 mL IP lysis buffer (TNE 450) containing 
RNase inhibitor SUPERase-In (1 U/mL) and protease and phosphatase inhibitor cocktail. 
The lysate was centrifuged for 20 min at 70 000 g at 4°C in a TLA55 rotor to clear the 
sample. The supernatant was immunoprecipitated for 1 hour at 4°C with Dynabeads 
Protein G that had been previously coupled to FUS or GST antibody (3 µg antibody/25 
µL beads). After immunoprecipitation, the beads were washed four times with lysis 
buffer. The bound RNA was then extracted with the RNeasy mini kit including the 
optional DNase treatment step. RNA and protein samples were collected accordingly 
during the process to compare input and IP samples. RNA samples were further analyzed 
with quantitative PCR and the Ct values of the IP samples were compared to the Ct values 
of the input to determine the percentage of recovery. 
Crosslinking binding assay of FUS to TAU pre-mRNA probes 
As in the FUS immunoprecipitation, the RNA binding assay is used to test the binding of 
endogenous mouse FUS to RNA. However, in this case, the lysate is incubated with 
labeled RNA probes prior to the immunoprecipitation. First, the mouse brains were 
homogenized as described above, however in the absence of RNase inhibitor. The lysate 
was centrifuged for 20 min at 70,000 g as described above, except that the supernatant 
was diluted with 2 volumes of lysis buffer lacking salt (TNE 0) to allow binding of 
protein to the RNA probes. In order to clear the lysate from endogenous biotinylated 
proteins, the lysate was incubated with streptavidin agarose before adding the RNA 
probes. After clearing, protein extracts (500 µg) were incubated with biotinylated RNA 
probes (4 µl of a 20 µL IT reaction) at RT for 30 min. The samples were crosslinked on 
ice with ultraviolet light irradiation at 254 nm, 400 mJ/cm
2
 with a StrataLinker 1800 and 
then treated with RNase A (10 mg/ml) for 15 min to digest unprotected RNA. After 
RNAse digestion, the samples were subjected to immunoprecipitation with FUS or GST 
antibodies as detailed above. The eluted protein samples were loaded on a SDS-PAGE gel 
and biotinylated RNA crosslinked to FUS was detected using streptavidin-peroxidase.  
3.2.1.3. 2N TAU antibody purification 
A 2N TAU specific polyclonal rabbit antibody was generated by immunizing rabbits with 
a GST-TAU exon 3 antigen (sequence DVTAPLVEERAPDKQATAQSHTEIPEGTTA). 
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The antibody was then purified from the rabbit final bleed in two steps, first negative 
selection against GST followed by positive selection against GST-TAU exon 3 and 
elution from the purification column. The GST and GST-TAU exon 3 antigens were 
produced in bacteria induced with IPTG and extracted by disrupting the bacteria with 
lysozyme (100 µg/mL), 5 mM DTT and 1% Triton X-100 followed by short sonication. 
The extracts were incubated with glutathion-beads for 30 min and washed with 
conjugation buffer before crosslinking with BS3 for 45 min at RT. After quenching with 
50 mM Tris buffer, the unbound GST fraction was eluted with acid elution buffer. The 
GST-Glutathion beads were loaded on a column for removal of anti-GST antibodies by 
negative selection. The diluted rabbit serum was passed three times through the column, 
the flow through being collected and reused each time. The negative selected serum, 
depleted from anti-GST antibodies, was then transferred to a column for the positive 
selection with GST-TAU exon 3 Glutathion beads. After several washes, the antibody 
was eluted in 1 mL fractions with elution buffer. The fractions were immediately 
neutralized with Tris buffer pH 9.5. The antibody concentration was determined and the 
fractions with the highest concentration were pooled. The antibody was tested by 
immunoblotting for specificity.  
3.2.2. Molecular Biology 
3.2.2.1. Molecular cloning  
Standard bacterial transformation  
Competent E. coli bacteria (eg. DH5α) were thawed on ice. The ligation reaction (see 
below) or 1µL of the plasmid to be re-transformed were incubated with 100 µL bacteria 
on ice for 20 min. A heat shock was then performed for 45 sec at 42°C to promote take-
up of the DNA. After adding 400µL LB medium without antibiotics, the mixture was 
incubated for 1h at 37°C with slow shaking. The small bacteria culture was finally plated 
on agarose LB plate containing the adequate antibiotics.  
Subcloning 
For subcloning, 3 µg of a plasmid containing the insert of interest was digested with 
enzymes that digest both ends usually for 1h at 37°C in the corresponding NEB buffer. 
Whenever possible, the reaction was stopped with a heat kill at 65°C for 20 min. The 
insert was isolated with agarose gel electrophoresis, the corresponding band cut out of the 
gel and extracted with a Gel Extraction kit (Macherey-Nagel). The backbone was 
Materials and Methods 
59 
prepared in the same way, except for an extra dephosphorylation step after the enzyme 
digestion. For this, the same reaction was further mixed with new NEB buffer and the 
phosphatase CIP and incubated for 1h at 37°C. A second heat kill was performed to stop 
the reaction. The backbone was then isolated with agarose gel electrophoresis as 
described above. Insert and backbone were ligated with T4 DNA ligase for >30 min at 
RT. The reaction was then transformed in competent bacteria, as detailed above.  
Cloning with oligonucleotides  
In order to clone oligonucleotides, for example for shRNAs, oligonucleotides were first 
dissolved in H2O to a concentration of 100 µM. They were then annealed by mixing 1µL 
of each forward and reverse oligonucleotide, with NEB buffer 4 and H2O. The reaction 
was heated to 95°C for 4 min and then let to cool down at RT. The backbone was 
prepared by digesting the plasmid with the corresponding enzymes, but without 
dephosphorylation of the ends. The annealed oligonucleotides were then ligated with the 
digested backbone using T4 DNA ligase for 1h at RT. In case the restriction sites were 
destroyed by correct oligo insertion, an extra digest was performed before bacteria 
transformation to exclude empty re-ligated backbones. The reaction was then transformed 
as usual in competent bacteria.  
shRNAs were cloned into a pSUPER backbone and then subcloned into a FUW lentivirus 
packaging vector (FU2) co-expressing mCherry or TagRFP from the human ubiquitin C 
promoter. 25 nucleotide long oligonucleotides were designed by assigning a specific seed 
region generally unique to the target using the iScore designer (http://www.med.nagoya-
u.ac.jp/neurogenetics/i_Score/i_score.html) and the BLAST web tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?CMD=Web&PAGE_TYPE=BlastHome). Whenever 
possible, shRNAs were first tested in HEK 293-FT cells for their knockdown efficiency 
by co-transfecting with a tagged overexpression construct. All constructs were verified by 
DNA sequencing. 
PCR product cloning 
The primers used for cloning PCR products were designed with restriction sites at both 
ends. The PCR product was first digested with the corresponding restriction enzymes 
usually overnight at 37°C followed by heat kill to stop the digestion. The digested PCR 
product was used as insert in the ligation reaction with the corresponding vector. In some 
cases, a TOPO cloning kit was used according to the manufacturer’s instructions.  
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The TAU pre-mRNA probes for the crosslinking experiments were generated by cloning 
250-400 bp PCR products, using genomic mouse DNA or MAPT BAC as template, into 
the pGEM3 vector or pCR-blunt2 TOPO. Overexpression constructs were cloned using 
the same strategy, except that cDNA was used as template for the PCR. For rescue 
experiments with human FUS, a silent mutation was added to make the HA-tagged 
human FUS construct resistant to the shRNAs. The HA-tagged human FUS construct was 
expressed under the human synapsin promoter in a lentiviral vector.  
The different TAU isoform expression constructs were cloned by first generating cDNA 
from rat neurons at different developmental stages (DIV1, DIV7, DIV14, DIV21). The 
PCR products were then cloned, followed by a selection based on the correct sequence 
corresponding to the different TAU isoforms.  
TAU minigene cloning 
The TAU minigene constructs containing mouse MAPT exon 9-11 or exon 1-4 were 
cloned by homologous recombination using the Red/ET system (Gene Bridges) starting 
with a mouse genomic BAC and a modified expression vector pBUD-CE, where the 
NheI/PciI fragment containing the EF1 expression cassette was excised. For better 
detection, the expression vector contained a myc-tag (N-term.) and a HA-tag (C-term.).  
3.2.2.2. Reverse transcription and quantitative PCR (RT-qPCR)  
RNA isolation 
RNA was isolated with the Qiagen RNAeasy kit following the manufacturer's 
instructions. In case the RNA was not immediately isolated, cells were kept in RNAlater 
at 4 °C. Whenever necessary, an additional DNase digest was performed during RNA 
extraction, according to manufacturer's instructions. 
Reverse transcription RT-PCR 
The isolated RNA was first diluted with RNAse-free H2O and reversely transcribed with 
random hexamer primers (N6) using TaqMan MicroRNA Reverse Transcription Kit 
following the manufacturer’s instructions to generate complementary DNA (cDNA). For 
the cDNA standard series, a mixture was prepared by pooling equal amounts of all RNA 
samples and this mixture was then serially diluted in 1/10 steps. The following table gives 
the details for the reaction. For each reaction the RNA sample was diluted nuclease-free 
H2O in 15µL and combined with 30µL reaction mix.  
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components µL 
100 mM dNTPs (with dTTP)  0.45 
MultiScribe™ Reverse Transcriptase (50 U/µL) 3 
10X RT buffer  4.5 
RNase inhibitor  0.55 
nuclease-free H2O 17 
N6 primer (50 ng/µl) 4.5 
reaction mix 30 
RNA sample diluted 15 
 
The mix was incubated on ice for 5 minutes before starting the reverse transcription 
reaction. The program for the RT-PCR reaction was: 
time temperature 
30 min 16 °C 
30 min 42 °C 
5 min 85 °C 
hold 4 °C 
Quantitative PCR (qPCR) 
The qPCR reaction with the SsoFast™ EvaGreen® (BioRad) reaction mix was prepared 
according to the manufacturer’s instructions by adding the cDNA diluted in H2O (usually 
1:1) and gene specific primers. YWHAZ was usually used as housekeeping gene. The 
relative mRNA expression was calculated with the BioRad CFX manager software using 
the delta-delta-Ct method. The following table gives the details for the reaction. 
components µL 
SsoFast™ EvaGreen® 2.5 
primer forward (400 nM) 0.05 
primer reverse (400 nM) 0.05 
H2O 0.4 
cDNA template 2 
total mix 5 
The qPCR ran for 50 cycles in the CFX384 Real-Time System quantitative PCR 
(BioRad) with the following program:  
step time temperature 
start 30 sec 95°C 
cycle 
(50x) 
5 sec 95°C 
5 sec 60°C 
 10 sec 95°C 
melt curve 5 sec (increment 0.5 °C) 65°C - 95°C 
 
The PCR products were usually sequenced to confirm the correct amplification.  
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Quantitative PCR primer design 
qPCR primers were design based on the NCBI database genomic and mRNA sequences 
of the gene and species of interest. The Spidey web tool (NCBI, 
http://www.ncbi.nlm.nih.gov/spidey/) was used to generate a multiple alignment between 
sequences. Regions (>22 bp) with perfect alignment were selected if a large intron 
(>1000 bp) was being spanned, to avoid detection of genomic DNA. The selected regions 
were then processed with the Primer3 web tool (http://bioinfo.ut.ee/primer3/) to generate 
primers with a product size 200-300 bp at an optimal temperature of 60°C. 
Endpoint PCR 
Endpoint PCRs were used to estimate the relative abundance of different PCR products, 
for example between inclusion and exclusion of a specific exon. A standard PCR reaction 
was prepared and run for 30 cycles. The PCR products were visualized with an agarose 
gel and the band intensities were quantified. A ratio was then calculated based on the 
intensities.  
3.2.3. Cell culture and lentivirus production 
Rat primary neurons 
For the neuronal culture, the brains of rat embryos (E18-E19) were collected from a 
pregnant mother that was sacrificed with CO2. The cortex or hippocampal region was cut 
out with microsurgical instruments. After washing cortices and hippocampi separately in 
5 mL cold HBSS, 500µL 2.5% trypsin was added to dissociate the tissue. For cortical 
neurons, DNase was also added (final concentration 0.7 mg/mL). After digestion, the 
tissue was washed with warm HBSS and gently dissociated into a cell suspension. For the 
feeder-free culture system, cells were plated in cell culture dishes previously coated with 
poly-D-Lysin (PDL) or PDL and Laminin, for culture on plastic or cover glasses, 
respectively (see buffer list). For immunofluorescence experiments, cover glasses were 
treated with nitric acid, washed, sterilized, before coating. Cortical neurons were kept in 
culture in Neurobasal medium supplemented with B27, penicillin/streptomycin and L-
glutamine. For hippocampal neurons, culture media was further supplemented with L-
glutamate (see buffer list).  
Cell culture of LUHMES cells 
LUHMES were cultured as dividing cells in DMEM/F12 medium supplemented with N2, 
bFGF and penicillin/streptomycin (see buffer list) in a cell culture flask previously coated 
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with poly-L-Lysin (PLL). LUHMES were passaged at 60-70% confluency and full 
confluency was avoided. For differentiating LUHMES into post-mitotic neuronal-like 
cells, cells were plated in normal medium on cell culture dishes previously coated in two 
steps, first with PLL and then with fibronectin. One day after plating, normal medium 
was changed to differentiating medium, consisting of DMEM/F12, 
penicillin/streptomycin, tetracycline, GDNF and dcAMP (see buffer list). Half of the 
culture media was exchanged every 2-3 days.  
Cell culture of human Embryonic Kidney cells (HEK 293-FT) 
HEK 293-FT cells were cultured in DMEM/Glutamax medium supplemented with 10% 
FCS, 1% penicillin/streptomycin and 1% non-essential amino acids (NEAA). HEK 293-
FT cells were used only at a low passage and full confluency was avoided for virus 
production. For passaging, cells were detached from culture flask with Trypsin/EDTA 
and replated with new medium.  
Virus production  
Virus was produced in packaging HEK 293-FT cells. For this, HEK 293-FT cells were 
expanded from a freshly thawed aliquot. One day after seeding, HEK 293-FT cells were 
transfected with Lipofectamine with three constructs: two that allow the formation of the 
lentivirus particles (pVSVg and pSPAX) and the construct of interest (lentivirus 
packaging construct). Usually, three 10 cm culture dishes were transfect for each 
construct. First, Lipofectamine was diluted in Optimem and incubated for 5 min at RT.  
 
 
 
The DNA was also diluted in Optimem, as follows: 
for 3x10 cm dishes DNA (µg)  
LTR-vector  18.6 
pSPAX2  11 
pVSVg  6.4 
total  36 
in Optimem (µl) 4500 
 
The DNA and Lipofectamine mixture was incubated for 20 min at RT prior to adding the 
3mL of the mixture to each dish. One day after transfection, medium was changed to high 
BSA HEK 293-FT medium (see buffer list). Two days after transfection, the supernatants 
for 3x10 cm dishes volume (µl) 
Lipofectamine  108 
in Optimem  4500 
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were recovered, filtered through a 0.45 µm PES membrane filter to remove cell debris 
and ultracentrifuged for 2 h at 64,000 g in a SW28 rotor. The virus pellet was re-
suspended slowly in Neurobasal medium for 5 h at 4°C. Aliquots were stored at -80°C.  
Cytotoxicity test 
XTT metabolic assay kit from Roche Applied Science was used for cytotoxicity 
measurements according to the manufacturer's instructions. Cells were treated with 
staurosporine (final concentration 1 µM for 4h) as a positive control.  
Splicing assay in HEK 293-FT cells 
For the splicing assays with TAU minigenes, HEK 293-FT cells were transfected 
sequentially. First with shRNA construct to allow sufficient knockdown and two days 
later with the TAU minigene construct using Lipofectamine. Before the second 
transfection HEK 293-FT cells were replated to avoid differences in cell number due to 
possible growth delay caused by the shRNA constructs. The transfections were performed 
as follows: 
first transfection in 10 cm dish 
10 µg DNA in 1,5 mL Optimem add 3mL 
per dish 108 µL L2K in 1,5 mL Optimem 
 
second transfection in 12 well 
1 µg DNA in 100 µL Optimem add 200µL 
per well 3 µL Lipofectamine in 100 µL Optimem 
 
Transfection of neurons with Lipofectamine 
Primary neurons were transfected in a 12 well culture plate, after changing medium to 
transfection medium (primary neurons medium without B27). For one well of the 12 well 
culture plate, 1.8 µg DNA and 3.2 µL Lipofectamine were diluted individually in 100 µL 
Neurobasal. The DNA and Lipofectamine transfection mixture was incubated for 20 min 
at RT prior to adding it to each well. After 45 min, transfection medium was discarded 
and the cells were washed once and placed back to the conditioned medium.  
Amaxa transfection of neurons 
For the analysis of neuronal morphology, neurons were transfected before plating using 
the Amaxa 4D-nucleofector with the primary culture kit P3 (Lonza) and using the 
program EM110. Neurons were then cultured on astrocyte feeder cells in N2 media. 
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3.2.4. Immunofluorescence 
Microscopy  
All images were taken either with a confocal laser scanning microscope (LSM510 or 
LSM 710, Zeiss) or with an epifluorescence microscope (Axiovert.A2, Zeiss). Confocal 
images were usually taken as Z-stacks and processed with LSM software or ImageJ.  
Immunostaining  
Neurons cultured on cover glasses were fixed with 4% PFA (PFA-fix) for 20 min at RT 
and then washed with PBS. The cover glasses were incubated with the primary antibody 
diluted in 1x GDB buffer at 4°C overnight. After several washes with PBS, the cover 
glasses were incubated with the secondary antibody diluted in 1x GDB at RT for 1 h. 
Nuclear staining with TO-PRO-3 diluted in H2O was performed after the incubation with 
the secondary antibody. After several washes with PBS, the cover glasses were briefly 
dipped in dH2O and mounted on object slides with Vectashield and fixed on the sides 
with clear nail polish.  
In order to better visualize nuclear proteins such as FUS, an additional permeabilization 
step was performed with Triton X-100. In summary, after fixing with 4% PFA for 20 min 
at RT, hippocampal neurons were quenched and permeabilized with 0.1% Triton X-100 
in 50 mM ammonium chloride. The fixed cells were then blocked with 2% fetal bovine 
serum, 2% bovine serum albumin and 0.2% fish gelatin dissolved in PBS. After blocking, 
neurons were handled as described above, except that 10% blocking solution was used 
instead of 1x GDB buffer.  
Fixation to visualize cytoskeleton in neurons 
A special fixation method modified from (Smith, 1994), was needed for the visualization 
of microtubules in neurons. The PHEM fixative, containing glutaraldehyde, was freshly 
prepared and pre-warmed at 37°C (see buffer list). The neurons were fixed with PHEM 
fixative for 15 min at RT and then washed three times with PBS. The neurons were then 
quenched for 10 min with 50 mM ammonium chloride and washed again three times with 
PBS. The fixed neurons were treated as usual for the immunostaining.  
Quantification of neuronal morphology 
The software Axio Vision (Zeiss) was used for length and area measurements. Image 
acquisition and quantification were done blind to the experimental conditions. Axonal 
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growth cone area, neurite number and axonal branching were quantified from a minimum 
of 45 cells per condition in three independent experiments. Axonal length, defined by the 
length of the longest process at the time point of analysis (DIV0+4), were quantified from 
a minimum of 99 cells per condition in three independent experiments.  
3.2.5. Statistical analysis 
All statistical analysis was performed with the GraphPad Prism software using t-test, one-
way or two-way ANOVA. Morphological analysis and quantification was performed 
blind to the experimental conditions. Statistical significance was considered as follows: * 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 
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4. Results 
4.1. FUS function in neurons 
4.1.1. FUS localizes predominantly in the nucleus of hippocampal rat neurons 
FUS is a predominantly nuclear protein, although prevalent dendritic/synaptic localization 
of transfected and endogenous FUS has been reported in some studies with cultured 
neurons (Belly et al, 2005; Fujii et al, 2005; Husi et al, 2000). I assessed the localization 
of endogenous FUS in cultured rat hippocampal neurons with immunofluorescence (IF) 
and detected exclusive nuclear FUS staining (Figure 6). There was no co-localization 
with the dendritic marker MAP2 (Figure 6A) nor with the synaptic marker synaptophysin 
(Figure 6B). This result strongly contrasts the studies mentioned above; however it does 
not exclude the possibility that a small FUS population, below the detection limit, could 
be localized in dendrites. 
Thus, FUS localizes predominantly in the nucleus of cultured rat neurons. Based on this, I 
focused on FUS nuclear function and its relevance in the pathomechanism behind ALS 
and FTLD.  
 
Figure 6 FUS is localized to the nucleus in rat hippocampal neurons  
Immunofluorescence images of untransfected mature neurons (DIV 20) with the indicated 
antibodies and TO-PRO-3 to label nuclear DNA. (A) MAP2 defines dendrites and (B) 
synaptophysin defines synapses. Note that FUS localizes exclusively to the nucleus and does not 
colocalize with MAP2 or synaptophysin. The rightmost panel (composite mag.) shows a 
magnification of the field marked with white box in the composite. 
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4.1.2. FUS knockdown in neurons is not toxic but enhances expression of 4R TAU  
In order to evaluate the physiological function of FUS, I cloned two shRNAs against rat 
FUS in a viral transfer vector and produced lentivirus to knockdown FUS in neurons. 
Hippocampal neurons were transduced with purified virus after two days in culture and 
harvested seven days later (DIV 2+7). Both shRNAs against FUS showed a knockdown 
efficiency of about 90% compared to a control shRNA (shLuc) targeting the non-
expressed gene firefly luciferase (Figure 7A). The abundance of synaptic proteins 
(GluR2, NR1, NR2A, synaptophysin) and cytoskeletal proteins -actin and -tubulin 
remained unaltered, as shown in the immunoblots (Figure 7A,C). TDP-43, another 
disease related DNA/RNA-binding protein, also remained unaltered (Figure 7C). Cell 
viability, assessed by a metabolic XTT assay, was also not affected (Figure 7B). In 
contrast, the immunoblots using a TAU antibody showed increased levels of heavier 
variants of TAU in FUS knockdown treated neurons (Figure 7C,D). TAU is alternatively 
spliced (Figure 8) and the two prominent bands observed in the shortly exposed 
immunoblots (Figure 7D) correspond to the most abundant 3R and 4R TAU isoforms, as 
shown by the immunoblots with isoform specific antibodies (Figure 7D). At this stage, 
more 3R TAU is expressed than 4R TAU, with a ratio of 80% 3R TAU to 20% 4R TAU 
(Figure 7D, note also the difference in abundance on mRNA level in Figure 9A). 
Immunoblots using the isoform specific antibodies showed a significant increase in 4R 
TAU upon FUS knockdown, but no effect on the 3R TAU. The lack of a reciprocal 
decrease in 3R TAU can be explained by differences in relative amounts.  
Together, this data indicates that FUS knockdown alters relative abundance of TAU 
isoforms, resulting in an enhanced expression of 4R TAU.  
4.1.3. FUS knockdown in neurons results in increased expression of 2N and 4R 
TAU isoforms  
In order to evaluate the abundance of individual TAU isoforms, I focused on quantitative 
PCR (qPCR) and endpoint PCR studies. Figure 8A shows the genomic structure of the 
MAPT gene, coding for TAU, with the alternatively spliced exons marked in red. Primers 
for qPCR were designed to amplify PCR products unique to each spliced exon (Figure 
8B). Primers for endpoint PCR are placed around exon 10 in the neighboring exons 9 and 
11, in order to evaluate exactly the inclusion/exclusion of exon 10 (Figure 8B). 
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Figure 7 FUS knockdown in neurons is not toxic but enhances expression of 4R TAU 
isoform  
Hippocampal neurons were transduced with lentivirus (DIV 2+7) to express the indicated shRNA 
directed against FUS (shFUS#1 or shFUS#2) or non-targeting control shRNA against firefly 
luciferase (shLuc). (A) Immunoblots with the indicated antibodies show expression of neuronal 
proteins, duplicates are shown. (B) Cell viability measured with XTT assay shows no significant 
alteration in FUS knockdown condition, mean +/- SEM are shown, one-way ANOVA, n = 12. (C) 
Immunoblots with the indicated antibodies. Note that the disease related DNA/RNA-binding 
protein TDP-43 remains unaltered in FUS knockdown conditions. The TAU blot shows a longer 
exposure (long exp.) and additional isoforms are visible. (D) Immunoblots with the indicated 
antibodies show total TAU protein and isoforms 4R and 3R, duplicates are shown. Note the 
increase in 4R Tau expression in the FUS knockdown samples.  
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Figure 8 MAPT/TAU genomic structure and primer design for quantitative PCR and 
endpoint PCR  
(A) Exon structure of the human MAPT gene. Alternatively spliced exons in the CNS are shown 
in red. Exon 4a (white) is included only in the peripheral nervous system and exon 6 and exon 8 
(dark grey) are not expressed in the human CNS. (B) Isoform specific primers for quantitative 
PCR. In the case of 0N, 1N and 3R, forward primers bind to the splice sites between exons E1-E4, 
E2-E4 and E9-E11, respectively. Primers for the 2N and 4R isoforms bind in exon 3 or exon 10, 
which are unique for the respective isoform. Specificity was confirmed by sequencing the PCR 
products. Endpoint PCR primers bind around exon 10 in the neighboring exons 9 and 11.  
The results from the endpoint PCR showed a significant increase (70%) of exon 10 
inclusion in neurons after FUS knockdown (Figure 9A). The qPCR results confirmed the 
knockdown efficiency and also revealed a specific increase in expression of TAU exon 3 
and exon 10 (resulting in isoforms 2N and 4R TAU). Total levels of TAU and splicing 
events involving 0N, 1N or 3R TAU, remained unaffected (Figure 9B).  
Results 
71 
In summary, end point PCR and qPCR confirm and clarify the exact splicing events 
altered upon FUS knockdown. Specifically 2N and 4R TAU levels are increased in 
hippocampal neurons after FUS knockdown.  
 
Figure 9 FUS knockdown enhaces inclusion of TAU exon 3 and exon 10 at mRNA level 
Hippocampal neurons were transduced with lentivirus (DIV 2+7) to express the indicated shRNA 
against FUS (shFUS#1 or shFUS#2) or non-targeting control shRNA (shLuc). Total RNA was 
analyzed by end-point PCR or quantitative PCR (qPCR) and shows enhanced expression of TAU 
exon 3 and exon 10 upon FUS knockdown. (A) Endpoint PCR after 30 cycles. PCR products were 
visualized in an agarose gel, duplicates are shown. The ratio of E10 inclusion to E10 exclusion is 
quantified in the right panel. n=3, mean +/-SEM are shown, student’s t-test: *p<0.05. Note the 
significant increase in E10 inclusion upon FUS knockdown. (B) Total RNA was analyzed by 
qPCR for FUS, total TAU and TAU isoforms. FUS and total TAU expression was normalized to 
the housekeeping gene YWHAZ and TAU isoform expression was normalized to total TAU 
levels. n=4, mean +/-SEM are shown, one-way ANOVA with Dunnett’s post-test: *p<0.05, 
**p<0.01, ***p<0.001.  
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4.1.4. Neurons in culture reflect the in vivo developmental changes in TAU 
alternative splicing  
In order to evaluate the applicability of our primary neuron model, I tested whether TAU 
alternative splicing in cultured neurons reflects the changes seen during postnatal 
development. For this, RNA was collected from cultured neurons at four different time 
points: DIV 1, DIV 7, DIV 14 and DIV 21. I then evaluated the expression of TAU 
isoforms by qPCR. 
With time, I detected increased expression of 4R TAU in comparison to 3R TAU. Also 
2N TAU became more preferentially expressed than the initial 0N TAU (Figure 10). The 
shift in TAU isoform expression showed the pattern expected based on the reported TAU 
expression in the murine brain (Kosik et al, 1989). In vivo, the shortest isoform 0N3R is 
highly expressed early in development. With time there is a shift in expression towards 
the longer TAU isoforms, reaching a peak in expression of the longest isoform 2N4R at 
adult stages. Regarding FUS expression over time, I detected a slight decrease of FUS 
expression, this was however not statistically significant (Figure 10). Interestingly, a 
similar decrease in FUS expression has been reported after differentiation of SY5Y cells 
with retinoic acid (Andersson et al, 2008). 
 
Figure 10 TAU isoform expression in cultured hippocampal neurons recapitulates in vivo 
TAU isoform expression during development 
Total RNA, collected form untreated hippocampal neurons at DIV1, DIV7, DIV14 and DIV21, 
was analyzed by quantitative PCR for FUS, total TAU and TAU isoforms. FUS and total TAU 
expression was normalized to the housekeeping gene YWHAZ and TAU isoform expression was 
normalized to total TAU levels. n=3, mean +/-SEM are shown, ANOVA with Dunnett’s post-test: 
*p<0.05, **p<0.01, ***p<0.001. Note the significant increase 2N and 4R TAU expression and 
decreased 0N and 3R TAU expression with time.  
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Altogether this result confirms that cultured rat hippocampal neurons reflect the normal 
development in vivo. Therefore, the increased expression of 2N and 4R TAU isoforms 
observed upon FUS knockdown in 9 day old neurons reflects the shift in isoform 
expression seen in older neurons (DIV 21).  
4.1.5. 2N TAU specific antibody detects overexpressed TAU isoforms 
The lack of commercial antibodies specific for the 0N, 1N or 2N TAU isoforms has 
hampered research on TAU splicing and its implications in disease. The results presented 
above highlighted the importance of having an antibody to detect 2N-TAU isoforms. 
Therefore, we set out to generate a 2N TAU specific antibody. For this, rabbits were 
immunized with rat TAU exon 3 fused to an N-terminal GST (Figure 11A). 
I transfected constructs expressing different TAU isoforms in HEK 293-FT cells (Figure 
11A) to validate antibody specificity. The final bleed serum specifically detected the 2N 
TAU isoform (Figure 11B). Although affinity-purification with the GST-exon 3 TAU 
antigen did reduce the background in immunoblotting, the purified antibody only detected 
overexpressed 2N TAU and was not sensitive enough to detect endogenous 2N TAU in 
cultured neurons (data not shown). Similar results were obtained in immunofluorescence 
staining. The antibody against 2N TAU labeled only those neurons that had been 
transfected to overexpress the 2N4R TAU isoform but not the surrounding untransfected 
neurons (Figure 11D).  
Taken together, the production and purification of an antibody against 2N TAU was 
successful. However, this antibody detects only overexpressed 2N TAU isoforms in 
cultured neurons. Furthermore, the detection limit might be overcome by using samples 
with higher abundance of 2N TAU isoforms, for instance in brain lysate of adult mouse 
tissue. 
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Figure 11 2N TAU specific antibody detects overexpressed TAU isoform  
(A) Anti-2N TAU polyclonal antibody produced by immunizing rabbits with the depicted antigen 
was purified and tested in immunoblots (C) and immunofluorescence (D). (B) Characterization of 
rat TAU isoform constructs used to test 2N TAU polyclonal antibody. Immunoblots with the 
indicated antibodies. (C) Immunoblots using the indicated sera and antibody. The purified 
antibody detects only the 2N4R TAU isoform without additional unspecific bands, compared to 
the final bleed serum. (D) Hippocampal neurons transfected to overexpress rat 2N4R TAU 
isoform and GFP to control the transfection. Immunofluorescence using the indicated antibodies. 
Note the specific signal of the 2N TAU antibody solely at the transfected cell but not surrounding 
processes as observed for the TAU antibody staining.   
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4.1.6. Knockdown of ALS/FTLD related proteins TDP-43, C9orf72, EWS or 
TAF15 does not alter TAU isoform expression  
In order to evaluate the specificity of the FUS effect on TAU splicing, I evaluated how 
the knockdown of other ALS/FTLD related proteins influences TAU splicing. 
Hippocampal neurons were transduced with lentivirus to express shRNAs (shLuc control 
or shRNA for knockdown). RNA samples were collected 7 days after transduction and 
analyzed by qPCR. 
TDP-43 and FUS are functionally related proteins that define different subgroups of ALS 
and FTLD pathology. Hippocampal neurons treated with lentivirus to knockdown TDP-
43 showed significant reduction of TDP-43 (>80% reduction). TAU isoform abundance 
and total TAU levels remained, however, largely unchanged compared to shLuc control 
samples (Figure 12A).  
Recently a higher frequency of AD pathology (including NFTs), has been reported in 
FTLD cases with C9orf72 mutation compared to FTLD cases with GRN mutation 
(Bieniek et al, 2013). I evaluated therefore if C9orf72 knockdown could alter TAU 
splicing. As seen in Figure 12B, the C9orf72 knockdown in neurons was highly efficient 
(>90% knockdown). Similar to the TDP-43 knockdown, there were no significant 
differences in the abundance of TAU isoforms between shLuc control and C9orf72 
knockdown. A slight decrease in 4R TAU was detected; however it did not reach 
statistical significance. Total TAU expression also remained unchanged (Figure 12B). 
FUS belongs to the FET family of proteins (including EWS and TAF15) that shares 
similar protein domain structure and potentially cellular functions. Hippocampal neurons 
treated with lentivirus showed good individual knockdowns of EWS (75% knockdown) 
or TAF15 (70% knockdown) respectively. TAU isoform abundance was not significantly 
altered in the knockdown samples compared to the control. There was, however, a trend 
towards a reduction in the abundance of 2N and 4R TAU in shTAF15 samples. Total 
TAU levels remained largely unchanged (Figure 12C).  
Taken together, this data confirms that TAU splicing is specifically altered in FUS 
knockdown and none of the ALD/FTLD related proteins tested (TDP-43, C9orf72, EWS, 
or TAF15) showed similar effects. This implicates FUS mediated TAU aberrant splicing 
directly with ALS/FTLD-FUS pathophysiology and not to ALS/FTLD-TDP.  
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Figure 12 Knockdown of ALS/FTLD related genes TDP-43, C9orf72, EWS or TAF-15 does 
not alter TAU isoform expression 
Hippocampal neurons were transduced with lentivirus (DIV 2+7) to express the indicated shRNA 
against (A) TDP-43, (B) C9orf72, (C) EWS, TAF-15 or non-targeting control shRNA (shLuc). 
Total RNA was analyzed by quantitative PCR. (A) TDP-43 and total TAU expression was 
normalized to the housekeeping gene YWHAZ and TAU isoform expression was normalized to 
total TAU levels. n=6, mean +/-SEM are shown, student’s t-test: **p<0.01. (B) C9orf72 and total 
TAU expression was normalized to the housekeeping gene YWHAZ and TAU isoform expression 
was normalized to total TAU levels. n=6, mean +/-SEM are shown, student’s t-test: 
****p<0.0001. (C) EWS, TAF-15 and total TAU expression was normalized to the housekeeping 
gene YWHAZ and TAU isoform expression was normalized to total TAU levels. n=4, mean +/-
SEM are shown, one-way ANOVA with Dunnett’s post-test: **p<0.01. 
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4.1.7. Reintroduction of human FUS rescues aberrant TAU splicing  
In order to confirm that aberrant TAU splicing is a direct consequence of FUS 
knockdown and to exclude an off-target effect, I performed rescue experiments by 
reintroducing human FUS into rat neurons treated to knockdown FUS. The human FUS 
construct was HA-tagged and was resistant to the shRNA due to a silent mutation of the 
shRNA seed region. Hippocampal neurons were doubly transduced with lentivirus to 
express shRNA (shLuc or FUS shRNA) and human wildtype FUS on day 2 and samples 
for immunoblotting and RNA were recovered 7 days after transduction. 
Reintroduction of HA-human FUS strongly increased the level of FUS in both control 
and FUS shRNA treated neurons compared to the shLuc control, that shows endogenous 
levels (Figure 13A). In the immunoblot, the HA-human FUS is observed slightly higher 
than endogenous FUS due to the HA-tag. Importantly, the expression of human FUS did 
not affect cell viability, compared to the control neurons expressing GFP (Figure 13B). 
Both immunoblots and qPCR showed that reintroduction of HA-human FUS completely 
rescued the altered splicing of TAU exon 3 and exon 10 (Figure 13A,C). The immunoblot 
using 4R TAU antibody shows that HA-human FUS not only rescues the increase in 4R 
TAU but it even suppresses 4R TAU expression below endogenous level (Figure 13A). In 
contrast, 3R TAU levels remained largely unchanged on protein level and showed a slight 
increase on mRNA level upon reintroduction of human FUS (Figure 13A,C).  
This data corroborates the specific effect of FUS in TAU splicing and confirms that the 
splicing events involving exon 3 and exon 10 are highly responsive to the levels of FUS 
in the neurons.  
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Figure 13 Reintroduction of human FUS fully rescues aberrant TAU splicing 
Hippocampal neurons were transduced (DIV2+7) with lentivirus to express the indicated shRNA 
against FUS (shFUS#2) or non-targeting control shRNA (shLuc) and co-transduced with 
lentivirus to express HA-tagged shRNA resistant human FUS. (A) Immunoblots using indicated 
antibodies. Note that overexpression of human FUS leads to a marked decrease in 4R TAU levels 
in both shLuc and shFUS conditions. (B) Cell viability measured with XTT assay shows no 
significant alteration upon FUS overexpression, compared to control cells expressing GFP. mean 
+/- SEM are shown, student’s t-test, n = 12. (C) Total RNA was analyzed by quantitative PCR for 
total TAU and TAU isoforms. Total TAU expression was normalized to the housekeeping gene 
YWHAZ and TAU isoform expression was normalized to total TAU levels. Note that samples 
from shLuc and shFUS treated neurons were statistically indistinguishable when co-transduced to 
express HA-tagged shRNA resistant human FUS. n=3, mean +/-SEM are shown, ANOVA with 
Bonferroni correction: **p<0.01. 
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4.1.8. Overexpression of FUS in hippocampal neurons alters TAU splicing 
After confirming the effect of reintroducing FUS to a control or knockdown condition, 
the question arose if the overexpression of FUS alone would also alter TAU alternative 
splicing. Animal models overexpressing wildtype or mutant FUS often show detrimental 
effects (Lanson Jr & Pandey, 2012; Shelkovnikova, 2013). It is, however, not known if 
these models also show altered TAU splicing. FUS mutations that cause ALS cluster 
around the NLS domain at the C-terminus of the protein (Dormann & Haass, 2013). This 
observation led to the notion that the NLS has an important role in the pathomechanism 
behind the disease. Therefore, for the overexpression experiments I also used FUSC 
mutant, which lacks the NLS domain (deletion of amino acids 514-526). 
 
Figure 14 Overexpression of FUS in hippocampal neurons alters TAU splicing  
Hippocampal neurons were transduced (DIV3+6) with lentivirus to express either HA-tagged 
human wildtype FUS (FUS wt), human mutant FUS (FUS ΔC) or GFP as a control. (A) Total 
RNA was analyzed by quantitative PCR for FUS and total TAU expression, normalized to 
housekeeping gene YWHAZ (B) TAU isoform expression was normalized to total TAU levels. 
n=4, mean +/-SEM are shown, one-way ANOVA with Dunnett’s post-test.  
Hippocampal neurons were treated with lentivirus on day 3 after plating to express GFP, 
wildtype or mutant FUS individually. RNA samples were collected after 6 days of 
transduction. The overexpression was assessed with qPCR, and both wildtype and mutant 
FUS showed a 10-12 fold higher expression than the GFP control (Figure 14A). Total 
TAU levels were decreased in mutant FUS samples, however, the difference was not 
statistically significant. As expected from the previous results, overexpression of wildtype 
FUS resulted in decreased expression of 2N and 4R TAU. Interestingly, mutant FUS 
overexpression reduced only 2N TAU levels and not 4R TAU levels (Figure 14B).  
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Overall, these results confirm the influence of FUS on TAU alternative splicing because 
increased wildtype FUS levels result in altered splicing of TAU exon 3 and exon 10. In 
contrast, overexpressed mutant FUS did not alter 4R TAU expression, which could 
indicate a loss of FUS function in regulating alternative splicing of TAU exon 10.  
 
4.2.  FUS interacts with TAU pre-mRNA 
4.2.1. FUS associates with TAU pre-mRNA in mouse brain 
FUS binds RNA and is known to be part of the spliceosome (Hartmuth et al, 2002; 
Rappsilber et al, 2002; Zhou et al, 2002). To test whether FUS associates with TAU 
mRNA, I performed immunoprecipitations (IP) of endogenous FUS from mouse brain 
(P15) extracts using a FUS antibody. A GST antibody was used as a negative control. The 
bound RNA was isolated from the immunoprecipitated samples and the abundance of 
RNA transcripts was estimated by comparing the percentage of recovery between control 
and FUS IP after reverse transcription and qPCR. Pre-mRNA levels were analyzed using 
intronic primers (Figure 15A) and mRNA levels using exonic primers.  
Immunoblotting confirmed specific immunoprecipitation of endogenous FUS compared 
to control IP with GST antibody (Figure 15B). The relative recovery of TAU pre-mRNA 
bound to FUS was significantly higher than the control IP, with about 1% recovery of the 
input material in the FUS IP sample (Figure 15C). Also total TAU mRNA was 
significantly enriched in the FUS IP, but to a lesser extent than TAU pre-mRNA. Two 
recently identified FUS binding targets SON and FUS mRNA (Hoell et al, 2011), served 
as positive controls and also showed significant association with FUS at comparable 
levels to the TAU mRNA. In contrast, neither glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) pre-mRNA nor mRNA showed a significant association to 
FUS, compared to the control IP (Figure 15C). The qPCR end product was visualized in 
an agarose gel and also confirms the qPCR results (Figure 15B,C). Additionally, PCR 
products were confirmed by sequencing. 
Taken together, these results show that FUS is associated with TAU pre-mRNA and 
mRNA in the mouse brain.  
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Figure 15 Endogenous FUS associates with TAU pre-mRNA in the mouse brain 
Mouse brain (age 15 days) lysates were used to perform immunoprecipiations with anti-FUS 
antibody and control anti-GST antibody followed by RNA extraction and quantitative analysis of 
the bound RNA. RNA associated with FUS was reverse transcribed and analyzed by quantitative 
PCR. (A) Primers used for TAU E10 pre-mRNA quantitative PCR bind in introns adjacent to 
TAU exon 10. (B) Immunoblot using anti-FUS antibody shows input material, FUS- and control-
immunoprecipitates (upper panel). PCR product after quantitative PCR analysis shown in (C) 
(lower panel). PCR products were confirmed by sequencing. (C) RNA recovery from FUS- and 
control-immunoprecipitates. For each group, individual immunoprecipitations from six mouse 
brains were analyzed by quantitative PCR. n=6, mean +/- SEM are shown, student’s t-test:  
*p<0.05, **p<0.01, ***p<0.001. Note that SON primers span a verified FUS-binding motif 
within a large exon and therefore amplify both pre-mRNA and mRNA. SON and FUS mRNA 
binding serve as positive controls.  
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4.2.2. Endogenous FUS directly binds TAU pre-mRNA 
To test whether the association of FUS to TAU pre-mRNA is direct and not mediated by 
an unknown co-immunoprecipitated protein, I performed RNA binding assays with biotin 
labeled RNA probes and a UV-crosslinking step. I used mouse TAU RNA probes 
surrounding the regulated exons 3 and exon 10 to roughly map the FUS binding regions 
(Figure 16A). Genomic TAU fragments covering the regions of interest were PCR 
amplified from mouse genomic DNA and cloned in a vector under a T7 promoter 
(pGEM3). Labeled RNA was generated by in vitro transcription using biotin-UTP as the 
labelling nucleotide. 
 
Figure 16 RNA binding assay setup to evaluate FUS interaction with TAU pre-mRNA in 
mouse brain lysates 
(A) Scheme of regions covered by the TAU RNA probes used for RNA-binding assay. The 
alternatively spliced exons are marked in red. (B) Experimental setup of RNA-binding assay. 
Biotin-labelled RNA probes (yellow) were incubated with mouse brain lysates. After crosslinking 
with ultraviolet (UV)-light, the samples were digested with RNAase A, followed by 
immunoprecipitation using anti-FUS antibody or control anti-GST antibody. Immunoprecipiated 
protein-RNA complexes were analyzed by immunoblotting with streptavidin-HRP and anti-FUS 
antibody.  
For the cross-linking experiments, biotinylated RNA probes were first incubated with a 
mouse brain extract. After incubation, the samples were subjected to UV crosslinking to 
capture interacting partners. In order to remove excess RNA, the samples were treated 
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with RNase A to digest unbound RNA. In this process, the protein-RNA interaction 
protects a short RNA fragment from being digested and the remaining peptide is 
sufficient to label the protein with biotin. FUS endogenous protein is then 
immunoprecipitated from the lysate to evaluate the potential binding to the labeled RNA 
probes. At the end, biotinylation of FUS, detected by immunoblot using streptavidin-
HRP, indicates a direct interaction with the labeled RNA (Figure 17).  
The mouse brain lysate used as an input for the RNA binding assay had to first be pre-
cleared from endogenous biotinylated proteins to allow a better signal detection. The pre-
clearing was successful as shown by the streptavidin-HRP immunoblot, with 
approximately less than 50% biotin signal left after pre-clearing (Figure 17A). Note that 
the prominent biotin bands in the brain lysate do not run in the SDS-PAGE gel at the 
same height as FUS (arrow, Figure 17A). Interestingly, the pre-clearing step does not 
influence the endogenous FUS levels suggesting that FUS is not endogenously 
biotinylated in the brain. As expected from the previous results, exonic GAPDH probes 
(GAPDH e3 and e5) showed no biotin signal in the FUS immunoprecipitates (compare 
Figure 15 to Figure 17C). Also the no-RNA control showed no positive signal. In general, 
FUS binding to TAU probes was more prominent at intronic regions. Exonic RNA probes 
e3 and e9 showed no binding, whereas probes e10 and e11 showed some binding. 
Significant binding was observed using intronic probes: i2-1, i10-1, i10-2, i9-4, i9-6, i9-1, 
i9-2 and i9-3 (Figure 17C,D). TAU intronic probes that were not bound at all (i10-3 and 
i9-5) further show the specificity of the binding in this assay because not all intronic 
probes show a biotin signal (Figure 17B,C). Interestingly, the probes with the most 
significant binding (i9-1, i9-2, i10-2) are all located around the regulated exon 10.  
These results indicate a direct binding of endogenous FUS to TAU pre-mRNA 
specifically at sites around the FUS-regulated exons 3 and 10.  
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Figure 17 Endogenous FUS directly binds TAU pre-mRNA in the mouse brain 
Mouse brain lysates (age 15 days) were incubated with biotin-labeled TAU RNA probes and 
crosslinked with ultraviolet (UV)-light. Protein-RNA complexes were immunoprecipitated with 
anti-FUS or anti-GST antibody as control and analyzed by immunoblotting with streptavidin-HRP 
and anti-FUS antibody. (A) Immunoblot with streptavidin-HRP of the mouse brain lysate after 
(clear) and before (crude) clearing. Note that the input was successfully cleared from biotin-
proteins without altering the FUS levels in the samples. The arrow points the location of the FUS 
band in the blot. Note that none of the prominent biotin bands runs exactly at the same position as 
FUS. (B, C, D) Immunoblots from FUS- and control-immunoprecipitates. Positive signal with 
streptavidin-HRP (Biotin-FUS signal) indicates direct binding between FUS protein and labeled 
TAU RNA probe. Lysates that were not incubated with RNA (no RNA) but otherwise treated as 
the other samples served as a negative control (B). (C) GAPDH RNA probes were also used as 
negative controls.  
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4.2.3. Endogenous FUS preferentially binds TAU pre-mRNA at conserved regions 
in introns 
In order to identify a sequence that could determine FUS binding to RNA, I first 
evaluated the conservation of sequences between mouse/rat/human in probes that showed 
strong binding. I then evaluated emerging sequence patterns among those probes.  
First, sequences from bound probes showed a good conservation between human and 
rodent, despite being intronic sequences (Figure 18). Such conserved regions in introns 
can point to regulatory elements in the sequence. Second, I evaluated the frequency of 
AUU-rich regions, which are reported to be a RNA motif preferentially bound by FUS in 
a recent crosslinking and immunoprecipitation (CLIP) study in HEK 293-FT cells (Hoell 
et al, 2011). I found many such AUU motifs in the binding probes. Interestingly, mouse 
TAU pre-mRNA contains three AUU-rich regions in intron 9 (9-17 AUUs in 300 
nucleotides). Probe i9-2, which is located closest to exon 10, encompasses 17x AUU 
motifs and shows a good conservation between rodents and humans (Figure 18B). AUUs 
were however not absolutely required, as a probe with low AUU content (e.g. i2-1) also 
showed strong binding (compare Figure 18A to Figure 17B).  
These results lead to the conclusion, that endogenous FUS in mouse brain binds TAU 
mRNA at conserved regions preferentially in introns. These regions were often, but not 
always, AUU-rich sequences. 
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Figure 18 Alignment of mouse, rat and human TAU pre-mRNA for FUS interacting probes 
i2-1, i9-2 and i10-2  
Alignment of sequences retrieved from Ensembl for the mouse TAU pre-mRNA probes i2-1 (A), 
i9-2 (B), i10-2 (C) and the homologue sequences in rat and human MAPT. Conserved residues are 
marked in red, semi-conserved in pink and gaps or residues not-conserved are marked in blue. 
AUU motifs in the mouse sequence are marked with a black bar above the mouse sequence. Note 
the high degree of conservation for probes that show strong binding to FUS protein (compare to 
Figure 17). 
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4.3.  FUS regulates TAU alternative splicing in human cell culture systems 
4.3.1. TAU minigene constructs to study alternative splicing in cell lines 
After confirming that FUS regulates alternative splicing of TAU through direct binding 
using rat hippocampal neurons and mouse brain extracts, the question arose if it would be 
possible to detect the influence of FUS on TAU splicing using a heterologous system. For 
this, two TAU minigenes constructs were cloned covering mouse exons 9 through 11 and 
exons 1 through 4, to evaluate the splicing events around exon 10 and exon 2/3 separately 
(Figure 19). The minigene constructs include the full intron sequences between the exons 
evaluated. Two tags, myc and HA, at the N-terminal and C-terminal part of the sequences 
respectively, allow detection of the spliced fragments at protein level by immunoblotting.  
 
Figure 19 FUS knockdown alters splicing of a TAU minigene in HEK 293-FT cells 
HEK 293-FT cells were co-transfected with TAU minigenes and the indicated shRNAs. The 
shRNA against FUS targets specifically the human FUS gene. The TAU minigenes reflect 
splicing events around exon 10 (A) or around exon 2 and exon 3 (B). The processed reporter 
protein is HA-tagged and is detected in immunoblotting with HA antibody. FUS and beta-actin 
blots confirm the knockdown efficiency. Note that FUS knockdown in HEK 293-FT cells results 
in a strong shift in alternative splicing only in the E9-E11 TAU minigene and not the E1-E4 TAU 
minigene. 
HEK 293-FT cells were first transfected on day 1 with constructs expressing shRNAs 
(shLuc control or FUS shRNA) to allow for sufficient knockdown. After re-plating on 
day 2, control and FUS knockdown HEK 293-FT cells were additionally transfected on 
day 3 with the TAU minigene constructs. The protein samples were analyzed with 
immunoblotting. HEK 293-FT cells transfected with the E9-E11 minigene construct and 
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control shRNA (shLuc) predominantly expressed the smaller TAU fragment 
corresponding to the 3R isoform and some 4R fragment. Upon FUS knockdown, 
however, there was a strong increase in expression of the 4R corresponding TAU 
fragment, indicating preferential exon 10 inclusion upon loss of FUS (Figure 19A). In 
contrast, the E1-E4 TAU minigene was processed similarly in both shLuc control and 
FUS knockdown HEK 293-FT cells. The samples showed similar abundance of the three 
protein products corresponding to the 0N isoform, lacking exon 2 and 3; 1N isoform 
containing only exon 2; and 2N isoform containing both exon 2 and exon 3 (Figure 19B). 
Together, these results confirm, in a heterologous system, that FUS knockdown results in 
preferential inclusion of exon 10. The splicing event involving exons 2 and 3 could not be 
confirmed in HEK 293-FT cells, which may be due to the lack of additional neuron-
specific splicing factors in these cells.  
4.3.2. LUHMES cells: human neuronal-like cell culture system to study TAU 
The alternative splicing of TAU is markedly different between mouse/rat and humans. 
Although the shift during development towards longer TAU isoforms is common to 
mouse, rat and humans, there is a marked difference in the ratio between 3R and 4R TAU 
reached in adulthood. Adult mice and rats express predominantly the largest 4R TAU 
isoform (Kosik et al, 1989). Adult humans, in contrast, express both 3R and 4R TAU 
isoforms at a delicately controlled 1:1 ratio (Gao et al, 2000). This ratio, when disturbed 
for example by MAPT mutations, can cause FTD (Brunden et al, 2008). In order to link 
the role of FUS on TAU splicing to human neurodegenerative diseases, it was very 
important to confirm the results also in human cells expressing TAU.  
For this, I used the human mesenchymal cell line LUHMES (Lund human 
mesencephalic), which is immortalized by myc-expression (Lotharius et al, 2002; 
Lotharius et al, 2005; Scholz et al, 2011). LUHMES cells, in the dividing culture, are 
small irregularly shaped cells that tend to form colonies (Figure 20B). By changing 
growth factors and adding tetracycline to repress the transgenic v-myc oncogene, 
LUHMES cells stop dividing and differentiate into postmitotic neuronal-like cells (Figure 
20A). The differentiation process is fast and cells begin to elongate and take a neuronal-
like shape already after 3 days of differentiation. By day 6, the cells reach the typical 
morphology of a mature neuron, including long neuronal processes and small rounded 
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cell bodies (Figure 20B). Cells at this stage show expression of neuronal and synaptic 
markers and lose expression of embryonic cell markers (Scholz et al, 2011). 
 
Figure 20 LUHMES cells as a human cell culture model to study TAU 
Lund human mesencephalic (LUHMES) cells are human mesencephalic cells transformed by 
overexpressing the v-myc oncogene controlled by tetracycline. The cell line is a subclone of the 
MESC2.10 cell line originating in Lund University, Sweden (Lotharius et al, 2002). (A) Scheme 
followed to differentiate the LUHMES cells line into neuronal-like cells. The coating condition 
(PLL or PLL + Fibronectin) and the medium supplemented with (N2 + bFGF) or (Tetracycline + 
cAMP + GDNF) provide the signals for the cells to stop dividing and to differentiate. After 6 
days, LUHMES cells have completed the differentiation process. Adapted from: (Lotharius et al, 
2005; Scholz et al, 2011). (B) Bright field images of living cells at the undifferentiated stage 
(upper panel) and after six days of differentiation (lower panel). Right panels show a higher 
magnification view of the area marked with white boxes in the left panel. Note the marked 
morphological changes that LUHMES cells undergo during differentiation. (C) Immunostaining 
of LUHMES cells after 3 days (upper panel) or 17 days (lower panel) of differentiation using 
phalloidin (red) to stain F-actin and using antibodies against acetylated tubulin (blue) or 
tyrosinated tubulin (green), to evaluate the stable and dynamic tubulin populations. The acetylated 
tubulin population generally represents stabilized microtubules and the tyrosinated tubulin 
population represents dynamic microtubules. Note that the acetylated population becomes 
prominent at later stages of differentiation. Right panels show a high magnification view of the 
area marked with white boxes in the left panel. 
The differentiation process and maturation of the cytoskeleton was monitored by 
immunofluorescence with cells fixed at different time points. The growth cone structure 
was visible from DIV 3 and showed typical neuronal growth cone shape with F-actin 
staining at DIV 17. Both acetylated and tyrosinated tubulins, used here as markers for 
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stabilized and dynamic microtubules respectively, showed the expected normal 
distribution, as in primary cultured neurons (Figure 20C) (Witte et al, 2008).  
In summary, LUHMES cells were successfully differentiated into neuronal-like cells with 
typical neuronal morphology of the cytoskeleton.  
4.3.3. FUS knockdown in LUHMES cells results in increased 4R TAU expression 
Transduction of differentiated LUHMES cells with lentivirus to knockdown or 
overexpress human FUS was successful, although compared to rat neurons, higher 
lentivirus concentration was needed to achieve >90% transduction efficiency. FUS 
knockdown was >95% efficient, as confirmed by immunoblotting and qPCR (Figure 
21A,B). Overexpression of HA-human FUS was also efficient and reached a 13x increase 
compared to control cells expressing GFP. Total TAU mRNA level was not significantly 
altered neither by FUS knockdown nor by FUS overexpression (Figure 21B). 
Interestingly, immunoblots with TAU antibody showed altered running behavior of the 
TAU isoforms in FUS knockdown samples (Figure 21A). The band pattern was, however, 
not identical to that of rat neurons (compare Figure 7 to Figure 21) and corresponded 
mainly to the 3R TAU isoforms. 4R TAU was undetectable in immunoblots. qPCR 
analysis revealed 0N3R as the most abundant TAU isoform expressed in LUHMES cells 
at DIV7+9 and confirmed the low expression of 4R TAU with markedly higher Ct values 
(data not shown). Further, qPCR analysis revealed a significant increase in 4R TAU 
expression upon FUS knockdown similar to the effect seen in rat primary neurons. Also 
as expected, FUS overexpression resulted in a slight decrease in 4R TAU expression. In 
contrast, TAU exon 3 splicing remained largely unchanged in LUHMES cells upon FUS 
knockdown.  
In summary, these results demonstrate that altering FUS levels in human neuronal-like 
cells also influences alternative splicing specifically of TAU exon 10. Different reasons 
could account for the discrepancies between rat primary neurons and human neuronal-like 
cells regarding splicing of exon 2 and exon 3, including missing co-regulatory factors in 
the differentiated human cell line compared to the rat primary neurons.  
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Figure 21 FUS knockdown in differentiated LUHMES cells results in increased 4R TAU 
expression 
LUHMES cells were transduced with lentivirus to express shRNAs (shLuc control or shFUS) 
after 7 days of differentiation. The shFUS construct used here targets specifically human FUS. 
Lentivirus was also used to overexpress GFP or HA-FUS wildtype in LUHMES cells. Protein and 
RNA samples were collected 9 days after transduction and analyzed with immunobloting or 
quantitative PCR respectively. (A) Immunoblot of LUHMES cell samples using anti-FUS and 
anti-TAU antibodies. The FUS blot confirms the efficiency of the knockdown and the TAU blot 
shows marked differences in the running behavior of TAU. (B) Quantitative PCR analysis of FUS 
knockdown or overexpression LUHMES cell samples. FUS and total TAU expression was 
normalized to the housekeeping gene YWHAZ. n=3, mean +/-SEM are shown. Note the 
efficiency of the FUS knockdown and HA-FUS overexpression. Total TAU levels were not 
significantly altered. (C) Quantitative PCR analysis of FUS knockdown or overexpression in 
LUHMES cell. TAU isoforms expression was normalized to total TAU levels. n=3, mean +/-SEM 
are shown, one-way ANOVA with Dunnett’s post-test: *p<0.05.  
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4.4. Functional consequences of FUS knockdown in neurons 
4.4.1. Early FUS knockdown in neurons results in shorter axons and aberrant 
growth cone morphology 
Based on the results presented here showing that FUS regulates the alternative splicing of 
TAU, I focused my evaluation of functional consequences of FUS knockdown on the 
development and morphology of neuronal axons. Additionally, neurons cultured from 
FUS knockout mice show altered spine morphology (Fujii et al, 2005), which also 
prompted an evaluation of the axonal morphology in FUS deficient neurons. 
 
Figure 22 Early FUS knockdown in hippocampal neurons does not affect neurite growth, 
axonal branching or cell viability 
Rat hippocampal neurons were co-transfected before plating with the indicated shRNAs (shLuc or 
shFUS) and pEYFP-C1 to control the transfection. (A) Immunostaining after 4 days in culture 
with the indicated antibodies. The arrows mark transfected cells. (B) Quantification of number of 
neurites, (C) number of axonal branch points, and (D) cell viability (DIV14) of neurons with early 
knockdown of FUS. Note that prolonged FUS knockdown did not significantly alter cell viability. 
Note also that control and FUS knockdown cells are statistically indistinguishable regarding 
number of neurites, number of axonal branch points or cell viability. Values presented as mean 
+/-SEM, n=3, student’s t-test, all not significant.  
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To address this question, freshly isolated rat hippocampal neurons were transfected before 
plating with shRNA control (shLuc) or against FUS (shFUS) using nucleofection 
(Lonza). After 4 days in vitro (DIV 4), FUS knockdown was confirmed by 
immunostaining. The transfected cells (arrows) expressed significantly less FUS 
compared to the non-transfected neighboring cells (Figure 22A). Cell viability was not 
affected and around 90% of the cells had formed an axon by day 4 in both control and 
knockdown conditions (Figure 22D). Also the number of neurites and the number of 
axonal branch points did not significantly change with FUS knockdown (Figure 22B,C).  
 
Figure 23 Early FUS knockdown in hippocampal neurons reduces axon length  
Rat hippocampal neurons were co-transfected before plating with the indicated shRNAs (shLuc or 
shFUS) and pEYFP-C1 to control the transfection. (A) Immunostaining after 4 days in culture 
with the indicated antibodies. TAU1 is used as axonal marker. The field marked with a white box 
in the left panel is shown in higher magnification in the right panel. (B) Quantification of axonal 
length (n= 325 shLuc, n= 388 shFUS#2) measured blinded to the experimental condition. The 
box-plots represent the lower quartile, median, and upper quartile. The whiskers represent the 5th 
and 95th percentile. For the morphometric analysis, the axon was defined as the longest process 
with proximal-to-distal TAU1 gradient. Mann–Whitney test: ***P<0.001. Scale bars: 25 µm. 
Despite the unchanged viability and normal axonal branching, the quantification of 
axonal length did show a small but significant decrease in axonal length in the FUS 
knockdown group (Figure 23).  
While quantifying images, I constantly noticed a disturbed morphology of the axonal 
growth cone in the FUS knockdown condition (Figure 23, 24). FUS knockdown neurons 
developed severely enlarged growth cones that, in contrast to the control conditions, 
showed prominent TAU staining.  
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Figure 24 Extensive TAU staining observed in enlarged axonal growth cone of FUS depleted 
hippocampal neurons 
Rat hippocampal neurons were co-transfected before plating with the indicated shRNAs (shLuc or 
shFUS) and pEYFP-C1 to control the transfection. Immunostaining after 4 days in culture with 
the indicated antibodies. TAU1 is used as axonal marker. The field marked with a white box in 
the left panel is shown in higher magnification in the right panel. For the morphologic analysis, 
the axon was defined as the longest process with proximal-to-distal TAU1 gradient. Scale bars: 25 
µm. 
F-actin and β3-tubulin stainings of control and FUS depleted neurons were used to better 
visualize the axonal growth cone (Figure 25). This staining corroborated the results 
previously obtained with TAU, since also the 3-tubulin staining showed prominent 
spreading of the microtubules further into the enlarged growth cone area, which had a less 
bundled appearance compared to the control transfected neurons (Figure 25). The 
quantification of the growth cone area showed a significant shift in the frequency of 
neurons showing enlarged growth cones. On average, the growth cones of FUS depleted 
neurons were twice as large as in the control cells (Figure 26).  
Interestingly, the cytoskeletal phenotype (shorter axons with enlarged growth cones) of 
FUS depleted neurons strongly resembles the aberrant growth cone structure observed in 
TAU/MAP1B-double knockout neurons (Takei et al, 2000). 
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Figure 25 Early FUS knockdown in hippocampal neurons results in microtubules spreading 
further into the axonal growth cone area 
Rat hippocampal neurons were co-transfected before plating with the indicated shRNAs (shLuc or 
shFUS) and pEYFP-C1. Immunostaining after 4 days in culture with the indicated antibodies and 
phalloidin to stain F-actin. Rightmost panels show a high magnification view of axonal growth 
cones, marked with white boxes in the middle panel. Scale bars: 25 µm.  
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Figure 26 Early FUS knockdown in hippocampal neurons results in significantly enlarged 
growth cones  
Rat hippocampal neurons were co-transfected before plating with the indicated shRNAs (shLuc or 
shFUS) and pEYFP-C1. (A) Immunostaining after 4 days in culture with the indicated antibodies 
and phalloidin to stain F-actin. Right panels show a high magnification view of axonal growth 
cones, marked with white boxes in the middle panel. (B) Quantification of growth cone area 
(n=147 shLuc, n= 164 shFUS#2) measured blinded to the experimental condition. The box-plots 
represent the lower quartile, median, and upper quartile. The whiskers represent the 5th and 95th 
percentile. For the morphometric analysis, the axon was defined as the longest process. Mann–
Whitney test: ****P<0.0001. Scale bars: 25 µm.  
All together, these results show that FUS has a crucial role in cytoskeletal organization 
especially at the axonal endings. In FUS knockdown cells, axons were significantly 
shorter and showed enlarged and disorganized growth cones.  
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5. Discussion 
5.1. Identification of TAU as the first physiological FUS splicing target in neurons 
FUS is genetically and pathologically linked to ALS and FTLD. On the one hand, 
pathogenic FUS mutations cause ALS, on the other hand, FUS positive neuronal 
cytoplasmic inclusions are found in a subset of ALS and FTLD cases (Kwiatkowski et al, 
2009; Neumann et al, 2009a; Vance et al, 2009). The majority of pathogenic mutations 
disrupts the nuclear localization signal of FUS and cause cytoplasmic mislocalization of 
the protein (Bosco et al, 2010; Dormann et al, 2010). Thus, the loss of important nuclear 
functions of FUS could contribute to disease progression. FUS is also known to be a part 
of the spliceosome (Hartmuth et al, 2002; Rappsilber et al, 2002; Zhou et al, 2002), 
however, the physiological splice targets were unknown. In this study I identified and 
confirmed TAU as the first physiological splice target of FUS in neurons. FUS 
knockdown in rat neurons resulted in increased inclusion of TAU exon 3 and exon 10, 
leading to increased levels of 2N and 4R TAU. Reintroduction of human wild type FUS 
fully rescued aberrant splicing and demonstrated the specificity of the effect. 
Overexpression of wild type FUS had the opposite effect and caused a decrease in 2N and 
4R TAU expression. In contrast, overexpression of mutant FUS lacking the nuclear 
localization signal (FUS ΔC) only influenced skipping of exon 3, but not of exon 10. 
These results confirmed that the N-terminal splice cassette (exons 2 and exon 3), and the 
C-terminal exon 10 can be regulated independently (Andreadis, 2005). They also suggest 
that FUS ΔC is somehow functionally impaired to influence specifically TAU exon 10 
splicing, probably by a missing correct interaction with other proteins. 
5.1.1. TAU splicing and functional consequences  
The expression of TAU isoforms is tightly regulated during development, with 
predominant expression of the shortest isoform (0N3R) early in development and 
increased expression of the longest isoforms (2N4R and 2N3R) in adult stages 
(Andreadis, 2005; Liu & Gong, 2008). In adult human brain, the overall levels of 4R to 
3R TAU are tightly regulated and kept at a 1 to 1 ratio. In contrast, adult mice and rats 
predominantly express 4R TAU. 
Due to this difference, I also determined whether the FUS regulation of TAU splicing is 
conserved in humans using a twofold strategy. First, I analyzed splicing of a mouse 
MAPT minigene in FUS knockdown HEK 293-FT cells. Second, I evaluated alternative 
splicing of endogenous TAU in human neuronal-like cells (LUHMES) also with FUS 
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knockdown. Both approaches showed a significant increase in exon 10 inclusion upon 
FUS knockdown, which demonstrates that human FUS is also able to regulate splicing of 
TAU exon 10. In contrast, FUS knockdown had no effect on the splicing of exon 2 and 
exon 3 in the minigene and endogenous TAU. These results strongly suggest that FUS 
regulates primarily TAU exon 10 splicing in human neurons without affecting splicing of 
exon 3.  
4R TAU isoforms have higher affinity to microtubules and contain additional 
phosphorylation sites, which can also regulate protein-protein interactions (Andreadis, 
2005). The function of the TAU N-terminal part, including the conserved exon 2 and 
exon 3, is still poorly understood (Andreadis, 2005). It has been shown to associate with 
the plasma membrane (Brandt et al, 1995) and could regulate microtubules spacing (Chen 
et al, 1992). Changes in microtubule spacing in axons could have important consequences 
for axonal transport and microtubule dynamics. In addition, the N-terminus of TAU 
mediates the interaction with the membrane associated tyrosine kinase Fyn (Lee et al, 
1998). Fyn functions in signaling pathways that regulate axon guidance, cell adhesion and 
cell differentiation by activating the small GTPase RAS. Interestingly, dendritic TAU has 
been shown in vivo to target Fyn to the postsynaptic compartment thereby transducing 
NMDA receptor mediated amyloid beta cytotoxicity (Ittner et al, 2010). Therefore, the 
cell signaling and structural functions of TAU could be directly affected by loss of FUS 
in neurons due to aberrant TAU alternative splicing.  
5.2. MAPT/TAU is one of the top hits in genome-wide studies of FUS target genes 
Concurrent unbiased studies have addressed the question of FUS splice targets and RNA 
binding partners on a genome wide level. They combined crosslinking 
immunoprecipiation (CLIP) and RNA sequencing to analyze changes in RNA metabolism 
upon loss of FUS in the mouse brain or in cultured neurons (Ishigaki et al, 2012; Lagier-
Tourenne et al, 2012; Nakaya, 2013; Rogelj et al, 2012). These studies reinforce the 
notion that FUS is a key regulator of alternative splicing in the brain, because loss of FUS 
mainly alters splicing rather than transcription (Rogelj et al, 2012).  
Importantly, the recent CLIP studies have robustly confirmed TAU as a FUS splice target 
(Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; Rogelj et al, 2012). This finding is 
truly remarkable, because the overlap among studies is otherwise very limited. Most 
splice targets were identified in only one study and only six targets are reported in at least 
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three out of four studies. Additionally, the exact splice event reported was not always 
identical among studies, with the exception of TAU and NTNG1 (see below) (Annex 2). 
Such discrepancies may be attributed to differences in experimental conditions, because 
alternative splicing events are often specific to the type and age of tissue studied (Orozco 
& Edbauer, 2013).  
In line with my results, the CLIP studies reported an increase of TAU exon 10 inclusion 
(Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; Orozco et al, 2012; Rogelj et al, 2012) 
and an increase in exon 2 and exon 3 inclusion upon loss of FUS (Annex 2) (Lagier-
Tourenne et al, 2012; Orozco et al, 2012). Very recently, the effect of FUS on splicing of 
TAU exon 10 was also reported in primary motor neurons, the primary site of ALS 
(Fujioka et al, 2013). Interestingly, the other robustly identified FUS splice target is 
Netrin-G1 (NTNG1), a membrane protein that functions in axon guidance. NTNG1 was 
previously linked to Parkinson’s disease and schizophrenia (Aoki-Suzuki et al, 2005; Lin 
et al, 2009). 
The biological relevance of hits identified in genome wide studies is validated with in 
depth analysis of the mechanism and functional consequences. In the case of FUS 
regulation of splicing, the candidate based approach presented here complements and 
expands the knowledge gained in the FUS CLIP studies. 
Lastly, I also demonstrated the FUS specific regulation of TAU splicing with 
knockdowns of other ALS/FTD related proteins, such as TDP-43, TAF15, EWS or the 
uncharacterized C9orf72 which did not alter TAU splicing in neurons. This is in line with 
reports showing that there is only a small overlap of common target RNAs between FUS 
and TDP-43 and that TAU splicing is not affected by TDP-43 (Honda et al, 2014; Lagier-
Tourenne et al, 2012; Rogelj et al, 2012). Also the binding pattern of RNA targets is 
markedly different between TDP-43 and FUS. TDP-43 binds the targets with surgical 
precision, whereas FUS binds targets more broadly along the nascent transcripts, which 
indicates a possible role in the stabilization of nascent RNA during transcriptional 
elongation and alternative splicing (Lagier-Tourenne et al, 2012; Rogelj et al, 2012).  
5.2.1. Specificity of FUS RNA binding  
When evaluating changes in alternative splicing, it is crucial to confirm a direct 
interaction between the protein and the target pre-mRNA, in order to exclude an indirect 
effect by other RNA-binding proteins or a general impairment of the spliceosome. In this 
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study, I first showed that endogenous TAU pre-mRNA is associated with FUS protein in 
mouse brain lysates using FUS-IP and qPCR analysis. Then, aiming for a more detailed 
understanding of the interaction, I corroborated the direct binding of FUS to TAU mRNA 
with RNA immunoprecipitation experiments using labeled-RNA probes. Interestingly, 
FUS was able to bind TAU pre-mRNA at the introns near the alternatively spliced exons.  
Based on a previous report on a preference for AUU-rich regions (Hoell et al, 2011), I 
evaluated the presence of this motif and found that, indeed, FUS bound RNA probes often 
contained multiple AUU motifs. However, this motif was not an absolute prerequisite for 
binding. Other studies could not identify a consensus sequence for FUS binding (Ishigaki 
et al, 2012; Lagier-Tourenne et al, 2012; Nakaya, 2013; Rogelj et al, 2012). In a subset of 
targets researchers found a significant preference for G/C (Ishigaki et al, 2012), C/U 
(Nakaya, 2013), GGU (Rogelj et al, 2012) or GUGGU (Lagier-Tourenne et al, 2012) 
motifs. The preferred sequences overlap with the motif GGUG originally identified with 
in vitro studies (Lerga et al, 2001). Alternatively, the RNA secondary structure might 
mediate FUS binding specificity. One study proposed a short stem loop motif (Hoell et al, 
2011), which was confirmed by some but not all studies (Ishigaki et al, 2012; Rogelj et al, 
2012). In conclusion, until further biochemical studies clarify RNA binding specificity 
(Nakaya, 2013), GGU and AUU rich sequences remain the best consensus sequence 
mediating FUS RNA binding.  
5.3. Functional consequences of FUS knockdown 
Based on the observation that the axonal protein TAU is mis-spliced upon FUS 
knockdown, I focused on the axonal architecture of FUS depleted neurons as a read out 
for the functional consequences on axonal development. After 4 days in culture FUS 
depleted neurons developed axons that were significantly shorter than those from the 
control cells. Neurite outgrowth and axonal branching events were, however, not affected. 
This is in line with previous studies that show decreased axon length but no effect on the 
length of minor processes in siRNA treated neurons to knockdown TAU (Qiang et al, 
2006). Also neurons cultured from MAP1b/TAU double knockout mice show 
significantly reduced axon length compared to the controls (Takei et al, 2000). In addition 
to the reduced axon length, I also observed a significant shift in the frequency of neurons 
with enlarged axonal growth cones in FUS depleted neurons. This phenotype was 
strikingly similar to the disturbed growth cone structure seen in neurons cultured from 
MAP1b/TAU double knockout mice (Takei et al, 2000). Remarkably, the two most robust 
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FUS phenotypes reported here (shorter axons and enlarged growth cones) have been 
previously reported in TAU/MAP1b deficient neurons. Although FUS target genes other 
than TAU may still contribute to the axonal phenotype, these results clearly indicate that 
loss of FUS regulates cytoskeletal dynamics. Neuronal growth cones have an important 
role not only in the development but also the repair of the adult nervous system. At adult 
stages, healthy growth cones are essential structures to repair damaged axons, as 
determined with in vivo studies (Bradke et al, 2012).  
Interestingly, gene ontology analysis of splice targets reported in CLIP studies 
consistently showed enrichment for proteins with axonal function, including 
axonogenesis, axon guidance, cell adhesion, neuron projection, vesicle transport, and 
cytoskeletal organization (Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; Nakaya, 
2013; Rogelj et al, 2012). Therefore, FUS seems to regulate the alternative splicing of a 
network of genes responsible for maintaining and growing axons. Consequently, loss of 
FUS function in ALS/FTLD-FUS cases could have direct adverse effect on physiological 
axon regeneration and thus promote disease progression by reducing the repair capacity.  
5.4. Pathomechanism model centered on FUS regulation of alternative splicing 
A new model for the pathomechanism behind ALS/FTLD-FUS emerges from the recent 
finding that FUS splice targets maintain and repair axons (Figure 27) (Orozco & Edbauer, 
2013). The model presented here is based on the multiple-hit hypothesis (Dormann & 
Haass, 2011) and on the role of FUS as central regulator of alternative splicing with RNA 
targets clustering in similar pathways (Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; 
Nakaya, 2013; Orozco & Edbauer, 2013; Rogelj et al, 2012). Such a central regulation of 
specific pathways is a common feature of RNA-binding proteins (Hogan et al, 2008; 
Keene, 2007; Ule et al, 2005). 
The model includes the following events. (1) The first step in the pathological cascade is 
the mislocalization of FUS to the cytoplasm caused, for example, by mutations in the 
NLS (Dormann & Haass, 2011). (2) The loss of nuclear FUS function leads to aberrant 
alternative splicing of several targets involved in axon maintenance and repair. As a 
consequence, neuronal connections with neighboring and distant cells are weakened. 
Cytoplasmic aggregates can also reinforce the mechanism by sequestering FUS and other 
RNA-binding proteins into the aggregates or by evoking aberrant protein-protein 
interactions. (3) In addition to the initial weakening, aging and other stressors (Dormann 
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& Haass, 2011; Dormann & Haass, 2013) can disturb neuronal integrity which results in 
denervation and may trigger early clinical symptoms. (4) Finally, progressive 
neurodegeneration is the consequence of disrupted repair mechanisms and limited tissue 
renewal in the brain.  
 
Figure 27 Hypothesis for pathomechanism in ALS/FTLD-FUS focused on FUS mediated 
alternative splicing 
(1) Impaired nuclear import of FUS, due to mutations in the NLS or transport defects, causes 
mislocalization of FUS to the cytoplasm. This leads to loss of nuclear function and thus changes 
in alternative splicing of axonal and cytoskeleton related genes. (2) Altered splicing disturbs 
axonal maintenance and repair resulting in axonal atrophy and loss of connectivity. (3) Aging and 
stress accelerate the process of neuronal denervation and lead to the first clinical symptoms, since 
synapses or neuromuscular junctions (NMJ) start to fade out. (4) Due to disturbed repair 
mechanisms, the affected neurons are not able to cope with the stress and to repair damaged 
connections. The result is progressive degeneration observed in disease. From (Orozco & 
Edbauer, 2013). 
5.4.1. Open questions 
Although the model offers an initial hypothesis to understand the role of FUS in the 
pathogenesis of ALS and FTLD, many new questions arise and need further investigation. 
FUS binds many RNAs that are apparently not affected in splicing or expression upon 
loss of FUS. Are all of these RNAs only transport targets or are they affected in other 
ways, for example in their stability? Also, FUS binds many long non-coding RNAs 
(lncRNA), which can regulate, among others, transcription, chromosomal dynamics and 
subcellular organization (Mercer et al, 2009). What is the function of FUS binding to 
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lncRNAs? Two interesting lncRNA targets are the maternally expressed 3 (Meg 3) and 
nuclear enriched abundant transcript 1 (NEAT 1) (Lagier-Tourenne et al, 2012), because 
of their reported dysregulated expression in HD (Johnson, 2012). Interestingly, in FTLD-
TDP cases TDP-43 showed increased binding of NEAT1, an essential regulator of 
paraspeckles in the nucleus, when compared to controls (Clemson et al, 2009; Tollervey 
et al, 2011). Furthermore, the nature of FUS aggregates in the cytoplasm remains unclear; 
how are they formed? Can that process be reversed? And finally, beside FUS function in 
alternative splicing, how are other functions affected by the mislocalization? One 
recurring theme among animal models has been the role of FUS in genomic stability 
(Hicks et al, 2000; Kuroda et al, 2000; Wang et al, 2013). This role could also be essential 
for normal cell function, as recent studies show that healthy post-mitotic neurons require 
constant genome repair, as double strand breaks result from normal synaptic activity 
(Suberbielle et al, 2013). In summary, loss of FUS could be detrimental to normal 
neuronal function by disturbing multiple pathways that together lead to ALS/FTLD.  
5.5. The link between TAU and FUS in disease 
In order to finally link FUS regulation of TAU alternative splicing to ALS/FTLD, it will 
be crucial to evaluate TAU alternative splicing and cytoskeletal aberrations in 
ALS/FTLD-FUS tissue, ideally using laser microdissection of neurons with FUS 
inclusions. Also, it will be important to investigate if other TAU related diseases 
(tauopathies) show FUS pathology or even FUS mutations.  
Tauopathies are defined neuropathologically by the presence of hyperphosphorylated 
TAU aggregates (Brunden et al, 2008; Lee et al, 2001). However, several animal models 
have shown that neuronal toxicity precedes TAU aggregation, demonstrating that non-
fibrillary TAU can cause neurodegeneration and cognitive symptoms (Brunden et al, 
2008; de Calignon et al, 2010). MAPT mutations around exon 10 in some inherited 
tauopathies suggest that misbalanced expression of TAU isoforms may cause disease 
(Goedert & Jakes, 2005; Lee et al, 2001). Importantly, enhanced expression of either 4R 
TAU or 3R TAU both result in disease in humans and animal models. This emphasizes 
the importance of TAU isoform balance for physiologic function (Brunden et al, 2008; 
Ishihara et al, 1999; Sergeant et al, 1997). In PD, for example, 4R TAU expression levels 
correlate with co-occuring dementia, although PD cases do not show overt TAU 
pathology (Caffrey et al, 2006; Tobin et al, 2008; Williams-Gray et al, 2009). Also the H1 
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haplotype at the MAPT locus, which enhances 4R TAU expression, was identified as a 
strong genetic risk factor for PD (Caffrey et al, 2006; Tobin et al, 2008).  
Interestingly, downregulation of FUS has been reported in PD (Stamper et al, 2008), 
again showing a link between FUS and TAU in disease. Furthermore, the role of FUS in 
essential tremor (ET), an adult-onset movement disorder, is still debated after a report that 
genetically associated FUS to ET through exome sequencing (Agúndez et al, 2013; 
Merner et al, 2012; Ortega-Cubero et al, 2013). Of note, TAU has also been genetically 
(Sundar et al, 2007) and pathologically (Buée-Scherrer et al, 1995) linked to the Guam 
variant of ALS, which demonstrates that alterations in TAU can also cause ALS. In 
summary, genetic and pathology aspects of neurodegenerative diseases may have 
previously linked FUS and TAU indirectly. The results presented in this thesis now 
provide a direct molecular link between FUS and TAU, by showing that loss of FUS 
enhances expression of 4R TAU, which is a well-established cause of disease even in the 
absence of TAU pathology (Brunden et al, 2008; Hutton et al, 1998; Tobin et al, 2008).  
5.5.1. Future challenges 
Future challenges include the generation of better animal models for ALS/FTLD-FUS 
and human TAU splicing. Emerging genome editing technologies could for the first time 
enable the study of FUS pathogenic mutations with endogenous expression. Also, in order 
to circumvent lethality in FUS KO mice, an inducible mouse line with neuron specific 
FUS depletion could be generated. Although the current FUS animal models already 
indicate that balanced FUS levels are essential for normal development and function, 
future models should also address the role of FUS in non-neuronal cells, since FUS 
patients also often show inclusions in glia cells (Ling et al, 2013; Neumann et al, 2009a). 
In a TDP-43 rat model, for instance, expression of human mutant TDP-43 specifically in 
astrocytes was sufficient to induce progressive paralysis due to denervation of skeletal 
muscles and motor neuron loss (Tong et al, 2013).  
Furthermore, new models are needed that recapitulate the unique regulation of human 
TAU alternative splicing, which is remarkably different than the regulation in the murine 
nervous system (Gao et al, 2000; Kosik et al, 1989). For this, one could apply human 
induced pluripotent stem cells (iPS) that are then differentiated into motor neurons 
suitable for longer cultures. Such powerful tools could help investigate the influence of 
misbalanced isoform expression on emerging roles of TAU protein, such as signal 
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transduction, stress response and neuronal signaling (Morris et al, 2011; Timm et al, 
2006). 
In conclusion, classification of different disease subtypes based on molecular pathology is 
a useful tool; however we should be aware of exceptions and embrace the opportunities 
behind shared pathomechanisms. Especially infrequent conditions such as ALS/FTLD-
FUS could benefit from ongoing clinical and pre-clinical studies focusing on other 
tauopathies. One example is the microtubule stabilizing agent NAP/davunetide which is 
currently tested in phase II clinical trials for FTLD-TAU patients and individuals with 
mild cognitive impairment (Morimoto et al, 2013; Morris et al, 2011; Trojanowski et al, 
2008).  
A greater understanding in the molecular mechanism behind the disease is the first step in 
the effective translation of our findings into treatment of patients suffering from 
devastating progressive neurodegeneration. 
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7. Annex 
Annex I 
 
Figure 28 Rat MAPT/TAU 2N4R isoform 
The MAPT nucleotide and protein sequence presented here is supported by cloning data and is 
based on the MAPT rat isoform sequences annotated in NCBI and Ensembl databases. Note that 
the exon names are given with quotation marks to avoid confusion, because the exon number can 
vary depending on the isoform. Characteristic protein domains, as the N-terminal inserts and 
microtubule binding domains (R1-4), are also labeled. Note that the microtubule domains contain 
the typical KXGS motif.  
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Annex II 
Table 1 Alternative splicing upon loss of FUS: hits identified in at least 3 studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The columns list the splicing event reported in each publication for the genes marked in the row 
headers. Each splicing event includes the type of event (eg. inclusion) and the identifier of the 
exon involved. All coordinates were analyzed with the Ensembl mouse genome NCBIM37. In 
case of ambiguity, all exons in the chromosomal region are listed. Exons identified more than 
once are marked in bold. ENSMUSE00000xxxxxx Ensembl unique and stable mouse exon 
identifier n.d. not detected. Adapted from (Orozco & Edbauer, 2013) and based on the 
publications (Ishigaki et al, 2012; Lagier-Tourenne et al, 2012; Nakaya, 2013; Rogelj et al, 2012).  
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Loss of fused in sarcoma (FUS) promotes pathological
Tau splicing
Denise Orozco1,2, Sabina Tahirovic1, Kristin Rentzsch1, Benjamin M. Schwenk1, Christian Haass1,3
& Dieter Edbauer1,3+
1German Center for Neurodegenerative Diseases (DZNE), Munich, Germany, 2The International Max Planck Research School
for Molecular and Cellular Life Sciences, Martinsried, Germany, and 3Adolf Butenandt Institute, Biochemistry,
Ludwig-Maximilians University Munich, Munich, Germany
A subset of amyotrophic lateral sclerosis (ALS) and fronto-
temporal lobar degeneration (FTLD) patients present pathological
redistribution and aggregation of the nuclear protein fused in
sarcoma (FUS) in the cytoplasm. Although FUS associates with
the spliceosomal complex, no endogenous neuronal splicing
targets have been identified. Here we identify Tau mRNA as a
physiological splicing target of FUS. In mouse brain, FUS directly
binds to Tau pre-mRNA, and knockdown of FUS in hippocampal
neurons leads to preferential inclusion of Tau exons 3 and 10. FUS
knockdown causes significant growth cone enlargement and
disorganization reminiscent of Tau loss of function. These findings
suggest that disturbed cytoskeletal function and enhanced
expression of the neurodegeneration-associated Tau exon 10
might contribute to FTLD/ALS with FUS inclusions.
Keywords: neurodegeneration; FUS; RNA-binding
protein; splicing; Tau (MAPT)
EMBO reports advance online publication 19 June 2012; doi:10.1038/embor.2012.90
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) and amyotrophic
lateral sclerosis (ALS) have recently been recognized as opposite
ends of a disease spectrum with overlapping clinical symptoms,
genetics and pathology [1,2]. These devastating neurodegenerative
diseases are now subdivided by specific marker proteins identified in
abnormal aggregates, including Fused in sarcoma (FUS) [2–4]. The
RNA/DNA-binding protein FUS normally resides predominantly in
the nucleus, but is found in cytosolic inclusions of both FTLD and
ALS patients. FUS binds to numerous mRNAs in HEK293 cells,
however with little correlation to transcript abundance [5]. Although
FUS associates with the spliceosomal complex [6], no endogenous
neuronal splicing target is known so far and the role of FUS-mediated
splicing in FTLD/ALS remains unclear. Two observations suggest
that the loss of nuclear FUS activity contributes to FTLD/ALS
pathophysiology: First, mutations disrupting the C-terminal nuclear
targeting sequence of FUS cause early-onset ALS [3,4,7]. Second,
even in the absence of FUS mutations, a partial nuclear clearing of
FUS is apparent in neurons with FUS aggregates [1].
Here we identify the microtubule-associated protein Tau (MAPT)
as a physiological splicing target of FUS in neurons and found
morphological alterations in axons and growth cones that are
reminiscent of Tau-knockout mice [8]. The MAPT gene consists
of 16 exons and gives rise to six main transcripts in the central
nervous system (supplementary Fig S1A online) [9,10]. The
shortest Tau isoform, termed 0N3R, lacks exons 2, 3 and 10.
Inclusion of exon 2 or exons 2 and 3 leads to insertion of one
or two 29-amino acid regions (1N, 2N). Inclusion of exon 10
gives rise to a fourth microtubule-binding region (4R). The
composition of the N-terminal projection domain determines
microtubule spacing and might affect cellular signalling [9,11].
Somatodendritic Tau aggregates with characteristic isoform
composition are found in Alzheimer’s disease and a subset of
FTLD collectively termed FTLD–Tau, including Pick’s disease and
corticobasal degeneration [2,12]. Mutations that lead to the
preferential inclusion of exon 10 cause frontotemporal dementia
and parkinsonism [13], showing the importance of exon 10
inclusion for FTLD–Tau disease pathology. Our data show that FUS
knockdown enhances expression of Tau exon 10. Tau aggregation
has so far not been described in patients with FUS pathology.
However, there is evidence that non-fibrillar Tau can cause
neurodegeneration and cognitive symptoms [14,15]. For example,
the H1 haplotype at the MAPT locus moderately enhances exon 10
inclusion and is a strong genetic risk factor for Parkinson’s disease,
which also lacks overt Tau pathology [16,17].
RESULTS AND DISCUSSION
FUS knockdown affects levels of 4R Tau
Tau has been linked to many neurodegenerative disorders
including FTLD–Tau. Therefore, we analysed Tau expression
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upon FUS knockdown in rat primary hippocampal neurons using
lentiviral expression of short hairpin RNAs (shRNAs). We
transduced neurons at day 2 in vitro and collected proteins 7
days later (DIV2þ 7). Two FUS-specific shRNAs (shFUS#1 and
shFUS#2) specifically suppressed FUS protein expression com-
pared with a control shRNA targeting the luciferase transcript
(shLuc; Fig 1A). An XTT-based cell viability assay confirmed that
FUS knockdown showed no overt toxicity in this context
(supplementary Fig S2A online). Although the main Tau isoform
(lower band) was unchanged, a larger isoform (upper band)
appeared upregulated in FUS-knockdown neurons (Fig 1A).
A Tau exon 10-specific antibody showed robustly increased
levels of 4R Tau (comigrating with the upper Tau band), suggesting
an effect of FUS on Tau splicing. In contrast, 3R Tau expression
was not significantly affected by FUS knockdown. The amount
and running behaviour of several other key synaptic proteins
were unaffected by FUS knockdown, including synaptic
scaffold proteins (PSD95), glutamate-receptor subunits (NR1,
NR2A and GluR2), synaptic vesicle proteins (synaptophysin)
and cytoskeletal proteins (b-actin and b-tubulin, Fig 1A;
supplementary Fig S2B online). Together, these data strongly
indicate that FUS knockdown affects splicing of Tau exon 10.
FUS knockdown affects Tau mRNA splicing
To further explore how FUS knockdown modifies Tau splicing in
neurons, we designed isoform-specific primers for the alterna-
tively spliced exons 2, 3 and 10 (supplementary Fig S1B online).
Reverse transcription and quantitative real-time PCR (qPCR)
allowed for quantitative comparison of exon insertion between
FUS knockdown and control shRNA-infected neurons. About 80%
reduction of FUS levels did not significantly affect total Tau mRNA
expression (Fig 1B), but caused significant upregulation of the
2N and 4R Tau isoforms.
As FUS and TDP-43 aggregation cause similar clinical
symptoms in FTLD and ALS patients, it is tempting to hypothesize
that FUS and TDP-43 regulate overlapping mRNA targets [1].
We therefore used lentiviral shRNA to downregulate TDP-43
in hippocampal neurons and analysed the expression of Tau
isoforms by qPCR. Consistent with previous results [18], splicing
of exons 2, 3 and 10 was not significantly affected by TDP-43
knockdown (supplementary Fig S3 online). Thus, aberrant Tau
splicing might contribute to FTLD/ALS pathophysiology with FUS
inclusions, but not with TDP-43 inclusions.
FUS reintroduction rescues altered Tau splicing
To confirm that altered Tau splicing upon shFUS treatment is
mediated by loss of FUS and not by off-target effects, we
performed rescue experiments by reintroduction of FUS in
shRNA-treated cells. We doubly infected neurons with lentiviral
vectors expressing shRNA (shLuc or shFUS#2) and haemagglutinin
(HA)-tagged wild-type human FUS resistant to shFUS#2. Trans-
duction with HA–FUS strongly increased FUS-expression com-
pared with the endogenous levels of shLuc control infected cells
(Fig 2A). Importantly, HA–FUS co-transduction not only prevented
the shFUS#2-mediated upregulation of 4R Tau, but even
suppressed its expression below shLuc control levels (Fig 2A).
Similarly, HA–FUS coexpression completely abolished the
induction of 2N and 4R isoforms by shFUS on mRNA level
(Fig 2B). The full rescue of the shFUS#2-mediated splicing effects
by overexpression of FUS strongly argues for a FUS-specific effect.
FUS is associated with Tau transcripts in the brain
To test whether FUS is associated with Tau RNA, we performed
immunoprecipitations from mouse brain (P15) extracts using a
FUS antibody and a GST antibody as a negative control, followed
by isolation of the bound RNA. By reverse transcription and qPCR
we amplified Tau pre-mRNA using intronic primers and compared
the recovery of Tau pre-mRNA from the immunoprecipitates.
While the control immunoprecipitates contained no detectable
Tau pre-mRNA (Fig 3A,B), FUS-immunoprecipitates recovered
about 1% of the input material, which strongly suggests a specific
interaction. Using intron-spanning primers, we also detected
spliced Tau mRNA specifically enriched (but to a lesser extent
than pre-mRNA) in FUS-immunoprecipitates. The enrichment of
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Fig 1 | FUS knockdown enhances expression of Tau exons 3 and 10. Hippocampal neurons (DIV2þ 7) were infected with lentivirus to knockdown FUS
(shFUS#1 and #2) or non-targeting control (shLuc). (A) Immunoblots with the indicated antibodies. Note that the two main Tau isoforms comigrate
with 4R and 3R Tau. Two replicates are shown. (B) Total RNA was analysed by quantitative PCR for FUS, total Tau and Tau isoforms. FUS and total
Tau expression was normalized to the housekeeping gene YWHAZ. Tau isoform expression was normalized to total Tau levels. n¼ 4, mean±s.e.m.,
one-way analysis of variance with Dunnett’s post-test: *Po0.05, **Po0.01, ***Po0.001. FUS, Fused in sarcoma; shFUS, short hairpin FUS; shLuc,
short hairpin RNA targeting the luciferase transcript; YWHAZ, tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein
zeta/14-3-3-zeta.
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Tau mRNA was comparable to two positive controls recently
identified by crosslinking and immunoprecipitation (CLIP)
analysis of FUS-bound RNAs in HEK293 cell, its own mRNA and
SON (Fig 3B; [5]). In contrast, glyceraldehyde-3-phosphate
dehydrogenase pre-mRNA and mRNA were not enriched in
FUS-immunoprecipitates. Taken together, these data show that
FUS is associated with Tau pre-mRNA and mRNA in mouse brain.
FUS directly binds to Tau transcripts at multiple sites
To analyse whether the interaction of FUS with Tau RNA is direct,
we incubated mouse brain extracts with biotinylated RNA
probes followed by ultraviolet crosslinking, RNase A digest
and FUS immunoprecipitation [19]. RNA probes covering the
FUS-regulated exon 10 and the neighbouring exon 11 resulted in
significant biotinylation of FUS compared with an exon 9
spanning probe, indicating a direct and specific interaction of
FUS with these RNA fragments (Fig 3C; supplementary Fig S5B
online). CLIP analysis in HEK293 cells had revealed preferential
interaction of FUS with AU-rich intronic RNA that was corrobo-
rated by in vitro binding assays with artificial AUU-repeats [5].
Interestingly, mouse Tau pre-mRNA contains three clusters
with multiple AUU motifs in intron 9 (9–17 AUU within B300
nucleotides) and RNA probes spanning these regions showed
strong interaction with FUS in the crosslinking assay (compare
i9-1, -2 and -3 in Fig 3C). Probe i9-2 is located closest to exon 10
and shows the strongest conservation between rodents
and humans (supplementary Fig S5A,C online). Although FUS-
knockdown led to preferential inclusion of Tau exon 3, we could
not detect significant interaction of an exon 3 spanning RNA
probe with FUS. However, the region within intron 2 with the
highest conservation between mouse and human Tau
(supplementary Fig S5A,D online) was strongly crosslinked to
FUS, although it contained only four AUU motifs. Thus, FUS
directly binds to Tau RNA at several sites near the FUS-regulated
exons 3 and 10.
FUS knockdown promotes exon 10 inclusion in minigene
To further analyse the effects of FUS on pathologically relevant
Tau splicing in a heterologous system, we used a minigene
construct covering mouse exons 9 to 11 that contains the full
intron sequences and expresses short HA-tagged Tau protein
fragments, corresponding to the 3R/4R Tau domains. HEK293
cells co-transfected with the 3R/4R minigene and a control shRNA
(shLuc) predominantly express fragments corresponding to 3R Tau
and some 4R Tau. However, FUS knockdown (using shFUS-hu)
led to a shift towards the longer fragment corresponding to 4R Tau,
suggesting that endogenous FUS promotes skipping of exon 10 in
the heterologous system (Fig 3D). These data corroborate the
effects of FUS knockdown on Tau 4R expression in hippocampal
neurons (Fig 1).
FUS knockdown disturbs cytoskeletal organization
To address whether FUS knockdown has functional consequences
on neuronal development, we transfected hippocampal neurons
before plating with shFUS#2 or an unspecific control (shLuc).
FUS knockdown was apparent by immunostaining at DIV4
(supplementary Fig S4A online). Toxicity assays performed
showed no difference between groups even after prolonged
knockdown (supplementary Fig S4C online). After 4 days in
culture, both neurons transfected with shLuc or shFUS sent out a
similar number of neurites (Fig 4A; supplementary Fig S4B online)
and had developed an axon (89% and 88%, respectively) that was
identified by immunostaining with the axonal marker Tau1 [20].
Furthermore, neurons lacking FUS showed normal axonal
branching (supplementary Fig S4B online). However, axons in
FUS-knockdown neurons were slightly, but significantly shorter
than in control cells (Fig 4B, left panel) and interestingly, the
shFUS-transfected neurons typically developed severely enlarged
growth cones. We found that the growth cone area of the shFUS-
transfected neurons was in average twice as large as in the control
cells (Fig 4B, right panel). When analysing tubulin and actin
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localization in axonal growth cones (Fig 4C), we observed that in
shFUS-transfected neurons microtubules spread further into the
enlarged growth cone area and appeared less bundled, which
resembles findings in Tau- and MAP1B-knockout neurons [8].
Together, these data indicate that FUS has an important role in
cytoskeletal organization, particularly in the organization of
microtubule network at axonal tips.
CONCLUSION
In this study, we established Tau as the first physiological splice
target of FUS in neurons. This was corroborated on both mRNA
and protein level. FUS knockdown promotes inclusion of exons 3
and 10 and thus expression of 2N- and 4R-containing Tau
isoforms. Moreover, regulation of exon 10 was confirmed in a
minigene reporter assay. We found that Tau pre-mRNA is
associated with FUS in the brain and demonstrated direct binding
to several intronic and exonic regions of Tau RNA, suggesting
a direct role in Tau splicing. Consistent with recent CLIP
analysis [5], we found the most robust binding of FUS to
intronic regions containing multiple AUU motifs, although this
was no absolute prerequisite for binding.
Enhanced expression of 4R Tau is a well-established cause of
neurodegeneration both in the presence and absence of overt
Tau aggregation [13–16]. Our data indicate that FTLD–Tau and
FTLD–FUS share disease mechanisms through increased Tau 4R
expression. Increased expression of 4R Tau has been linked to
Parkinson’s disease and is a strong predictor of progression
to dementia [16,17,21]. Interestingly, FUS is downregulated
in brains from Parkinson patients [22]. Furthermore, Tau variants
are a risk factor for the Guam variant of ALS [23]. The
consequences of enhanced 2N expression are poorly
understood. Because the interaction of the Tau N-terminal
region with Fyn has been linked to excitotoxicity, altered Tau
splicing might contribute to the loss of mature dendritic spines
observed in FUS-knockout mice potentially causing synaptic
dysfunction in FTLD/ALS [9,24,25].
We observed shortened axonal length and growth cone
enlargement on FUS-knockdown that are reminiscent of
Tau-knockout mice [8]. Although we cannot exclude that other
FUS-regulated genes contribute to this phenotype, altered Tau
isoform expression might disturb cytoskeletal function in the axon
and thus affect growth cone organization. It will be crucial to
investigate Tau splicing and cytoskeletal aberrations in FTLD/ALS
cases with FUS pathology and vice versa look for altered FUS
expression in other tauopathies.
METHODS
Antibodies. FUS (Bethyl, A300-292A), Tau (Dako, A 0024), 3R
Tau (Millipore, 8E6/C11), 4R Tau (Millipore, 1E1/A6), Tau1
(Millipore, PC1C6), b-actin (Sigma, AC-15), b3-Tubulin (Sigma,
SDL.3D10 and Covance, Tuj1), synaptophysin (Millipore, SY38),
PSD95 (Neuromab, K28/43), NR1 (BD, 54.1), NR2A (Covance,
PRB-513P), GluR2 (Neuromab, L21/32), and GFP (rabbit,
Fitzgerald Industries International) were used.
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Fig 3 | FUS is associated with Tau pre-mRNA in brain and affects splicing of a minigene reporter construct. (A) Anti-FUS immunoblot of mouse brain
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DNA constructs and transfection. shRNA targeting FUS (rat #1
50-ggcctaggcgagaatgtta-30, rat #2 50-gtgcaaggcctaggcgaga-30,
human 50-ggacagcagcaaagctatg-30), TDP-43 (50-gtagatgtcttcattccc
aaa-30) and firefly luciferase (50-cgtacgcggaatacttcga-30) at the
indicated sites were cloned into pSUPER (Oligoengine). For
lentiviral knockdown, the shRNA-expression cassette was sub-
cloned into a lentiviral vector coexpressing mCherry from human
ubiquitin C promoter [26]. HA-tagged human FUS complemen-
tary DNA containing silent mutations in the shRNA-binding
sites were expressed under the human synapsin promoter in a
lentiviral vector [26].
A Tau minigene construct containing exons 9 to 11 was
cloned by homologous recombination using the Red/ET system
(Genebridges) from a mouse genomic BAC (Imagenes) into an
expression vector (derived from pBUD-CE4, Invitrogen)
containing an N-terminal myc-tag and a C-terminal HA-tag.
For the splicing assay, the minigene construct was co-transfected
in HEK293 cells that had been transfected with shRNAs two days
earlier using Lipofectamine 2000 (Invitrogen) to allow sufficient
FUS knockdown.
To generate RNA probes for the crosslinking experiments,
250–400 bp fragments of Tau pre-mRNA were cloned from mouse
genomic DNA into pGEM3 (Promega) or pCR-blunt2 TOPO
(Invitrogen) and transcribed into RNA using the MAXIscript T7 kit
(Invitrogen) in the presence of biotin-16-UTP (Biotin RNA
labelling mix, Roche) according to the manufacturer’s instruction.
All constructs were verified by DNA sequencing. All oligos are
listed in supplementary Table S1 online.
Neuronal culture, transfection and immunostaining. Hippo-
campal neurons for lentiviral infections were cultured from
embryonic day 18 or 19 rats, as described previously, in a feeder-
free system using B27 (Invitrogen) [26]. Neurons were lysed in
Laemmli buffer and run on 10% denaturing SDS–PAGE gels. Cell
viability was measured using the XTT cell proliferation kit (Roche).
For the analysis of neuronal morphology (neurite number, axonal
length and branching), we cultured rat hippocampal neurons on
astrocyte feeder cells using N2 media [27]. The neurons were
transfected before plating using an Amaxa 4D-Nucleofector (Lonza)
with primary culture kit P3 (program EM110).
Hippocampal neurons were fixed with 4% paraformaldehyde,
quenched in 50mM ammonium chloride and permeabilized with
0.1% Triton X-100. After blocking with 2% fetal bovine serum
(Invitrogen), 2% bovine serum albumin (Sigma-Aldrich), and 0.2%
fish gelatin (Sigma-Aldrich) dissolved in phosphate-buffered saline
neurons were incubated with primary antibodies diluted in 10%
blocking solution.
For the quantification of growth cone area, neurite number and
axonal branching, a minimum of 45 cells per condition were
analysed in three independent experiments. For axonal length
quantifications, a minimum of 99 cells per condition in three
independent experiments were measured using AxioVision
software (Zeiss).
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percentile. Mann–Whitney test: ***Po0.001, ****Po0.0001. (C) Staining for F-actin (using phalloidin) and b3-tubulin. Right panels show a high-
magnification view of axonal growth cones. Scale bars, 25mm. FUS, Fused in sarcoma; shFUS, short hairpin FUS; shLuc, short hairpin RNA targeting
the luciferase transcript; YFP, yellow fluorescent protein.
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Reverse transcription and quantitative PCR analysis. Total RNA
was extracted using RNeasy Mini Kit (Qiagen) and reverse
transcribed with random hexanucleotide primers using TaqMan
Reverse Transcription Kit (Applied Biosystems, Invitrogen).
The complementary DNA was amplified using qPCR SsoFast
Evagreen Supermix (Biorad) and analysed in the CFX384
Real-Time System (Biorad).
FUS immunoprecipitation and RNA isolation. Mouse brains (day
15) were homogenized in 2-ml lysis buffer (20mM Tris–HCl, pH
7.4, 450mM NaCl, 0.1mM EDTA, 1.5mM MgCl2, 1mM CaCl2,
0.6% Triton X-100) containing SUPERase RNase inhibitor
(Ambion, 1U/ml) and protease and phosphatase inhibitor cocktails
(Sigma). After 70 000 g centrifugation (20min), supernatants were
immunoprecipitated for 1 h with Dynabeads Protein G (Invitrogen)
precoupled with FUS or GST antibody (10 mg antibody/75ml
beads). After four washes with lysis buffer, the bound
RNA was extracted using RNeasy Mini Kit including treatment
with DNase (Qiagen).
Crosslinking of FUS with Tau pre-mRNA. Direct interaction of
FUS with RNA was analysed analogous to protocols established
for TDP-43 [19]. Mouse brains (day 15) were homogenized as
described above (but in the absence of RNase inhibitor). After
centrifugation, the supernatant was diluted with 2 volumes of lysis
buffer lacking salt (20mM Tris–HCl, pH 7.4, 0.1mM EDTA,
1.5mM MgCl2, 1mM CaCl2, 0.6% Triton X-100). Endogenously
biotinylated proteins in the lysates were depleted using strepta-
vidin agarose (Sigma). Protein extracts (500mg) were incubated
with biotinylated RNA probes for 30min at room temperature and
crosslinked on ice by ultraviolet irradiation (254 nm, 400mJ/cm2)
using a StrataLinker 1800 (Stratagene). After RNase A digestion
(15min, 10mg/ml, Sigma), the lysates were subjected to immuno-
precipitation using anti-FUS or anti-GST antibodies as described
above. Crosslinking of biotinylated RNA was detected using
Streptavidin-Peroxidase (Sigma).
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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Abstract Mutations in fused in sarcoma (FUS) in a subset of
patients with amyotrophic lateral sclerosis (ALS) linked this
DNA/RNA-binding protein to neurodegeneration.Most of the
mutations disrupt the nuclear localization signal which strongly
suggests a loss-of-function pathomechanism, supported by
cytoplasmic inclusions. FUS-positive neuronal cytoplasmic
inclusions are also found in a subset of patients with fronto-
temporal lobar degeneration (FTLD). Here, we discuss recent
data on the role of alternative splicing in FUS-mediated pa-
thology in the central nervous system. Several groups have
shown that FUS binds broadly to many transcripts in the brain
and have also identified a plethora of putative splice targets;
however, only ABLIM1, BRAF, Ewing sarcoma protein R1
(EWSR1), microtubule-associated protein tau (MAPT),
NgCAM cell adhesion molecule (NRCAM), and netrin G1
(NTNG1) have been identified in at least three of four stud-
ies. Gene ontology analysis of all putative targets unanimously
suggests a role in axon growth and cytoskeletal organization,
consistent with the altered morphology of dendritic spines and
axonal growth cones reported upon loss of FUS. Among the
axonal targets, MAPT/tau and NTNG1 have been further
validated in biochemical studies. The next challenge will be
to confirm changes of FUS-mediated alternative splicing in
patients and define their precise role in the pathophysiology of
ALS and FTLD.
Keywords FUS . Alternative splicing . ALS . FTLD . Tau .
MAPT . NTNG1 . Neurodegeneration
Amyotrophic lateral sclerosis/frontotemporal lobar
degeneration pathology and genetics
Cytoplasmic aggregates of the DNA/RNA-binding protein
fused in sarcoma (FUS), also known as translocated in sarcoma
(TLS), define a subgroup of both amyotrophic lateral sclerosis
(ALS; also known as LouGehrig's disease) and frontotemporal
lobar degeneration (FTLD) [1–3]. In ALS, motor neurons
degenerate, and patients rapidly succumb to progressive mus-
cular weakening and paralysis. ALS is the most common form
of motor neuron disease in adults, with a lifetime risk of 1/600
to 1/1,000 [4]. Disease onset occurs on average at the age of
55 years, and the 3-year survival rate is close to 50 % [5]. In
FTLD, patients suffer from region-specific neurodegeneration
in the frontotemporal cortex that affects higher cognitive func-
tions such as speech, language, and personality. FTLD is the
second most common cause of dementia under 65 years [6].
Many patients show signs of both motor neuron loss and
dementia, and thus, ALS and FTLD are now considered ex-
treme ends of a disease spectrum [7, 8].
Both ALS and FTLD have a strong genetic component
because 20–50 % of patients have a family history of neuro-
degeneration (familial cases) [5, 6, 9]. The discovery of dom-
inant disease-causingmutations in several genes further linked
these diseases and led to a pathological subdivision defined by
the main aggregating protein (FUS, TAR DNA-binding pro-
tein 43 (TDP-43), tau, or SOD1) [8–11].
Aggregation of the microtubule-associated protein tau
(MAPT) in the form of neurofibrillary tangles is often caused
by pathogenic tau mutations that alter its affinity for microtu-
bules [12]. Cytoplasmic redistribution and aggregation of the
nuclear DNA/RNA-binding protein TDP-43 (or TARDBP) is
the key pathological feature in most FTLD and ALS patients,
hence called FTLD/ALS-TDP [13]. The nuclear DNA/RNA-
binding protein FUS forms cytoplasmic inclusions in neurons
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and glia in a distinct group of patients, termed FTLD/ALS-FUS
[1–3, 14]. Mutations in TDP-43 cause predominantly ALS and
rarely FTLD, and mutations in FUS cause exclusively ALS [8].
While loss-of-function mutations in the growth factor
progranulin (GRN) cause FTLD-TDP [15], no other mutations
have been linked to FTLD-FUS so far. The most common
genetic cause for ALS and FTLD is the recently discovered
massive expansion of a GGGGCC repeat in the first intron
of the uncharacterized gene C9orf72 , which causes TDP-43
pathology by an unclear mechanism possibly involving RNA
toxicity [16–18]. Aggregation of TDP-43 and FUS strongly
suggests that dysregulated RNA processing is an important
factor in the pathogenesis of ALS and FTLD. In this review,
we focus on the role of aberrant splicing in this process.
FUS pathophysiology in ALS and FTLD
FUS is ubiquitously expressed and is predominantly localized
in the nucleus. FUS mediates mRNA transport by shuttling in
and out of the nucleus [19, 20]. Mislocalization of FUS to the
cytoplasm is presumably the first step in the pathophysiolog-
ical cascade that leads to neurodegeneration. ALS-FUS mu-
tations cluster around the C-terminal nuclear localization sig-
nal (NLS) and disrupt the nuclear import of FUS [1, 2, 21].
The other members of the FET family of proteins, Ewing
sarcoma protein (EWS) and TATA-binding protein-associated
factor 15 (TAF15), are imported normally into the nucleus.
FUS inclusions therefore lack EWS and TAF15 [14]. In con-
trast, FTLD-FUS cases show inclusions where the entire FET
family coaggregates [14]. Thus, in FTLD-FUS, which typical-
ly lacks FUS mutations, nuclear import of the FET family may
be more broadly impaired, although other unrelated transportin
1 cargos are not affected. This topic was discussed in the recent
review by Dormann and Haass [11].
Regardless of the mechanism, mislocalization of FUS
results in a reduction of nuclear function and an increase of
cytoplasmic FUS prone to aggregation [22]. Cytoplasmic
FUS may result in toxic gain of function by disrupting extra-
nuclear RNA metabolism [23].
FUS animal and cell culture models have been generated to
dissect loss- and gain-of-function pathomechanisms. Two FUS
knockout mouse lines show surprisingly different phenotypes.
Inbred knockout mice fail to suckle and die within a few hours
after birth [24]. In contrast, outbred knockout mice reach adult-
hood, but the males are sterile [25]. Despite the different
phenotypes, both knockout mice show genomic instability.
Furthermore, loss of FUS alters neuron morphology. Cultured
neurons from knockout mice have fewer mature spines, but
more filopodia-like dendritic protrusion than wild-type neurons
[26]. Early FUS knockdown in hippocampal neurons results in
enlarged axonal growth cones with disorganized cytoskeleton
[27]. Gain-of-function mouse models that overexpress wild-
type FUS succumb to progressive paralysis and die after
12 weeks. These mice show FUS-positive inclusions in spinal
cord motor neurons and, therefore, replicate some aspects of
human pathology [2, 28]. Together, these results suggest an
important role of FUS in neurons during development.
They also point to a combined loss-of-function and toxic gain-
of-function pathomechanism in ALS/FTLD-FUS [29]. Thus,
it is critical to understand the physiological function of FUS in
the brain.
Alternative splicing in the brain
Alternative splicing drives and vastly extends the diversity of
the transcriptome and proteome. One single gene may give
rise to many different protein isoforms, often with distinct
functions [30–32]. Tailored protein function is possible due
to tissue- and development-dependent regulation of alterna-
tive splicing. Compared to other tissues, the human brain
shows exceptionally high levels of alternative splicing, with
more than 40 % of genes being alternatively spliced [33]. A
complex interplay of cis - and trans -acting elements regulates
alternative splicing. The cis -acting elements are splicing en-
hancer and inhibitory sequences within the pre-mRNA that
recruit trans -acting RNA-binding proteins (RBP), which may
themselves be further regulated by posttranscriptional modifi-
cations. The spliceosome, a RNA–protein complex consisting
of small nuclear RNAs (U1, U2, U4, U5, and U6) and several
RBPs, catalyzes splicing [34].
FUS is also part of the spliceosome and directly binds pre-
mRNA [27, 35–38] and the splicing factors: splicing component
35 (SC35), polypyrimidine tract-binding protein (PTB), and the
serine arginine (SR)-related proteins SRm160 and SRp75
[39–41]. Splicing of pre-mRNA transcripts starts during tran-
scription, and both processes are tightly integrated [42]. FUS
also regulates RNA polymerase II-mediated transcription by
binding its C-terminal domain and regulating its phosphorylation
[43]. Thus, FUS may integrate transcriptional and splicing reg-
ulation through RNA–protein and protein–protein interactions.
Until recently, the analysis of FUS-mediated splicing was
limited to artificial exogenous splicing targets [39, 44]. The
recent identification of endogenous neuronal splicing targets
such as MAPT/tau [27] will allow detailed analysis of regu-
latory elements and will help to pinpoint the role of FUS in
alternative splicing.
Pathogenic mutations highlight the importance of alternative
splicing in neurodegeneration. In FTLD-tau patients, for exam-
ple, MAPT mutations around exon 10 alter its splicing, thereby
causing tau aggregation and impairing the axonal function of tau
[45]. Moreover, mutations in trans-acting factors such as the
RBP survival motor neuron protein 1 (SMN1) cause spinal
muscular atrophy [46, 47]. Thus, identifying the splicing
J Mol Med
targets of FUS will help us to understand the pathogenesis of
ALS/FTLD-FUS.
FUS-mediated alternative splicing in the brain
RNA-binding and alternative splicing targets of FUS have been
studied previously in cell culture models (human embryonic
kidney 293 cells [23, 43], motor neuron-like cells NSC-34 [48])
or in Xenopus laevis embryos [49]. Recently, four independent
studies analyzed RNA bound to FUS in neuronal tissue
[35–38] using different cross-linking and immunoprecipitation
(CLIP) technologies and next-generation sequencing [50, 51].
The four groups then correlated CLIP results to the splicing
changes detected in FUS knockout brains or cultured neurons
with FUS knockdown, in order to identify FUS splicing targets
in the nervous system. The experimental approach and results
are compared in Table 1.
The four studies are largely consistent in their conclusions:
firstly, in the brain, FUS regulates primarily alternative splic-
ing events rather than transcription or constitutive splicing.
Secondly, FUS binds several thousand transcripts and favors
very long introns. FUS-binding sites often flank the regulated
alternatively spliced exon. However, only 42 % [38] to 55 %
[37] of transcripts differentially spliced after FUS knockdown
were direct binding targets of FUS. Additionally, two studies
that applied CLIP technology to human and mouse brain
tissue [37, 38] found highly comparable RNA-binding pro-
files and a high correlation of binding targets between humans
and mice.
Thirdly, no simple RNA sequence can explain the RNA-
binding pattern of FUS. In a fraction of targets ranging from
10% [35] to 60 % [37], different groups detected a significant
preference for G/C [35], C/U [38], GGU [36], or GUGGU
[37] motifs, although the enrichment was rather low. The
GGU and GUGGU motifs are similar to the GGUG motif
identified previously through in vitro affinity selection [44].
Two groups also evaluated the enrichment of RNA structure
motifs, such as the short-stem loop motif proposed by Hoell
et al. [23]. Ishigaki et al. [35] found a modest enrichment of
short-stem loop in FUS RNA targets, but Rogelj et al. [36] did
not. Further biochemical studies are necessary to fully under-
stand the RNA-binding specificity of FUS in the brain [38].
Fourthly, gene ontology analysis revealed that FUS splice
targets are predominantly involved in the following pathways:
axonogenesis, axon guidance, cell adhesion, neuron projec-
tion, vesicle transport, and cytoskeletal organization [35–38].
Among other splicing events, loss of FUS leads to inclusion/
exclusion of exon cassettes (e.g., MAPT/tau) [35–37], selection
of alternative 3′ untranslated regions (UTRs) (e.g., ABLIM1)
[36] and intron retention (e.g., small nuclear ribonucleoprotein
70 (snRNP70)) [38]. Intron retention typically leads to insertion
of a premature stop codon and may be a mechanism to regulate
protein abundance through nonsense-mediated mRNA decay.
Interestingly, a previous study using FUS knockdown in
X. laevis observed extensive intron retention with functional
effects on the fibroblast growth factor pathway [49].
Finally, the studies comparing binding targets of TDP-43
and FUS detected only few RNAs bound by both proteins.
Despite their structural homology, these two proteins seem to
regulate a vastly different set of genes [36, 37]. Also, TDP-43
binds its targets with surgical precision, whereas FUS typically
binds broadly along nascent transcripts with long introns,
leading to a characteristic saw-tooth pattern of binding [36,
37]. This could indicate a role of FUS in stabilizing nascent
RNA during transcriptional elongation.
Despite the consensus regarding pathways regulated by
alternative splicing, only six genes were identified in at least
three studies (Table 2), and 71 genes were identified in at least
two studies (Table 3). Only netrin G1 (NTNG1), previously
linked to Parkinson's disease (PD) and schizophrenia, was
identified in all four studies [35–38]. MAPT/tau was identified
in three studies and, additionally, also in our candidate-based
approach [27, 35–37]. FUS also bindsMAPT/tau mRNA in the
human brain [38]. The overlapping targets NTNG1, MAPT,
ABLIM1, NRCAM and BRAF are discussed below.
The differences in experimental approach and statistical
analysis are probably responsible for the limited overlap of
splicing targets (Table 1). Differences in transcript abundance
between whole brain tissue [36, 37], cultured neurons [35], or
neurons differentiated from mouse embryonic stem cells [38]
also limit the comparison. The use of FUS knockout brains
[36, 37] in contrast to FUS knockdown in vitro [35, 38] or
in vivo [37] could also account for the differences. Finally,
Nakaya et al. [38] report several RBPs among the FUS targets,
for example, EWS [36, 38] and snRNP70 [38], and suggest
that FUS cross-regulates the RBP network. The lists of FUS-
regulated genes inevitably include indirect splicing events.
Interestingly, independent studies of TDP-43 that applied
CLIP technology [52–54] also showed limited overlap
among targets [51]. A recent comparison of these studies
also points to methodological differences as the underlying
cause [51].
We considered only the top splicing targets for the discus-
sion on potential implications for ALS/FTLD.
FUS regulates alternative splicing of proteins related
to axonal biology
MAPT/tau
Three FUS CLIP/exon array studies and our candidate-based
study identified increased MAPT/tau exon 10 inclusion upon
loss of FUS [27, 35–37]. Additionally, both our study [27] and
that of Lagier-Tourenne et al. [37] reported an enhanced
J Mol Med
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inclusion of exon 2 (ENSMUSE00000107966) and exon 3
(ENSMUSE00000107958) upon FUS knockdown (Table 2).
Although formal proof that FUS regulates splicing of MAPT/
tau in the human brain is still missing, there is strong evidence
for functional conservation [37, 38].
The MAPT gene, encoding the protein tau, consists of 16
exons and is mainly expressed in the nervous system. Tau
shows a complex alternative splicing regulation of an N-
terminal cassette (exons 2 and 3) and exon 10 that leads to six
different isoforms (0N3R, 1N3R, 2N3R, 0N4R, 1N4R, 2N4R)
[55] (Fig. 1a). Inclusion of exon 2 or exons 2 and 3 adds one or
two short acidic regions (termed 1N and 2N) in the so-called
projection domain. Inclusion of exon 10 inserts a fourth micro-
tubule binding region (4R), which increases affinity to micro-
tubules compared to the shorter 3R isoforms [56]. During
development, expression shifts toward longer isoforms.
Tauopathies are characterized by neurofibrillary tangles,
which consist of aggregated hyperphosphorylated tau. Such
aggregates are found in corticobasal degeneration, progressive
supranuclear palsy, frontotemporal dementia and parkinsonism
linked to chromosome 17 (FTDP-17), as well as Alzheimer's
Table 3 Putative splicing targets of FUS. Hits were identified in at least
two studies
Gene Ishigaki
et al. [35]
Rogelj
et al. [36]
Lagier-Tourenne
et al. [37]
Nakaya
et al. [38]
1 NTNG1 ✓ ✓ ✓ ✓
2 MAPTa ✓ ✓ ✓
3 ABLIM1 ✓ ✓ ✓
4 NRCAM ✓ ✓ ✓
5 BRAF ✓ ✓ ✓
6 EWSR1 ✓ ✓ ✓
7 2700081O15RIK ✓ ✓
8 5330434G04RIK ✓ ✓
9 5730419I09RIK ✓ ✓
10 ALCAM ✓ ✓
11 ANKRD32 ✓ ✓
12 ANKS1 ✓ ✓
13 ANKS1B ✓ ✓
14 BIRC6 ✓ ✓
15 CAPN10 ✓ ✓
16 CLEC16A ✓ ✓
17 CNKSR2 ✓ ✓
18 COPE ✓ ✓
19 DLGAP1 ✓ ✓
20 DNAJA1 ✓ ✓
21 DTNA ✓ ✓
22 EIF4G2 ✓ ✓
23 ENAH ✓ ✓
24 ENO2 ✓ ✓
25 EPB4.1L2 ✓ ✓
26 EPB4.9 ✓ ✓
27 ERC2 ✓ ✓
28 ETL4 ✓ ✓
29 GRIA2 ✓ ✓
30 GTF2IRD1 ✓ ✓
31 H13 ✓ ✓
32 HNRNPK ✓ ✓
33 HUWE1 ✓ ✓
34 INPP5F ✓ ✓
35 LPHN3 ✓ ✓
36 LSM14B ✓ ✓
37 MAGI1 ✓ ✓
38 MARCH8 ✓ ✓
39 MBOAT7 ✓ ✓
40 MEAF6 ✓ ✓
41 MMP11 ✓ ✓
42 MVD ✓ ✓
43 NEO1 ✓ ✓
44 NRXN1 ✓ ✓
45 PHKB ✓ ✓
46 PITPNC1 ✓ ✓
47 POT1A ✓ ✓
48 PRRT2 ✓ ✓
Table 3 (continued)
Gene Ishigaki
et al. [35]
Rogelj
et al. [36]
Lagier-Tourenne
et al. [37]
Nakaya
et al. [38]
49 PTDSS2 ✓ ✓
50 RABL2 ✓ ✓
51 RAP1GDS1 ✓ ✓
52 RAPGEF4 ✓ ✓
53 RASGRF1 ✓ ✓
54 RASGRP2 ✓ ✓
55 RRAGD ✓ ✓
56 SEC63 ✓ ✓
57 SLC25A14 ✓ ✓
58 SLITRK4 ✓ ✓
59 SMG7 ✓ ✓
60 SORBS1 ✓ ✓
61 SORT1 ✓ ✓
62 SPP1 ✓ ✓
63 ST3GAL3 ✓ ✓
64 TECR ✓ ✓
65 TIA1 ✓ ✓
66 TMEM150C ✓ ✓
67 TSC22D2 ✓ ✓
68 TTLL12 ✓ ✓
69 UBA3 ✓ ✓
70 ZFML ✓ ✓
71 ZFP273 ✓ ✓
72 ZFP553 ✓ ✓
aMAPT is also an alternative splicing target of FUS in the study of
Orozco et al. [27]
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disease [57]. Tau mutations in FTDP-17 patients promote tau
aggregation either by disturbing the tightly controlled 4R/3R
ratio [58] or by affecting the interaction of tau with microtu-
bules [56]. The changes in microtubule stability directly affect
the transport along microtubules. Interestingly, increased 4R
expression may cause neurodegeneration even in the absence of
visible tau aggregation [59]. In mouse models of tauopathies,
toxicity precedes tau aggregation [60]. In PD, 4R expression is
correlated with progression to dementia without detectable tan-
gles [61–63]. The H1 MAPT haplotype, which enhances 4R
expression [64], has been genetically linked to PD. Finally, tau is
also genetically [65] and pathologically [66] linked to the Guam
variant of ALS. Thus, a shift toward 4R tau may contribute to
neurodegeneration in ALS/FTLD-FUS, despite the lack of overt
tau aggregation [67, 68].
Netrin G1
NTNG1, also known as laminet-1, belongs to the netrin family,
with the distinction of being membrane bound via a
glycosylphosphatidylinositol (GPI) anchor [69–71]. Netrins
provide important guidance cues during brain development
[72]. For example, NTNG1 and its ligand NGL-1 regulate
axon guidance as well as synapse formation and maintenance
[70]. Nine different isoforms resulting from alternative splicing
of the exons 5–9 have been reported so far [71]. The protein
contains several laminin- and non-laminin-type epidermal
growth factor (EGF) domains.
NTNG1 is the only target identified in all four FUS CLIP/
exon array studies. Rogelj et al. [36] report an increased
inclusion of exon 9 (ENSMUSE00000511732) upon FUS
knockdown, while Ishigaki et al. and Lagier-Tourenne
et al. [35, 37] report exon inclusion in a PCR amplicon
spanning exon 7 (ENSMUSE00000670473) to exon 9
(ENSMUSE00000511732). Exons 8 and 9 insert laminin-
type EGF domains. In contrast, Nakaya et al. [38] report an
increased inclusion of exon 10 (ENSMUSE00000947279) that
codes for an extracellular EGF domain. Little is known about
the differential function of NTNG1 isoforms. Based on the
number of EGF-like domains, the isoforms might have differ-
ent affinities for the ligand NGL-1 [69]. Selective reduction of
the G1c isoform has been observed in familiar cases of schizo-
phrenia [73] and bipolar disorders [69]. Interestingly, NTNG1
is also linked to PD in a genome-wide association study [74].
ABLIM1, NRCAM, and BRAF
Altered splicing of ABLIM1, NRCAM, and BRAF upon loss
of FUS was reported in at least three studies (Table 2). The
actin-binding LIM protein ABLIM1 is expressed throughout
the body and exists in three different isoforms ABLIM1-s,
ABLIM1-m, and ABLIM1-l, which differ in the number of
LIM domains [75]. In contrast to NTNG1 and MAPT/
tau, the reported effects in splicing vary among the studies.
Lagier-Tourenne et al. and Nakaya et al. detected prefer-
ential skipping of exons ENSMUSE00000292146 and
ENSMUSE00000292118, respectively [37, 38]. The specific
function of these exons is unknown. Rogelj et al. [36] detected
an alternative 3′ splice site event at ENSMUSE00000640490,
which is almost identical to exon ENSMUSE00000292146
except that it is annotated to be 5 bp longer. The protein
product of this transcript lacks the C-terminal vinillin head-
piece that mediates the binding of F-actin. Lastly, Lagier-
Tourenne et al. [37] detected an alternative start site at
ENSMUSE00000793956. The mouse genome database
(NCBIM37) lists only one short transcript with this alternative
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Fig. 1 Genomic structures and isoforms of MAPT/tau and NTNG1. a
The humanMAPT gene encodes for the tau protein and contains 16 exons.
E0 and E14 (white) are noncoding, E6 and E8 (brown) are not expressed
in the human brain, and E4a is only expressed in the peripheral nervous
system. The N-terminal part of the protein shows a complex alternative
splicing of the cassettes E2 and E3. Inclusion of E3 is coupled to the
inclusion of E2. Inclusion of E2 or E2/E3 adds one or two acidic regions
(1N, 2N) in the projection domain (N-terminal part). Alternative splicing
of E10 is regulated independently. Exons 9–12 code for microtubule
binding domains. Inclusion of E10 adds extra fourth microtubule binding
region (4R). b The human NTNG1 gene contains 10 exons. E1 (white) is
noncoding. Complex alternative splicing of E5, E6, E7, E8, and E9 results
in at least nine different isoforms termed G1a, G1b, G1c, G1d, G1-e, G1-l,
G1-m, G1-n, and G1-o. E exon
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start site, which also lacks the C-terminal vinillin headpiece.
ABLIM1 binds F-actin, bridges the actin cytoskeleton, and is
known to mediate axon guidance and outgrowth [76]. Interest-
ingly, netrin signaling has been shown to activate ABLIM1 [77].
NRCAM is a transmembrane protein that belongs to
the L1 family of cell adhesion molecules [78]. Alternative
splicing of NRCAM results in more than a dozen isoforms
that are differentially regulated during development [79]. The
function of the different isoforms is unknown. Similar
to ABLIM1, there is limited overlap in the reported affected
exons upon loss of FUS. Rogelj et al. [36] reported
skipping of exon ENSMUSE00000325244, which codes
for an Ig-like beta sandwich domain. In contrast, Lagier-
Tourenne et al. and Nakaya et al. [37, 38] report skipping of
exon ENSMUSE00000325376 and inclusion of exon
ENSMUSE00000325135, respectively (Table 2). Interestingly,
these are neighboring exons, and the latter also encodes
an Ig-like domain. NRCAM is crucial for axon growth and
guidance, synapse formation, and neurite outgrowth [78] and
has been linked to different forms of cancer and autism [78].
The BRAF gene codes for the B-raf protein member of the
Raf family of kinases (including A-raf and C-raf). Raf kinases
are part of the mitogen-activated protein kinase (MAPK)
cascade, which activates gene expression upon growth factor
stimulation. B-raf is highly expressed in the CNS [80] and is
the major activator of the extracellular signal-regulated kinase
(ERK)1/2 pathway in neurons [81, 82]. Both in vitro and
in vivo studies have demonstrated the essential role of B-raf
in neuronal survival and differentiation [82, 83]. Interestingly,
conditional double knockout of B-raf and C-raf resulted in
reduced axon growth [83]. Alternative splicing of BRAF
results in 10 isoforms expressed in different tissues. The
longest isoforms are abundant in the CNS [80]. Ishigaki
et al. [35] report exon skipping in the region encompassing
exons ENSMUSE00000618025, ENSMUSE00000951452,
and ENSMUSE00000562746 after FUS knockdown.
Lagier-Tourenne et al. [37], however, report preferential in-
clusion of exon ENSMUSE00000618025. This discrepancy
could reflect differences in FUS regulation of alternative
splicing in different cell populations in the brain, since
Ishigaki et al. [35] analyzed cultured neurons, and Lagier-
Tourenne et al. [37] analyzed whole mouse brain. Nakaya
et al. [38] report skipping of exon ENSMUSE00000618032
upon loss of FUS. All known isoforms can activate ERK1/2
1. FUS mislocalization 2. loss of axonal
maintanance and repair,
loss of connectivity
3. aging and/or
stress accelerate
deterioration
4. progressive neuronal 
loss
FUS
aberrant exon inclusion
dendrite
or NMJ
FUS
normal exon exclusion
synaptic vesicles
FUS protein
FUS inclusions
neuronal connectivity
stress
Fig. 2 Hypothesis of splicing centered pathomechanism in ALS/FTLD-
FUS. 1 Impaired nuclear import of FUS, due to mutations in the NLS or
transport defects, causes mislocalization of FUS to the cytoplasm. This leads
to loss of nuclear function and thus changes in alternative splicing of axonal
and cytoskeleton related genes. 2 Altered splicing disturbs axonal growth
andmaintenance and results in axonal atrophy and loss of connectivity.
3 Aging and stress accelerate the process of neuronal denervation
and lead to the first clinical symptoms. Connections to dendrites or
neuromuscular junction (NMJ) are affected. 4 Due to disturbed repair
mechanisms, the affected neurons are not able to cope with the stress and
to repair damaged connections. The result is progressive degeneration
observed in disease
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signaling [80], but alternative splicing might modulate kinase
activity and substrate specificity, thus altering growth factor
signaling [80].
Consequences for ALS and FTLD
Tau, NTNG1, ABLIM1, NRCAM, and B-raf exemplify a com-
mon theme among FUS splice targets, because they all affect
cytoskeletal organization and, in particular, axon growth and
maintenance. The recent identification of ALS-causing muta-
tions in profilin 1 [84], a protein that regulates actin polymeri-
zation, as well as mutations in the neurofilament subunit H [85],
further highlights the importance of the cytoskeleton in the
pathogenesis of neurodegenerative diseases. Altogether, FUS
mislocalization to the cytoplasm may impair maintenance and
repair of long axons. Interestingly, the earliest signs of ALS are
axon retraction and denervation, which clearly occur before the
loss of neuronal cell bodies [86, 87].
How could impaired FUS-mediated alternative splicing
render neurons more vulnerable in ALS/FTLD-FUS? We
propose the following model (Fig. 2): (1) in ALS or FTLD,
pathogenic mutations or impaired nuclear import causes cy-
toplasmic mislocalization of FUS [88]. Reduction of nuclear
FUS results in aberrant alternative splicing of axonal and
cytoskeleton-related transcripts, such as MAPT/tau. (2) The
network responsible for axonal growth, maintenance, and
repair deteriorates, and neuronal connections are weakened.
Secondary effects, such as misregulation of other RBPs [38]
or their sequestration into aggregates, may enhance
neurodegeneration. (3) Aging and other stressors [11, 88]
can trigger denervation and early clinical symptoms. Lastly,
(4) due to disrupted repair mechanisms, the damaged tissue
cannot be repaired resulting in progressive neurodegeneration.
Conclusions and key open questions
We have reviewed here the alternative splicing targets of FUS
reported by four independent groups. The most robustly iden-
tified targets are linked to cytoskeleton, axon growth, and
maintenance [35–38]. However, FUS binds manymore RNAs
apparently without changing splicing or expression. How are
these RNAs affected by FUS? Furthermore, it is unclear how
FUS affects the bound long noncoding RNAs, for example,
maternally expressed 3 (Meg3) and nuclear enriched abundant
transcript 1 (NEAT1 ) [37]. Meg3 and NEAT1 have been
linked to neurodegeneration, because their expression is sig-
nificantly dysregulated in Huntington's disease [89]. More-
over, it will be important to understand how FUS aggregates
might impair cytoplasmic RNA metabolism [23]. Finally, to
fully understand the pathomechanism of ALS and FTLD with
FUS pathology, we should also consider other potential roles
of FUS in the nervous system, particularly genomic stability.
Even postmitotic neurons seem to require constant genome
repair, because cellular stress and normal synaptic activity can
cause double-strand breaks [90].
In conclusion, we now know that loss of FUS alters splic-
ing of key components of the cytoskeleton and related pro-
teins that promote axonal maintenance and repair. The next
challenge will be to confirm these findings in ALS and FTLD
patients and relate them with the pathology and symptoms.
Only then, we can begin to translate these findings into
therapeutic approaches for these devastating diseases.
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